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I. Abstract: 
 
Hydrophilic matrix tablets present a convenient method for oral modified 
drug delivery. The performance of such dosage forms is affected by 
multiple factors, amongst which the influence of tablet shape and 
structural properties have been partially investigated in previous 
literature. This work focused on investigating the influence of changing 
tablet properties on the in-vitro behaviour of hydrophilic matrix tablets, in 
particular, the influence of tablet face curvature on the hydration and drug 
release behaviour of round and elongated Xanthan Gum tablets 
containing the two model drugs Orphenadrine Citrate and Orphenadrine 
Hydrochloride. The influences of tablet overall porosity and of the 
formulation used on tablet behaviour were also investigated, in addition to 
the investigation of any interactions between the influences of tablet and 
formulation variables. 
 
Initially the properties of the powders incorporated into the various 
formulations used were characterised. The physical properties of the dry 
tablets were then investigated in terms of tablet tensile strength and 
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structural properties. The hydration behaviour of the various tablets was 
investigated quantitatively using live in-situ swelling studies and 
qualitatively using rheological and calorimetric methods. Finally the 
process of drug and polymer dissolution from the tablets was 
investigated.  
 
The results of the work indicated that tablet face curvature had a 
significant influence on the physical properties of the dry tablets as well 
as on the hydration and dissolution patterns associated with the hydrated 
tablets. The influence of tablet overall porosity was profound on the 
properties of the dry tablets but became rather minor upon tablet 
hydration. The type of formulation had a major influence on the properties 
of dry tablets. Moreover, ionic interactions between the two drugs and 
Xanthan Gum had a significant influence on the properties of hydrated 
tablets. Thus, tablet face curvature, porosity of the tablets and physico-
chemical properties of the drugs need to be considered when formulating 
a hydrophilic matrix tablet. 
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CHAPTER ONE 
 
1. Introduction: 
1.1. Hydrophilic matrix systems: 
1.1.1. General features: 
Matrix systems containing hydrophilic “swellable” polymers continue to 
form an important part of modified release dosage forms. They are 
referred to using various names, including hydrocolloid matrices (Mockel 
and Lippold 1993), hydrogel matrices (Lee 1985), and swelling-controlled 
release systems (Korsmeyer and Peppas 1983). However the most often 
used terms are hydrophilic matrix tablets (Ford 1994), and swellable 
matrix tablets (Colombo et al 2000). Such devices have been used for 
many routes of drug delivery, such as buccal, ocular, rectal, and vaginal. 
However, they are mainly used in the formulation of oral solid dosage 
forms, and they present a variety of advantages over other delivery 
systems. Most importantly the low cost of carrier polymers, availability of 
equipment needed to produce them, and ease of formulation and 
manufacture (Melia 1991, Collett and Moreton 2002). 
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Melia (1991) also listed a few advantages related to the type of carrier 
polymers used in these systems including the availability of the 
polysaccharides used as carriers, which permits the manipulation of the 
formulation to achieve individual needs. Moreover, the matrices produced 
are bio-erodible, i.e. they erode as they descend through the GI tract and 
thus avoid any accumulation of exhausted systems (“ghosts”) inside the 
body, and this is a major advantage over inert matrices that remain 
undissolved in the GI tract. One disadvantage associated with the 
naturally occurring hydrophilic polymers used in the production of such 
systems is the batch to batch variability in polymer properties. 
 
 
1.1.2. Mechanism of action: 
1.1.2.1. Hydration: 
Hydrophilic matrix systems are hydration activated systems; i.e. the 
action of such systems and hence drug release from them depends upon 
the interaction of the polymer molecules with the hydration medium, 
causing a cascade of changes that lead at the end to the release of the 
drug substance into the surrounding medium.  
 
Upon contact with an aqueous medium, water penetration into the 
dosage form is initiated, causing the polymer molecules on the periphery 
to hydrate. Furthermore, water decreases the glass-transition 
temperature of the polymer which undergoes a process of relaxation and 
swelling forming a rubbery gelatinous layer that retards further water 
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penetration, and impedes the rate of drug release into the surrounding 
medium. With further hydration and swelling of polymer molecules on the 
surface of the gel layer, they could reach a certain concentration called 
the polymer disentanglement concentration at which individual polymer 
molecules undergo a process of disentanglement causing their slow 
erosion from the periphery of the matrix and their subsequent transport to 
the bulk medium. These two mechanisms lead to the characteristic cycle 
of the gel layer formation. At the beginning of water penetration into the 
matrix, this causes the relaxation and swelling of the polymer molecules 
on the surface of the matrix which leads to the formation and thickening 
of the gel layer. Continuous hydration of the polymer leads to the 
disentanglement of fully hydrated polymer molecules from the surface of 
the polymer. When the two processes of polymer swelling and erosion 
are synchronised, the thickness of the gel layer remains constant for a 
while. With further hydration, polymer erosion starts taking over leading to 
the thinning of the gel layer (Colombo et al 1996, 1999, 2000). 
   
Several studies have examined the ingress of water into hydrophilic 
matrix systems and the formation of the gel layer. They have shown the 
formation of a multilayered system inside the dosage form as a result of 
water penetration, and the presence of three fronts moving inside the 
dosage form, starting from an erosion front on the interface with the 
surrounding medium, then a diffusion front and finally a swelling front 
(Colombo et al 1999, Ferrero-Rodriguez et al 2000). 
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The erosion front lies on the interface between the surrounding medium 
and the dosage form, and represents the boundary at which polymer and 
drug molecules are released into the surrounding medium. The diffusion 
front represents the boundary between the dissolved and undisolved drug 
molecules in the gel layer, and this front is more apparent with less 
soluble drug substances where the movement of the solvent into the 
dosage form is not matched by the dissolution of the drug molecules. The 
swelling front however represents the boundary between the gel layer 
region containing the hydrated polymer, and the dry core of the dosage 
form. 
  
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Schematic representation of the various layers and fronts 
formed within a hydrating hydrophilic matrix dosage form. 
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The movement of the previous three fronts and the resulting gel layer 
they form inside the dosage form have been shown to be a principle 
factor that governs the release of the drug substance from a hydrophilic 
matrix system (Colombo et al 1999, Ferrero Rodriguez et al 2000). 
 
 
1.1.2.2. Drug release: 
The type of the gel layer formed, more precisely the thickness and the 
physical and mechanical properties of the gel layer are the principle 
factors affecting drug release from hydrophilic matrix systems. Drug 
transport is governed by a balanced mechanism arising from the two 
processes that control the gel layer formation. On one side there is the 
hydration and swelling of the polymer forming the gel layer that acts as a 
physical barrier hindering the free movement of the drug molecules and 
forcing them to diffuse through it, and on the other side there is the 
disentanglement of the polymer molecules into the surrounding medium 
which reduces the thickness of the gel layer and at the same time causes 
the drug molecules if still un-dissolved to erode into the surrounding 
medium. The effect of each of the previous processes differs with the 
differing solubility of the drug. Drugs with sufficient solubility depend 
mainly on diffusion through the gel layer and hence are affected by the 
rate of drug dissolution, and by polymer erosion which governs the gel 
layer thickness through which drug molecules have to diffuse. Drugs with 
insufficient solubility would be released mainly by the erosion of their 
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particles into the surrounding medium with eroding polymer molecules 
(Huber et al 1966, Colombo 1996). 
 
 
1.1.3. Polymers used in the formulation of hydrophilic matrix 
systems: 
Many polymers of varying properties have been utilised in the preparation 
of hydrophilic matrix dosage forms, all of which share a common feature 
of being hydrophilic polysaccharides. However, such polymers differ a lot 
in their physicochemical properties, giving rise to matrix systems with 
varying properties, and with different patterns of hydration. The following 
are some of the major types of hydrophilic polymers successfully 
employed in the preparation of hydrophilic matrix systems: 
 
 
1.1.3.1. Natural Polymers: 
1.1.3.1.1. Xanthan gum: 
Xanthan gum is a microbial extra-cellular anionic polysaccharide 
produced by various strains of the bacteria Xanthomonas Camperisis 
(Lachke 2004). This gum has wide applications in the pharmaceutical 
industry due to its thickening and emulsifying effects. It was also 
successfully incorporated into oral modified release solid dosage forms 
like TIMERx® in which the advantageous synergistic gellation between 
Xanthan Gum and Locust bean gum were exploited (Anand et al 1991, 
1992a, 1992b). 
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 Several workers evaluated the use of xanthan gum in the formulation of 
modified drug delivery systems (Fu Lu et al 1991, Dhopenshwarker and 
Zats 1993, Ntawulkulilyayo et al 1996, Billa et al 2000, Andreopoulos et al 
2001). Several studies reported the ability to obtain constant “zero-order” 
drug release using Xanthan Gum, especially at higher gum contents 
(Sujja-Areevath 1996, Talukdar et al 1996b, Munday and Cox 2000).  
 
Comparing the efficiency of Xanthan Gum in modifying drug release with 
that of other polymers has also been addressed. When compared with 
HPMC, Xanthan Gum showed higher drug sustaining ability, in addition to 
other advantages such as the lack of burst effect and the possibility of 
obtaining zero order drug release patterns (Talukdar et al 1996b). The 
more rapid drug release from HPMC matrices was attributed to higher 
drug diffusion in the gel layer of HPMC matrices compared to Xanthan 
Gum matrices (Talukdar et al 1997). More insight into this difference 
could be accomplished by observing earlier results reported by the same 
group; they compared the rheological properties of Xanthan Gum and 
HPMC solution at concentrations of 4 and 7% which are similar to 
polymer concentrations in the outer gel layer. They found that the 
behaviour of Xanthan Gum solutions at such concentrations is 
comparable to a gel and that the dynamic behaviour of Xanthan Gum is 
only weakly affected by the frequency of the shear it is subjected to. 
HPMC solutions however were not able to form a gel and behaved like 
normal polymer solutions; the dynamic behaviour of HPMC solutions was 
more prone to variation in the rate of shear (Talukdar et al 1996a). 
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Drug release from mini-matrices containing Xanthan Gum and other 
gums was evaluated and it was shown that the ability of Xanthan Gum to 
sustain drug release was higher than other natural gums (Sujja-Areevath 
et al 1996). Further investigation revealed that Xanthan Gum had the 
highest swelling ability that was also accompanied by a moderate erosion 
rate. Other natural Gum like Karaya Gum however had a moderate 
swellability, but also a low erosion rate (Sujja-Areevath et al 1998). 
However, conflicting results were noted by Munday and Cox (2000) who 
reported that Xanthan Gum matrices exhibited a higher degree of 
swelling and less degree of erosion than Karaya Gum matrices. One 
possible factor influencing such a difference in results may lie in the 
nature of dosage forms used in both studies; both studies report using 
USP basket method for erosion studies. However, Sujja-Areevath et al 
(1996, 1998) used mini-matrices of smaller diameter than the ones used 
by Munday and Cox (2000). The small size of the mini-matrices could 
have caused faster hydration especially when the polymer used has 
enhanced swelling properties. This factor when coupled with the attrition 
effect of the basket could lead to more erosion of the highly hydrated 
matrices.  
 
One major determinant of the swelling ability of Xanthan Gum and hence 
its efficiency in modifying drug delivery is the ionic strength of the 
hydration environment. Talukdar et al (1993) reported rapid disintegration 
of tablets containing small amounts of Xanthan Gum when placed in a 
NaCl solution of 0.1 M or more leading to rapid drug release, and this was 
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slightly overcome by increasing the polymer content and inclusion of 
binders (Talukdar et al 1993). With further investigation they noted that 
the swelling of Xanthan Gum tablets had a reciprocal relationship with the 
ionic strength of the dissolution medium and that was not affected by the 
type of ions present (Talukdar et al 1995). This phenomenon had a more 
pronounced effect on the release of water soluble drugs that are released 
mainly by diffusion; the release of such agents was enhanced in the 
presence of salt into the dissolution medium (Talukdar et al 1997). 
Dhopenshwarker and Zats (1993) found that the pH of the hydration 
medium on drug release from Xanthan Gum tablets is only apparent with 
the initial phase of drug release which was faster in simulated gastric fluid 
than simulated intestinal fluid. However, no apparent difference was 
reported for drug release in later stages and this was attributed to the 
faster erosion at the surface of the tablets before sufficient polymer 
hydration and swelling has taken place. 
   
 
1.1.3.1.2. Galactomannans: 
Guar gum is a poly-galactomannan gum in which the structural chain is 
made up of D-mannose units with 1-4 linkages (Lawrence 1973). The use 
of Guar Gum in the formulation of hydrophilic matrix based systems is 
mentioned in the literature; Khullar et al prepared matrix tablets 
containing Guar Gum with Theophylline anhydrous as a model drug. 
They noted the ability of guar gum in sustaining drug release for a long 
period of time which was mainly through diffusion. This was attributed to 
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the steady swelling of the gum (Khullar et al 1998). The ability of Guar 
gum to provide sustained release of Diltiazem, whether used alone or 
mixed with smaller amounts of other hydrophilic polymers, was 
comparable to that of commercial slow release Diltiazem tablets, with little 
effect caused by the change of gum batch or dissolution hydrodynamics 
(Altaf et al 1998). 
 
Krishnaiah et al studied the use of Guar Gum matrix tablets in sustaining 
the release of the highly water soluble model drug Metoprolol tartrate. 
They reported that normal matrix tablets failed to sustain the release of 
the drug. However, a developed three layered Guar Gum matrix tablet 
with two drug free layers on the outer part provided sustained drug 
release which was not affected by storage (Krishnaiah et al 2001). 
 
Locust Bean Gum is another Galactomannan obtained from the fruit 
seeds of the Locust or Carob tree, (Lawrence 1973). Uner et al (2004) 
investigated the release of Theophylline from matrix tablets prepared with 
honey locust bean gum. They showed that there was no difference in 
drug release between commercial tablets and those prepared using 
honey Locust Bean Gum which maintained a zero-order release process.  
When compared with other gums in the preparation of mini-matrices, 
locust been gum showed an ability in sustaining drug release similar to 
Xanthan and Karaya gums (Sujja-Areevath et al 1996). However it had a 
higher rate of erosion compared to the other gums (Sujja-Areevath et al 
1998). 
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1.1.3.1.3. Chitosan: 
Chitosan is a de-acetylation derivative of chitin which is a natural polymer 
found in crab and shrimp shells. (Bhardwaj et al 2000). Several works 
have studied the combination of Chitosan with other hydrophilic polymers. 
Hasan et al (2003) demonstrated the ability of a combined polymer 
mixture of Chitosan with Alginate in sustaining the release of the drug 
Metoclopramide both in vitro and in vivo.  When comparing different 
polymer mixtures, a Chitosan Alginate mixture was better in sustaining 
the release of the drug Diltiazem Hydrochloride than a Chitosan 
Carrageenan mixture (Tapia et al 2004). 
 
The ability of Chitosan to form various salts has also been examined. An 
acetate salt derivative of Chitosan prepared by spray drying 
demonstrated its ability to sustain the release of Theophyline when used 
as a binder in tablets at a concentration of 3 % w/w (Nunthaid et al 2004). 
 
 
1.1.3.1.4. Sodium Alginate: 
Alginates are hydrophilic polymers obtained from Alginic Acid which is a 
phyco-colloid found in brown algae (Lawrence 1973). Guinchedi et al 
(2000) studied the ability of alginate in retarding the release of 
Ketoprofen. They found that matrices prepared with alginate alone, or in 
combination with HPMC were able to sustain the release of the drug 
Ketoprofen.  However, alginate based systems are highly affected by 
crosslinking agents. Incorporation of calcium gluconate into the matrices 
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prepared by Guinchedi et al (2000) reduced the ability of the matrices to 
retard drug release. This was attributed to the cross-linking of alginate in 
the presence of the calcium ions and the effect this may have on the gel 
layer. Moreover, the soluble calcium ions have the ability to act as a 
channelling agent in the gel layer and thus increase the porosity of the 
matrix. 
 
When compared with Carbopol which is a highly cross linked polymer, the 
linear alginate showed less ability in sustaining the release of the drug 
Furosemide. This was explained by the different drug release behaviour 
of the two polymers in aqueous media; drug release from alginate was 
mainly through polymer erosion and polymer dissolution, whereas 
Carbopol had a combined diffusion and polymer relaxation mechanism. 
(Eftekanis et al 2000) 
 
Opposing effects of the pH of the dissolution medium on the release of 
water soluble and poorly soluble drugs were reported by Hodsdon et al 
(1995); a faster release of Chlorpheniramine Maleate, which is a water 
soluble drug, from alginate matrices occurred in simulated gastric fluid 
when compared to simulated intestinal fluid. An opposing effect occurred 
with the poorly soluble drug Hydrochlorthiazide. The previous effect was 
attributed to the different natures of the gel layer within the different 
media. Moreover, and as mentioned previously, the change in drug 
solubility causes a change in the mechanism mainly responsible for its 
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release. Thus, the change in the properties of the gel layer may have 
varying effects on drugs with varying solubility. 
 
 
1.1.3.1.5. Other natural polysaccharides: 
Other natural gums and polysaccharides that have been studied as 
carriers in hydrophilic matrix systems include Karaya Gum (Sujja-
Areevath et al 1996, Sujja-Areevath et al 1998, Munday and Cox 2000),  
Khaya gum ( Odeko et al 2004) and tamarind seed polysaccharide 
(Sumathi et al 2002). 
 
 
1.1.3.2. Synthetic and modified polymers: 
1.1.3.2.1. Cellulose ethers: 
Cellulose ethers are widely used in the preparation of hydrophilic matrix 
dosage forms, and Hydroxypropyl Methylcellulose (HPMC) could be 
considered the most used matrix former for hydrophilic matrix systems. A 
large amount of literature dealt with the properties of these polymers and 
evaluated their ability as hydrophilic matrices.  
 
The different types of cellulose ethers seem to differ in their hydration 
behaviour upon contact with water, and hence produce matrix systems 
with differing nature. Ferrero Rodriguez et al (2000) compared the 
swelling and drug release properties associated with tablets containing 
different cellulose ethers. They reported several differences between the 
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various polymer types; for example erosion of the polymer was only high 
with Hydroxyethyl Cellulose (HEC) which may contribute significantly to 
drug release, whereas from Methylcellulose matrices drug release was 
mainly through diffusion. Drug release from matrices containing other 
cellulose ethers was due to a combination of diffusion and erosion. When 
comparing Hydroxypropyl Cellulose (HPC) and Hydroxyethyl Cellulose 
(HEC), Roy et al (2002) found that HEC matrices had a higher degree of 
swelling and erosion than HPC matrices. The release of the water soluble 
drug Chloropheniramine Maleate was through diffusion and matrix 
swelling, whereas for HPC matrices it primarily occurred by diffusion 
through the gel layer. 
 
Vueba et al (2004) compared the ability of different cellulose ethers in 
modifying the release of Ketoprofen from matrix tablets. They reported 
that Methylcellulose and Hydroxypropyl Cellulose were not able to sustain 
the release of the drug, whereas HPMC was able to do so. When 
comparing the drug release mechanism and rate, they found that 
changing the type of the polymer did not affect the mechanism of drug 
release, but tablets formulated using HPMC gave the highest mean 
dissolution time for Ketoprofen.  
 
 
1.1.3.2.2. Other synthetic polymers: 
Other synthetic polymers have also been studied and used successfully 
in the preparation of hydrophilic matrix systems, and they include 
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Carbomer (Perez-Macros et al 1991), and Polyethylene Oxides (Kim 
1998, Maggi et al 2002). 
 
 
1.1.3.2.3. Modified starches: 
Several modified types of starch have been studied as polymers for 
modified drug release.  Retrograde starch was prepared by Wierik et al 
and it was able to retard the release of various drugs with differing 
physicochemical properties. Moreover the release of the drugs was not 
influenced by inclusion of a lubricant or by the activity of α-amylase in the 
dissolution medium (Te Wierik et al 1996, 1997a, 1997b). 
 
 
1.1.4. Sources of variation in the behaviour of hydrophilic matrix 
systems: 
The behaviour of hydrophilic matrix systems, and more precisely the 
process of drug release from such systems, may be easy to evaluate in 
terms of the underlying structural changes leading to it, and the main 
mechanisms responsible for drug release. However, the overall drug 
release process is a much more complicated process in which multiple 
factors are involved, and play varying roles in modulating the release 
process in terms of rate and pattern. Certain trends can be associated 
with some variables, but verifying specific effects for each variable is not 
a clear cut matter. This could be due to several causes, mainly the 
varying types of hydrophilic polymers utilised in the formulation of 
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hydrophilic matrix systems; each having different physicochemical 
properties from the others, and this, as will be seen shortly, is a major 
determinant of the degree and nature by which several factors present 
themselves.  
 
Another cause of such complexity observed in the behaviour of 
hydrophilic matrix systems arises from the interference of the effects 
associated with the various factors influencing the processes of polymer 
hydration and drug release. In the following section, a review of the main 
variables affecting the behaviour of hydrophilic matrix dosage forms is 
presented.  
 
1.1.4.1. Formulation ingredients: 
1.1.4.1.1. Drug: 
The properties of the drug incorporated into hydrophilic matrix systems 
have a great effect on the behaviour and properties of such systems. 
Drug properties were reported to have a major effect on matrix swelling 
and subsequently on the release characteristics of the drug itself. 
 Drug solubility, as mentioned previously, is a major determinant of the 
drug release mechanism. It also has an effect on the rate by which the 
drug is released from the system; the rate of drug release from 
hydrophilic matrix dosage forms is reported to be higher for drugs with 
higher aqueous solubility (Lapidus and Lordi 1968, Colombo et al 1995, 
Yang and Fassihi 1997, Zuleger and Lippold 2001). This is probably due 
to higher dissolution rate of such drugs upon contact with the penetrating 
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water which causes the formation of a concentration gradient that 
enhances the release of the drug out of the system. As the aqueous 
solubility of the drug decreases, the release rate of the drug is also 
decreased, (Colombo et al 1995) and this in turn could be due to slow 
dissolution of the drug which may decrease the driving concentration 
gradient. With further decrease in drug solubility, the ingress of water into 
the matrix causes the hydration of the polymer with minimal drug 
dissolution, causing the suspension of the un-dissolved drug particles in 
the swollen gel layer which are released into the surrounding medium 
when polymer erosion is initiated at the erosion front after sufficient 
polymer hydration takes place. (Kim 1998). Kim studied the effect of drug 
solubility on drug release from PEO tablets, and he reported slower 
release of the drug Sulfathiazol compared with other drugs with higher 
water solubility. The release profile of Sulfathiazole was sigmoidal in 
shape indicating the presence of a lag time before drug release is 
enhanced. (Kim 1998). Such results come in accordance with earlier 
similar results reported by Ford et al (1985b) for the drug Indomethacine 
using HPMC matrices. 
 
Drug solubility could also lead to variation in the release behavior with 
time, through affecting the properties of the formed gel layer.  Bettini et al 
(2001) monitored this aspect in HPMC matrices using the three model 
drugs Buflomedil Pyridoxalphaosphate (BPP), Sodium Diclofenac (DCN) 
and Nitrofurantion (NTF), with decreasing aqueous solubility respectively. 
They reported that initial drug release rate was directly related to drug 
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solubility. However they also report acceleration of the release of DCN 
after full hydration of the matrix core, and this effect was also observed 
and more pronounced with NTF which is the least soluble. The change in 
drug release rate was also coupled with complete disintegration of the 
matrices containing the less soluble drugs within the dissolution medium, 
and this was justified by the process of polymer relaxation which caused 
the dragging of the un-dissolved particles of the less soluble drugs 
towards the outer region of the gel layer causing a reduction in their 
diffusion path and at the same time weakening of the gel layer. Ferrero-
Rodriguez et al (2000) reported similar results with matrices formed using 
cellulose ethers. 
 
Another factor exerting an effect on matrix behaviour and drug release is 
the content of the drug; an increase in the release rate of the drug was 
reported with the increase in its content (Yang and Fassihi 1997). Similar 
results were also reported for matrices in which erosion is the 
predominant factor affecting drug release (Zuleger and Lippold 2001),   
 
The reduction of drug particle size is usually associated with better 
hydration and dissolution of the drug. However, various trends were 
reported regarding the effect of drug particle size on drug release 
patterns from hydrophilic matrix dosage forms. In HPMC matrices 
containing two model drugs; Propranolol Hydrochloride and 
Aminophylline, changing the particle size of the model drugs did not have 
any significant effect on drug release (Ford et al 1985a). In HPMC 
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matrices containing the drug Oxazepam, increasing the drug particle size 
while keeping a constant drug to polymer ratio, caused a decrease in its 
dissolution rate and a shift towards erosion mediated drug release (Tros 
de llarduya et al 1997). However, when examining this factor in tamarind 
seed matrices containing caffeine, the increase in drug release was 
manifested at higher size ranges only and this was attributed to the 
increase in the porosity of the matrix (Sumathi et al 2003). Such 
variations in the effect associated with drug particle size could be highly 
correlated with other factors such as the solubility of the drug itself, or the 
properties of the hydrophilic polymer utilised in the formulation, and also 
the properties of other formulation ingredients used. 
 
Fu et al (2003) studied the influence of drug molecular properties; they 
compared matrix systems containing four water soluble drugs with 
different molecular volumes and they observed an exponential 
relationship between the diffusion coefficients of the drugs and their 
molecular volumes in which drugs with smaller molecular volumes had 
higher diffusion coefficients. 
 
 
1.1.4.1.2. Hydrophilic polymer: 
The role of the polymer in hydrophilic matrix systems is the formation of 
the gel layer on the outer surface of the dosage form upon contact with 
an aqueous medium. As discussed previously, drug release is achieved 
mainly by diffusion through this gel layer or through erosion of the 
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hydrated polymer chains at the outer surface of the gel layer. Thus, the 
properties of the polymer would have a major effect on the structure of 
the gel layer and subsequently on the process of drug release. 
 
In addition to the type of polymer used in the formulation of hydrophilic 
matrix systems which have been shown to be a major determinant of the 
behaviour of such systems, other polymer related variables have been 
examined. 
 
Decreasing the content of the polymer in the formulation lead to an 
increase in the drug release rate (Huber et al 1966). However, increasing 
the polymer content in the matrix system was reported to cause the 
formation of a thicker gel layer and hence decrease the release rate of 
water soluble drugs due to increased diffusion pathway (Rekhi et al 1999, 
Sujja-Areevath et al 1996). The release rate of water insoluble drugs was 
also reported to decrease with increasing polymer content (Xu and 
Sunada 1995, Talukdar et al 1998) and this could be explained by the 
formation of a stronger gel layer that resists erosion. 
 
Several studies reported the significant influence of polymer particle size 
on the performance of hydrophilic matrix dosage forms; for Xanthan Gum 
tablets, decreasing the particle size of the polymer resulted in a more 
sustained release. This was noted with both water soluble and sparingly 
soluble drugs (Dhopenshwarkar and Zats 1993). Such behaviour could 
be attributed to the ability of the fine polymer particle to rapidly hydrate, 
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forming a dense gel layer. On the other hand, coarse fractions of polymer 
particles resulted in tablet breakage due to their inability to hydrate 
quickly and form a robust gel layer upon contact with water 
(Dhopenshwarkar and Zats 1993). Similar results were observed with 
HPMC tablets in which drug release increased with increasing polymer 
particle size (Campus-Aldrete and Villafuerte-Robles 1997, Velasco et al 
1999).  
 
Another aspect affected by polymer particle size is the very initial phase 
of drug release; the lag time before drug release is decreased with 
increasing polymer particle size, and for HPMC matrices no lag time was 
observed for tablets made with particle size fraction of 150-250 µm, 
whereas smaller size fractions were able to induce lag time and decrease 
the burst effect. This was attributed to the fast formation of a gel layer by 
the rapidly swelling of small particles. (Campus-Aldrete and Villafuerte-
Robles 1997) 
 
However, the effect of polymer particle size is highly correlated with the 
content of the polymer in the formula; its significance is more evident at 
lower polymer content. Whereas higher polymer content may obscure the 
effect of particle size (Campus-Aldrete and Villafuerte-Robles 1997, Heng 
et al 2001). In their study, Heng et al (2001) monitored this phenomenon 
in HPMC tablets and they reported that when the polymer content was 
less than 5 %, rapid drug release occurred with all size fractions. At 
higher polymer content, increased drug release was only apparent with 
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larger size fractions, and when the polymer content was higher than 20 % 
the difference between various particle size fractions was less evident. 
 
For polymers having several viscosity grades, as is the case with 
cellulose ethers and other synthetic polymers like Polyethylene Oxides, 
this variable could also influence the behaviour of the dosage form into 
which they are formulated. Studies showed that increasing the viscosity 
grade of the polymer resulted in an increase in the swelling ability of the 
polymer molecules and hence decreased drug release rate.(Campus-
Aldrete and Villafuerte-Robles 1997, Lee et al; 1999, Katzhendler et al 
2000). 
 
 
1.1.4.1.3. Diluents: 
Diluents or fillers are of great importance in the formulation of 
pharmaceutical tablets due to the multiple advantages they present, 
starting from increasing the bulk of the formula, modifying the physical 
properties of the products, and modifying the behaviour of the system in 
terms of drug release.  A substantial amount of literature is available 
about the effect of different diluents on the behaviour of hydrophilic matrix 
dosage forms. Two main variables related to such materials are their 
content and physicochemical nature. Various, and sometimes different, 
observations have been reported about the effect of such variables on the 
behaviour of hydrophilic matrix dosage forms, which proves, once more, 
the complexity of such systems. 
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Lapidus and Lordi reported an increase in drug dissolution rate when 
replacing some of the polymer with either soluble or insoluble diluents. 
They also reported that only at higher diluent content it was possible to 
differentiate between the effect of water soluble and insoluble ones 
(Lapidus and Lordi 1966, 1968). In a similar study Ford et al (1987) 
compared the effect of two diluents on the release of Promethazine HCl 
from HPMC matrices, namely soluble spray dried lactose and insoluble 
calcium phosphate, and they observed that replacing part of the polymer 
with either diluent increased the release rate of the drug, but diffusion 
remained as the major release mechanism. Moreover, they reported that 
the difference between the effects of the two diluents was only possible 
when they are incorporated at high levels, where the effect of spray dried 
lactose on drug release was more apparent than that of calcium 
phosphate. 
 
Sujja-Areevath et al (1996) examined the effect of diluent solubility on the 
release of Diclofenac Sodium from mini-matrices containing different 
natural gums. They reported that increasing the content of diluent in the 
formulation resulted in an increase in drug release. Furthermore, drug 
release pattern shifted more towards erosion than diffusion. They also 
report that the solubility of the diluent had no significant effect on its 
effect. Somewhat different results were observed by Cox et al (1999) with 
Xanthan Gum mini-matrices containing the drug Ibuprofen. They 
examined the effect of inclusion of various diluents, namely spray dried 
lactose, microcrystalline cellulose (Avicel®) and Dibasic Calcium 
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Phosphate Dihydrate (Emcompress®). They reported that the different 
diluents had different effects on the release of Ibuprofen from the mini-
matrices; little difference was seen in drug release between matrices 
containing spray dried lactose and Emcompress®. However, matrices 
containing Avicel® exhibited higher drug release and this was attributed to 
the disintegration enhancing effect of Avicel®, and its influence on the 
integrity on the matrix and hence on drug release (Cox et al 1999). 
 
The effect of manipulating the polymer to diluent ratio was also examined, 
and studies were undertaken on Carbopol matrices using lactose, 
microcrystalline cellulose (MCC) and starch as diluents. Results 
demonstrated that all diluents enhanced the release of Ibuprofen when 
incorporated into the matrices. However, the effect of the different 
diluents varied in its degree; it was highest for starch, which was reported 
to exert an “explosion effect”, followed by MCC and then lactose. 
Moreover, increasing the polymer content seemed to have a more drastic 
effect on the ability of lactose to enhance drug release than that of the 
two other diluents. (Khan et al 1998, 1999).   
 
Upon comparison of the results reported by various studies, it becomes 
evident that careful deductions should be made. This is due to the high 
complexity and correlation between the variables associated with the 
various diluents, and those associated with other formulation ingredients, 
such as the solubility of the drug. Moreover, the chemical and 
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hydrodynamic properties associated with the dissolution environment 
could have significant effects on matrix hydration and drug dissolution. 
                                 
1.1.4.1.4. Lubricants and glidants: 
Several workers examined the effect of adding various lubricants and 
glidants on the behaviour of hydrophilic matrix tablets and especially on 
the process of drug release. Once again, varying results were reported; 
Sheskey et al (1995) reported that changing the level of Magnesium 
Stearate from 2.0 % to 0.2% in HPMC 2208 tablets resulted in the 
production of tablets with higher crushing strength. However, neither the 
level of the Magnesium Stearate, nor the mixing time had a significant 
effect on drug release. Similar results were reported by Gupta et al (2001) 
with Carrageenan matrices. They reported that Magnesium Stearate 
(0.5%) and Stearic Acid (1%) had no significant effect on the release rate 
of Theophylline from the tablets. However, Magnesium Stearate at a level 
of 1% significantly slowed down the release of Theophylline after 4.5 h. 
 
The effect of added lubricants is in turn influenced by the type of polymer 
used; Lee et al (1999) reported opposing results of the effect of the 
hydrophobic lubricant, Magnesium Stearate on drug release from tablets 
containing HPMC of different grades.  
 
From this, and other previously mentioned examples, one could see that 
the overall formulation rather than a single ingredient is the most 
significant factor in determining the behaviour of the system. 
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1.1.4.1.5. Interactions between formulation ingredients: 
Potential ionic interactions between the various formulation ingredients, 
incorporated into hydrophilic as well as other matrix systems, could have 
a profound effect on the behaviour of such systems and on the 
dissolution patterns associated with them.  
 
The occurrence of ionic interactions between formulation ingredients has 
been utilised to manipulate the dissolution of drugs from matrix systems. 
One of the reported methods depends on the incorporation of ionic 
surfactants into the formulation. Such surfactants have the ability to 
interact with oppositely charged drugs and thus retard the process of drug 
release from the matrix systems. Several workers have focused on this 
technique and among the surfactants investigated is the anionic 
surfactant Sodium Lauryl Sulfate (SLS) which was shown to retard the 
release of the cationic drug Chlorpheniramine Maleate from HPMC 
matrices (Feely and Davis 1988, Daly et al 1984). The release of the 
cationic drug Propranolol Hydrochloride from HPMC-Eudragit matrices 
was also reduced by the addition of the anionic Sodium Lauryl Sulphate, 
with little effect noted with the addition of the cationic surfactant Cetyl 
Trimethyl Ammonium Bromide (CTAB). However, incorporation of the 
cationic CTAB into matrices containing the anionic SLS resulted in faster 
drug release and this was explained by the interaction of the two 
oppositely charged surfactants (Nokhodchi et al 2002). 
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However, some of the most studied interactions are those occurring 
between ionic polymers and oppositely charged drugs. Such interactions 
occur between oppositely charged moieties in the structure of the 
polymer and drug. Such ionic interactions have been studied and 
attempts have been made to employ their occurrence in modifying the 
behaviour of matrix systems, more precisely the process of drug release 
from them. Several ionic polymers have been investigated. The ionic 
interaction of the anionic Lambda Carrageenen with cationic drugs, 
mainly Diltiazem Hydrochloride has been examined and compared with 
other drugs. Moreover, the physicochemical, tabletting, and dissolution 
properties of the resulting ionic complex between the drug and polymer 
were examined (Bonferroni et al, 2000a, 2000b, 2004, Aguzzi et al 2002). 
This polymer was able to modify the release of other cationic drugs from 
its matrices including Salbutamol Sulfate and Chlorpheniramine Maleate 
(Bonferoni et al 1993, 1994, 1998).  
 
Other anionic polymers were also shown to be able to retard the release 
of oppositely charged drugs from their matrices including the retarding 
influence of Carbopol 934P on the release of Verapamil Hydrochloride 
through the ionic interaction between the carboxylic groups of the 
polymer and the tertiary amine groups of the drug (Elkheshen 2001), The 
cationic polymer Chitosan was also investigated, and it was shown to be 
able to retard the release of the anionic drug Salicylic Acid when 
incorporated into its films, through ionic interaction (Puttipipatkhachorn et 
al 2001).  
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Takka et al (2001) Showed that changing the type of the anionic polymer 
incorporated into HPMC matrices had a marked effect on the release of 
the cationic drug Propranolol Hydrochloride in different dissolution media. 
In a later study Takka (2003) explained that the previously noted change 
in drug release behaviour with the change in the type of the anionic 
polymer resulted from the change in the ionic interaction potential 
between the drug and the various polymers. 
 
It could thus be seen that the occurrence of ionic interactions between the 
different materials incorporated into hydrophilic matrix systems, mainly 
between the ionic polymers and oppositely charged drugs, could actually 
be regarded as an advantageous point in the development and 
manipulation of hydrophilic matrix dosage forms. 
 
 
1.1.4.2. Dosage form: 
The shape properties of dosage forms based on hydrophilic matrix 
systems is one of the major factors affecting the behaviour of such 
dosage forms. This will be discussed in detail in the next section. 
However, other variables associated with the nature and with the 
production of such dosage forms have been examined in terms of their 
effect on the behaviour of hydrophilic matrix systems. 
 
The compression force used in the production of tablets seems to exert 
an effect on the initial phase of drug release; Huber et al (1968) reported 
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that tablets made at various compression force levels did not exhibit 
significantly different release patterns.  HPMC tablets produced at lower 
compression force values exhibit a more apparent burst effect in terms of 
drug release. However, after swelling of the tablet, the reported results 
show no difference between tablets made at different compression force 
values (Kabanda et al 1994). Similar results were demonstrated by Rizk 
et al (1994) for matrix tablets formulated with the polymer Scleroglucan. 
They reported that the compression force which decreases tablet porosity 
has little effect on drug release. 
 
The storage conditions of matrix tablets seem to have minor effect on 
their ability to sustain drug release. For Carrageenan tablets, their ability 
to sustain the release of Theophylline was not affected by three months 
storage at 37°C and a humidity of 75% (Gupta et al 2001). 
 
 
1.1.5. Importance of the dosage form shape in matrix systems: 
Properties associated with the shape of dosage forms based on 
hydrophilic matrix systems seem to have a significant effect on the 
behaviour of such dosage forms, mainly on the process of drug release. 
 
Several studies examined the effect of the geometric shape of the dosage 
form on drug release. Cobby et al (1974a, 1974b) made some 
investigation into the effect of varying tablet shape on drug release from 
insoluble matrices. They developed an equation describing the 
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dissolution kinetics of drugs from slow release matrix systems based on 
previous work by Higuchi (1963), taking into account what they called 
“shape factors” of the tablets (Equation 1.1.).  
 
ft = G1 Krt
1/2 – G2(Krt
1/2)2 + G3(Krt
1/2)3                                          Equation 1.1. 
 
where ft is the fraction of drug released from the matrix at time t, G1, G2, 
and G3  are factors based on the shape of the tablet undergoing 
dissolution, and Kr is a rate constant describing the process of drug 
release from such tablets, which is calculated using equation 1.2. 
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where A  is the total weight of drug in the tablets, r0 is the initial radius of 
the tablet, D is the drug diffusion coefficient in the dissolution medium, ε 
and τ are the porosity and turtuosity of the matrix, respectively, and Cs is 
the solubility of the drug in the dissolution medium.  
 
The values of the three shape factors were reported for spherical, 
cylindrical and biconvex tablets, and it was noted that for the spherical 
and cylindrical tablets the values of the three shape factors are constant 
and could be obtained from the initial dimensions of the dry tablets prior 
to dissolution. On the other hand, there is time dependent variation in the 
values of the three shape factors for biconvex tablets. 
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Subsequent experimental results showed that actual experimental drug 
release rates varied clearly with varying tablet shapes between cylindrical 
and biconvex, with the lower release being for biconvex tablets. However, 
no significant differences were noted between tablets with different 
shapes with regards to the drug release constants obtained from fitting 
the data to the proposed equation (Cobby et al 1974a, 1974b). 
 
The actual implementation of such equations for the investigation of the 
drug release process from matrix tablets, including hydrophilic ones, 
should always take into account the influence of other hydration-
associated phenomenon on the overall drug release process; processes 
affecting the integrity of the system during its dissolution like crack 
formation due to the relaxation of stresses formed within the tablets 
during the manufacturing process could enhance the drug release rate 
and cause considerable deviations from the theoretical outcomes. 
 
Karasulu et al (2000, 2002) studied the release of Theophylline from 
HPMC tablets of different geometric shapes namely triangular, cylindrical 
and half spherical tablets and they compared the rate of drug release 
from the various tablets using the Higuchi model. They reported that the 
highest drug release rate was observed with the triangular tablets 
followed by the cylindrical ones and then the half-spherical.  
 
The effect of tablet surface area on drug release has also been 
examined, and results obtained with flat HPMC tablets of varying radius 
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and convex tablets demonstrated that drug release rate was directly 
proportional to tablet surface area, and it was concluded that maximum 
control of drug release could be obtained when tablets are nearest to the 
spherical shape (Ford et al 1987).   Siepmann et al (2000) studied several 
variables associated with cylindrical matrix tablets in terms of their effect 
on the release of Propranolol HCl and Chlopheniramine HCl from such 
tablets, and they reported that both varying the half height and radius of 
the cylinder had an effect on drug release. However, increasing the 
radius of the cylinder had a much more pronounced effect on the release 
of the drugs than increasing the half height of the cylinder and this was 
explained by the variation in the surface area of the cylinder and more 
precisely the surface area to volume ratio, which was more affected by 
changes in the radius than the half height of the cylinder. 
 
In an extension of the previously mentioned work of Siepmann et al. 
Reynolds et al (2002) examined the effect of surface area to volume ratio 
on the release of three model soluble drugs from  HPMC tablets made of 
different shapes, namely oval, round concave flat-faced bevelled edge, 
and flat faced round tablets,  and they reported that surface area to 
volume ratio was more significant in controlling and predicting the release 
of the drugs from various tablets, they found that drug release from 
tablets with similar surface area to volume ratio was similar whether in 
tablets made of the same shape or among tablets of different shapes, 
whereas, tablets having similar surface areas but different surface area to 
volume ratios exhibited different drug release rates. Recently, similar 
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results were reported by Parojcic et al (2004) for tablets made with 
Carbopol; they found that tablet diameter is the major shape variable 
affecting drug release from the tablets, but for tablets manufactured with 
different heights or of different shapes, the relative surface area, which is 
the same as the previously mentioned surface area to volume ratio, could 
be more helpful in terms of comparison. 
 
Other trends in increasing the area available for hydration have also been 
addressed for various tablet shapes. Ertan et al (1997) studied the effect 
of varying the surface area on the release of drug from a cylindrical 
implant. They adopted techniques such as coating and introduction of 
varying number of holes into the structure of the tablet, they reported that 
increasing the surface area available for hydration led to an increase in 
drug release. Similar results were observed by Cheng et al (1999) using 
donut-shaped HPMC tablets with varying number of holes. 
 
 
1.1.6. Methods used in the evaluation of hydrophilic matrix dosage 
forms: 
Due to the importance of the changes taking place within hydrophilic 
matrix dosage forms that are responsible for sustaining drug release, in 
vitro techniques have been developed to evaluate such dosage forms. 
Such techniques have focused primarily on studying the nature of 
structural changes and correlate them either qualitatively and 
quantitatively with the process of drug release. 
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Several techniques have been used to monitor the in vitro behaviour of 
hydrophilic matrix dosage forms, ranging from simple visual and imaging 
techniques to more sophisticated ones utilising modern microscopic, and 
non invasive methods. The following are some of the major techniques 
successfully employed in the investigation of hydrophilic matrix systems. 
 
 
1.1.6.1. Macroscopic swelling studies: 
Monitoring the extent of dimensional changes occurring within hydrophilic 
matrix systems is a major method utilised in the evaluation of, and 
comparison between various formulations and dosage forms. This is 
particularly important as such changes are usually highly correlated with 
the hydration patterns associated with hydrophilic matrix systems. 
 
Simple methods in which visual monitoring of the expansion of the 
hydrophilic matrix dosage form takes place have been reported by 
several authors. The simplest of such methods depend on monitoring the 
expansion behaviour of matrix tablets upon placement in a hydration 
medium (Sujja-Areevath et al 1998, Talukdar et al 1995 , Parakh et al 
2003). 
 
For monitoring the swelling in the axial dimension, Panomusk et al (1995) 
developed a method in which a hydrophilic matrix tablet is placed in a test 
tube containing the hydration medium in a way that allows a single face of 
the tablet to be hydrated and hence swell. The increase in tablet height is 
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measured directly. One drawback of such method is the limited hydration 
and hindered swelling of the tablet. Talukdar et al (1995) used a dial 
indicator to measure the axial swelling of a tablet. However, they report 
that the weight of the indicator may impede the axial expansion of the 
tablet. 
 
The use of photographic methods has also been reported for monitoring 
the swelling of hydrophilic matrix dosage forms. In their study, Sujja-
Areevath et al (1998) used simple photography to monitor the axial 
swelling of matrix tablets. 
 
Using photography to investigate the internal changes within a hydrating 
tablet in addition to the overall swelling is also possible. In a series of 
studies, Colombo et al developed a method in which a hydrophilic matrix 
tablet is placed between two plexiglass slides, thus allowing only radial 
water ingress and swelling to take place when introduced into a 
dissolution medium. This method enabled them to evaluate radial 
swelling, and also the movement of the various fronts within the hydrating 
tablet. To obtain clearer results, they incorporated a coloured drug into 
the matrix tablet which allowed better identification of the various regions 
inside the hydrating tablet (Colombo et al 1995, 1996, 1999). 
 
Image capture and analysis systems have also been used successfully in 
monitoring the swelling of hydrophilic matrix dosage forms. Moussa et al 
used a method in which matrix tablets were placed in the hydrating 
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solution at a constant temperature, and at various time intervals a tablet 
was transferred to an image analysis apparatus in which the radial 
swelling is recorded directly and the axial after cutting the tablet into half. 
By using a source of light placed underneath the tablet, they were able to 
monitor the water concentration gradient across the tablet depending on 
the difference in the intensity of light transmitted through the various 
regions of the tablet (Moussa et al 1996, 1998). A similar method was 
used by Maggi et al to study the swelling of tablets made with different 
Polyethylene Oxides. They used a photographic camera with a 
microscope to take images of hydrating tablets after cutting, and the 
images where analysed with an image analysis software to measure the 
dimensions of the tablet and the gel layer (Maggi et al 2002). One major 
drawback of such techniques is the lack of live in situ measurements; the 
removal of the tablet from the hydration medium could alter the structure 
of the outer tablet surface. This problem was overcome in the method 
developed by Gao and Meury (1996) in which they used an image 
capture and analysis system to obtain live in situ images of hydrating 
tablets placed within a stirred medium. Samples from the medium were 
also withdrawn to study the release of drug from the tablet at various time 
intervals. However, it may be difficult to compare the results of such a 
method with of the studies due to the temperature at which the tablets 
were hydrated which is 22º Celsius. 
 
Other techniques focused on live monitoring of the swelling of hydrophilic 
matrix tablets in situ. Quintanar-Guerrero et al (1999) developed a system 
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in which the tablet was placed in a stirred hydrating medium kept at 37º 
Celsius through a peristaltic pump. They monitored the swelling of the 
tablet by placing the hydration vessel on top of a projector and projecting 
the image of the swelling of the tablet on a wall, they also used still 
photography to obtain images of the swelling tablet. 
 
Studying the dimensional changes occurring within a hydrating matrix 
dosage form enabled researchers to compare between various 
formulations through monitoring. Other methods described in the 
literature investigated matrix swelling in terms of weight changes 
occurring within the hydrating dosage form (Parakh et al 2003, Desai and 
Kumar 2004). 
 
However, emphasis should be made that the process of weight change is 
not caused by water uptake only. It is a net process arising from several 
contributing factors, mainly water ingress into the dosage form, and a 
number of counteracting processes, namely the erosion of the polymer, 
and the release of the drug and other formulation ingredients. Thus 
consideration should be given to both the wet weight of the tablet and its 
weight after drying.  
 
Recently, Baloglu et al (2004) investigated a new method for monitoring 
the swelling of hydrophilic matrix bioadhesive tablets using a technique 
based on spectrocolorimetry. Their method is based on the gradual 
change in the colour of hydrophilic matrix tablets during the hydration 
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process. One limitation of such technique might lie in the different 
properties of various formulations in terms of the extent and nature of 
colour change. This may limit the applicability of such system in the 
comparison between different formulations. 
 
 
1.1.6.2. Microscopic studies: 
Several microscopic techniques have been adapted and used to 
investigate the behaviour of hydrophilic matrix dosage forms. Such 
techniques enabled more insight into the behaviour of such dosage 
forms, through enabling the visualisation, and monitoring of structural 
changes, and movements taking place within the dosage form. This had 
particular advantage for investigating the hydrated gel layer. 
 
Simple light microscopy was used to compare the thickness of the gel 
layer formed on the radial faces of hydrating slabs formulated with 
different polymers. Such method had the advantage of avoiding the 
swelling restrictions applied by the previously mentioned plexiglass 
method. However, the gel layer formed on the axial face of the slabs had 
to be removed to obtain a clear picture using the microscope. Such 
manipulation may give rise to significant alterations in the actual structure 
of the gel layer (Zuleger et al 2002). 
 
Scanning electron microscopy (SEM) has been employed successfully in 
the study of hydrophilic matrix dosage forms. In their investigation of the 
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deferring behaviour of sodium alginate matrices when placed in simulated 
gastric fluid or simulated intestinal fluid, Hodsdon et al (1995) used 
cryogenic scanning electron microscopy. The results obtained with this 
technique revealed a difference in the nature of the gel layer formed by 
such matrices in the different media; it was tough and porous in simulated 
gastric fluid and highly hydrated and continuous in simulated intestinal 
fluid. Moreover, the difference in the hydration pattern across the gel 
layer formed within simulated intestinal fluid was also observed; 
cryogenic scanning electron microscopy showed that it was extensive at 
the outer surface of the gel layer, whereas it was less extensive and less 
regular in the inner region of the gel layer. 
 
The source of gas bubbles, usually associated with the hydrated gel layer 
formed within hydrophilic matrix dosage forms, was investigated in 
Xanthan Gum and HPMC matrices using optical microscopy and 
cryogenic SEM which revealed their accumulation in the region near the 
interface between the core of the matrix and the rest of the gel layer 
(Melia et al 1993). 
 
Scanning electron microscopy was also used to study the interactions 
between the different ingredients of the hydrophilic matrix system. 
Katzhendler et al (1998, 2000) used Scanning electron microscopy to 
investigate the different release patterns of the drug Carmazipine from 
hydrophilic matrix systems formulated using HPMC or egg albumin. They 
revealed that the polymeric carriers had different effects on the crystalline 
                                                                                                     Chapter 1 
 68
properties of the drug within the hydrated gel layer of the tablet which led 
to different behaviour of the two matrix systems.  
 
Another technique that has been adapted to study hydrophilic matrix 
dosage forms in confocal laser scanning microscopy (CLSM). This 
technique presents several advantages over normal microscopic 
technique including the ability to visualise internal structural properties 
and changes within a system without the need to physically cutting it, and 
without interference from out of focus light which produces clearer images 
(White et al 2005). In the area of hydrophilic matrix dosage forms, several 
studies report the use of this microscopic technique. Alder et al (1999) 
tried to quantify the dimensional expansion of hydrophilic matrix tablets 
formulated with Xanthan Gum and HPMC by using CLSM. Cutts et al 
evaluated the diffusion of a fluorescent compound in a hydrating 
hydrophilic matrix through monitoring the rate and shape of recovery of a 
bleached florescent spot (Cutts et al 1996). The ingress of fluorescently 
labelled water into hydrophilic matrix tablets was also investigated using 
CLSM (Bajwa et al 2006). 
 
However, some limitations are encountered when using technique, 
namely the usual low penetration power of the used laser beam which 
could hinder its use in the investigation of whole tablet structures. 
Moreover, the possible interaction of the ionic fluorescent materials used 
in this technique with formulation ingredients within the matrix system 
may give rise to artefacts and unexpected behaviours. 
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1.1.6.3. Magnetic resonance studies: 
Nuclear magnetic resonance (NMR) and magnetic resonance imaging 
(MRI) are non-invasive techniques that have been used by several 
groups in an attempt to study various aspects of the behaviour of 
hydrophilic matrix systems. 
 
Rajabi-Siahboomi et al (1994) used NMR-imaging to probe the swelling of 
different varieties of HPMC, and this technique enabled them to monitor 
the expansion of both the forming gel layer and the core of the tablet, 
They reported that in terms of gel layer formation, the effect observed 
was the same in both the axial and radial directions. However, expansion 
of the tablet core was only observed in the axial direction. Moreover, they 
observed that the hydration of the edges of the tablets was more 
pronounced leading to the formation of a concaved gel layer. Similar 
results regarding the faster hydration of tablet edges were also reported 
by Botwell et al (1994). 
 
Fyfe et al (1997) compared the swelling of two matrix tablets with different 
thickness using NMR imaging and they found that the swelling behaviour 
was similar for both tablets during the initial hydration, but when the 
thinner tablet became fully hydrated it underwent faster swelling. 
 
Kojima et al (2002) used MRI to compare water mobility in matrices 
prepared using different ethyl cellulose derivatives, and they report that in 
all matrices the mobility of water is dependent upon the location within the 
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matrix system; on the outer surface water mobility was similar to that of 
free water whereas near the core of the tablet was highly restricted. MRI 
images also allowed the monitoring of dimensional changes within the 
hydrating tablets. When comparing the growth of the gel layer they found 
that it was different between the various cellulose ethers used with 
Hydroxypropyl Cellulose having the thickest gel layer. The reported 
observation of a water mobility gradient across the gel layer agrees with 
earlier results obtained by Rajabi-Siahboomi et al (1996) with HPMC 
matrices. 
 
 
1.1.6.4. Dissolution and erosion studies: 
In vitro dissolution studies form a major part in the evaluation of 
hydrophilic matrix dosage forms. Analysing the process of drug release 
from such dosage forms usually comprises the main aspect of 
comparison between various systems. 
 
Several dissolution techniques have been used in the evaluation of drug 
release from hydrophilic matrix dosage forms, each with its advantages 
and disadvantage. The USP paddle method is one of the predominant 
methods used, with various rotation speeds. This method could provide 
the advantage of unhindered swelling especially for larger dosage forms. 
However, its use with certain dosage forms is considered problematic by 
some studies, especially with sticking and floating dosage forms. This is 
due to the limited surface area, within the dosage form, that is available 
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for contact with the hydrating medium, and hence for drug release (Melia 
1991). 
 
The USP basket method has also been used in the evaluation of 
hydrophilic matrix dosage forms. However one main disadvantage of this 
method could arise when using larger dosage forms, and is due to the 
hindered swelling of the systems because of the limited size of the basket 
(Melia 1991). 
 
Monitoring the release of hydrophilic polymer from the dosage form 
through erosion studies is also of importance, especially with systems in 
which the erosion process is enhanced, or could contribute significantly in 
the process of drug release. Several studies have reported the use of 
erosion studies where the hydrophilic matrix dosage form is withdrawn 
from the dissolution medium at consecutive time intervals and the weight 
difference calculated after drying the dosage form is used in the 
evaluation of the erosion process (Sujja-Areevath et al 1998, Munday and 
Cox 2000). 
 
It becomes evident that each of the previously mentioned techniques 
presented certain advantages, and enabled the investigation of particular 
processes occurring within hydrophilic matrix system. Hence, the use of a 
combination rather than single methods would provide a clearer picture 
about the in-vitro behaviour of hydrophilic matrix systems, including 
tablets. 
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1.1.6.5. Methods used in the evaluation of the dissolution patterns 
from hydrophilic matrix dosage forms: 
Initial work by Higuchi (1963) intended to describe the release of drugs 
from planar matrix systems, and he produced a model ( Equation 1.3.) 
describing drug release from a planar system formed of a homogeneous 
matrix, assuming perfect sink conditions apply throughout the release 
process. 
 
Q= (D(2A-Cs)Cst)
1/2                                                                        Equation 1.3. 
 
where Q is the amount of drug released at time t per unit area of the 
planar  matrix system, A is the initial amount of drug in the system, Cs is 
the solubility of the drug in the penetrating medium and D is the diffusivity 
or diffusion constant of the drug in the matrix (polymer).  
 
A modified version of the previous equation is used to express drug 
release from granular matrices in order to accommodate for the 
difference in the effective diffusional path (Equation 1.4.): 
 
Q = (Dε/τ (2A – εCs) Cst)
1/2                                                                                    
Equation 1.4. 
 
where τ is the tortuosity factor of the system, and ε is the porosity of the 
system (Higuchi 1963).  
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From the previous two equations it is clear that modifying the release of a 
drug from a matrix system can be achieved through modifying several 
factors; the initial concentration of drug within matrix, the polymer forming 
the matrix system, the porosity and tortuosity of the matrix system and 
the solubility of the drug. 
 
A simple version of the Higuchi model (Equation 1.5.) is used by most 
studies: 
Q = k t1/2                                                                                                                               Equation 1.5. 
 
where K is the dissolution rate constant of the drug. 
  
 
 Korsmeyer et al (1983) introduced an exponential equation (Equation 
1.6.) describing the release of a solute from controlled release devices. 
 
Mt/M∞ = kt
n                                                                                                                         
Equation 1.6. 
 
where Mt   is the amount of drug released at time t, M∞  expresses the total 
amount of drug present in the device, k is a constant related to the 
properties of the system and the drug, and n is the “diffusional exponent” 
(Korsmeyer et al 1983).  
 
Peppas et al applied the previous equation to study the first 60% of drug 
release from various devices, and they reported that the value of n could 
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vary with the geometry of the controlled release device; for pure 
diffusional release (Fickian Diffusion) the value of n is 0.5, 0.45 and 0.43 
for thin films, cylinders and spheres respectively. When other 
mechanisms such as polymer relaxation are involved in the process of 
drug release (anomalous or non-Fickian drug transport) the value of n is 
increased until it reaches a value where drug transport is said to be of 
case II transport in which the major mechanism governing the transport 
process is polymer relaxation, and they reported different ranges for the 
value of n for different controlled devices shapes. (Peppas 1985, Ritger 
and Peppas 1987a, 1987b). 
 
In further development of their equation, and depending on the results 
they obtained which show that the value of n for case II drug release is 
about twice the value for pure Fickian diffusion, Peppas and Sahlin 
(1989) introduced a modified version of their previous formula with 
separate terms expressing the contribution of Fickian and relaxation 
processes (Equation 1.7.). 
 
Mt/M∞ = k1t
m +k2t
2m                                                                     Equation 1.7. 
 
The first term of the equation expresses the contribution of the Fickian 
diffusion process, whereas the second expresses the contribution of the 
relaxation process in drug transport.  k1 and k2 are constants related to 
the diffusion and relaxation processes respectively, and m is the Fickian 
diffusion exponent for a controlled release device of any shape. From this 
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equation the relative contribution of both mechanisms on the process of 
drug transport can be calculated according to the following equation 
(Equation 1.8.): 
 
R/F = (k2/k1) × t
m                                                                        Equation 1.8. 
 
where R and F are the percentage contributions of Relaxation and 
Fickian processes respectively (Peppas and Sahlin 1989). 
 
One major limitation associated with all of the previously mentioned 
model-dependent approaches, lies in the fact that they are mainly 
deducted from a limited portion of the drug release profile. Moreover, 
such models usually overlook the initial phase of drug release, the so 
called “burst effect” which could lead with some formulations to the 
release of a considerable amount of drug from the dosage form. 
 
Other published work has focused on studying the potential for model 
dependent approaches in the investigation of the hydration and erosion 
aspects of hydrophilic matrix systems. Tahara et al (1995) proposed two 
equations for the infiltration of the hydration medium into HPMC tablets, 
and the erosion of the matrix from such tablets. According to their results 
the ingress of the hydration medium into HPMC tablets could be 
described in terms of the square root law proposed by Higuchi according 
to equation 1.9.  
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Qw = k1 t 
1/2                                                                               Equation 1.9. 
 
where Qw is the percentage of the hydration medium in the matrix, k1 is a 
rate constant describing the infiltration of the hydration medium into the 
interspace of the tablet. 
 
On the other hand, the process of matrix erosion was described in terms 
of a qube root equation (Equation 1.10.). 
 
tk
W
W
i
d
2
3/1
1−=





                                                                       Equation 1.10. 
 
where Wi is the initial dry weight of the tablet, Wd is the dry weight of the 
tablet after immersion for a specified time in the hydration medium, and k2 
is a rate constant describing the erosion of the tablet. 
 
Siepmann and Peppas (2001) discussed the overall process of drug 
release from HPMC systems including polymer erosion from such 
systems. They stated that above a critical water concentration resulting 
from the ingress of the hydration medium into the system, polymer chains 
located at the surface of the system start to disentangle and diffuse into 
the surrounding hydration medium. Thus the process of erosion could be 
expressed in terms of polymer diffusion according to equation 1.11. 
 
Mpt = Mp0 - kdiss At t                                                                   Equation 1.11. 
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where Mpt and Mp0  are the weights of the dry matrix at time t and 0, 
respectively.  kdiss  is a rate constant describing the loss velocity of the 
polymer from the system, normalised to the surface area of the system at 
the specified time point which is At. 
 
One possible source for considerable deviations from such an equation is 
embedded in the formulation of hydrophilic matrix systems, which usually 
contain a number of materials in addition to the matrix forming polymer. 
The presence of such materials in the hydrated matrix, especially the 
ones with low solubility in the hydration medium, may affect the integrity 
of the overall hydrated matrix and enhance the erosion process even 
before the polymer chains reach their disentanglement concentration. 
 
  
1.2. Influence of tablet face curvature on the properties of 
pharmaceutical tablets: 
Tablets continue to constitute a major part of available pharmaceutical 
dosage forms as they present several advantages over other 
pharmaceutical dosage forms, mainly the ease of their production which 
is accompanied by the ability to control the stability, amount, and 
properties of the active ingredients incorporated in them. Moreover, 
tablets could be produced using a variety of techniques, and they offer an 
easy and safe manner for drug delivery (Alderborn 2002). Tablets are 
available in a variety of shapes for multiple reasons associated with 
manufacturing, identification and ease of use. The majority of available 
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tablets are round or capsule shaped with varying degree of face 
curvature.  
 
The introduction of a certain degree of face curvature to pharmaceutical 
tablets could have a profound influence on the physical properties of the 
tablets. Several workers in literature have focused on investigating the 
impact of tablet face curvature on the various physical and structural 
properties associated with the tablets (Eiliazadeh et al 2003, Sinka et al 
2004, Sugimori et al 1989, Pitt et al 1988, 1989). 
 
Variations in the face curvature of pharmaceutical tablets lead to 
significant variations in the density distribution within the tablet. Various 
methods have been employed in the investigation of this phenomenon. 
Eiliazadeh et al (2003) investigated radial and axial powder movements 
within the powder column during powder compaction, and the resulting 
density distribution in flat and convex tablets formulated with 
microcrystalline cellulose, by introducing a coloured layer into the 
structure of the tablets and using image analysis to investigate the 
density distribution. They noted that the density distribution was not 
homogenous in both flat and convex tablets, with higher density regions 
occurring within tablet parts in contact with the die wall due to friction 
forces. They also noted that density variation increased with the increase 
in compaction pressure. Moreover, they showed that the density 
distribution was different between flat and convex tablets, as the effect of 
die wall friction was more noticeable in convex tablets. This lead to higher 
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degrees of stress relaxation in convex tablets, leading to lamination which 
originated within the weaker sections located in the centre of the convex 
tablets. Similar findings in terms of density variation within flat and convex 
tablets had also been noted using a technique based on gamma radiation 
attenuation which was influenced by the density variation within the tablet 
(Charlton and Newton 1985).  
 
Sinka et al (2004) used X-ray Microtomography to get a profile of density 
distribution within capsule shaped tablets of varying cup geometry. They 
found that considerable variations in density distribution were present 
within the same tablet, and between tablets with different cup geometry. 
However, they also stated that density distribution investigations should 
not be used as a generalised rule due to the multiple factors, associated 
with material properties, tablet properties, and the actual compaction 
process, which could influence the compaction patterns within the 
different tablets. Recently Djemai and Sinka (2006) reported similar 
findings with regards to density variations within and between tablets 
using NMR imaging of round and capsule shaped microcrystalline 
cellulose tablets.  
 
The direct compression process of tablets with different degrees of face 
curvature, and the influence of die wall pressure on tablet properties were 
also investigated. Sugimori et al (1989) monitored the die wall pressure 
resulting during the compression of both flat and convex tablets and they 
reported higher residual wall pressure towards the end of tablet 
                                                                                                     Chapter 1 
 80
decompression, in the case of convex tablets. Moreover, this 
phenomenon was noted in certain tablets which where characterised by 
having a smaller height. The higher values of residual wall pressure were 
also associated with the occurrence of capping within the tablets which 
resulted ultimately in a drop in the value of residual wall pressure in the 
case of convex tablets as compared to flat ones.   
 
Another important aspect which has been investigated, and shown to be 
influenced by the change in tablet face curvature, is tablet tensile 
strength. The change in tablet face curvature was reported to cause 
significant variations in the tensile strength of round tablets (Pitt et al 
1988, Pitt et al 1989, Newton et al 2000a). Such variations could be 
attributed to variations in powder movement within tablets with different 
face curvature during compression, and thus to the previously mentioned 
variation in the density distribution within the tablets and its potential to 
influence the formation and propagation of cracks within the tablet 
structure. Similar results were also reported with elongated tablets, in 
which variations in the height of tablet face curvature led to clear 
variations in the tensile strength of the tablets (Newton et al 2000b). 
 
The influence of tablet face curvature on other physical properties 
associated with pharmaceutical tablets has also been studied. Chowhan 
et al (1992) studied the influence of tablet face curvature on the friability 
of round tablets. They suggested that the influence of tablet face 
curvature on tablet friability is characterised by the presence of a “critical 
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level” for tablet face curvature, above which tablet friability was noticeably 
reduced. However, no differences were noted between tablets with lower 
degrees of face curvature.  
 
 
1.3. Aims and objectives: 
A limited amount of literature is available about the influence of tablet 
face curvature on the properties of matrix tablets, more specifically, 
hydrophilic matrix tablets. Recently Pajander et al (2006) investigated the 
hydration patterns of cylindrical and convex tablets using the hydrophobic 
starch acetate as a matrix former. They noted different hydration patterns 
associated with cylindrical and convex tablets. They also studied the 
process of crack formation within the tablets and correlated this with the 
dissolution properties of these tablets. With respect to hydrophilic matrix 
tablets, Djemai et al (2005) studied the occurrence of cracks in round 
HPMC convex tablets with two degrees of face curvature, manufactured 
using both a single punch press and a rotary tablet press. In addition to 
investigating the use of NMR imaging as a tool to detect internal 
structural defects in convex tablets, they correlated the presence of such 
defects with the bursting of some convex tablets during tablet hydration.  
 
The previous studies investigated certain phenomena occurring within 
round convex tablets with particular degrees of face curvature, and 
formulated using a single formulation. However, tablets, including 
hydrophilic matrix based ones, could be made from multiple formulations 
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using different ingredients. Moreover, tablets could be made with different 
shapes and different degrees of face curvature. These variables could 
affect the behaviour of the tablets, whether in their dry state, or upon 
hydration. Moreover, the hydration of hydrophilic matrix tablets 
encompasses multiple features, especially tablet structural expansion and 
the formation of the gel layer on the tablet surface. Thus, investigating the 
impact of changing tablet shape and structural properties and the 
properties of the formulation used in tablet production need to be done 
concurrently, as their influences on tablet integrity, hydration and 
dissolution characteristics could be highly correlated. 
 
The overall aim of this work was to study the influence of dosage form 
variables, in terms of tablet face curvature and tablet overall porosity, and 
the type of formulation used on the overall in-vitro behaviour of both 
round and elongated hydrophilic matrix tablets. Multiple degrees of tablet 
face curvature and tablet overall porosity, and different formulations were 
used with both tablet shapes to be able to describe the influence of these 
variables comprehensively. 
 
The objectives of the work were the investigation of the influence of the 
studied factors on the physical properties of the tablets in their dry state, 
monitoring the structural changes occurring within the tablets upon 
hydration, and the differences in such changes between the different 
tablets studied. A further objective was to correlate the nature of the 
structural changes occurring within the hydrating tablets with the nature 
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and properties of the gel layer formed within the various tablets. Another 
objective of the study was to investigate the influence of the studied 
variables and the resulting structural variations within the tablets, in their 
dry and hydrated states, on the dissolution characteristics of the two 
drugs from the various tablets. 
 
Finally, one objective of the study was to explore the potential use of 
statistical analysis techniques in the investigation, comparison, and 
presentation of the in-vitro behavioural patterns associated with 
hydrophilic matrix tablets with different structural and formulation 
properties. 
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CHAPTER TWO 
 
2. Materials and Methods: 
2.1. Materials: 
2.1.1. Xanthan Gum: 
Xanthan Gum is an anionic polysaccharide produced by the gram positive 
bacteria Xanthomonas campestris. It has a high molecular weight of 
about 2 x 106. The chemical structure of Xanthan Gum consists of 
repeating pentasaccharide units each containing two glucose residues, 
two mannose residues and one glucoronic acid residue. The backbone of 
the polysaccharide is virtually identical to that of cellulose; formed of β-D-
glucose units linked together at the 1 and 4 positions. However, the 
Xanthan Gum structure differs from that of cellulose by the presence of a 
trisaccharide side chain, formed of two mannose residues and one 
glucoronic acid residue, and attached to each alternate glucose residues 
at the 3rd position.  Most of the mannose residues at the terminal position 
of the side chain have a pyruvate moiety and the mannose residues 
closest to the backbone could be acetylated at the 6 position (Lachke 
2004, Singh 2006) 
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The usual chain structure of Xanthan Gum could exist as a single, double 
or triple helix. The helical structures of adjacent Xanthan Gum molecules 
can interact, giving rise to a weakly bound network (Singh 2006). 
 
As a powder Xanthan Gum occurs as a cream or white coloured free 
flowing powder which is mainly fine in size. It is soluble in cold and warm 
water but practically insoluble in ethanol and ether (Singh, 2006). 
 
The intrinsic ability of Xanthan Gum to form weak gel structures gives rise 
to its wide applications. It is used as a thickening agent and emulsifier in 
the food and confectionary industry due to its lack of toxicity. It has also 
applications as a stabilizer, emulsifier and suspending agent in many 
industries, including cosmetics, agriculture, paint production, ceramics 
and textile (Lachke 2004). 
 
In terms of its pharmaceutical applications, Xanthan Gum is used in the 
production of hydrophilic matrix systems, mainly tablets. It has been 
reported that Xanthan Gum gives rise to stable gel structures that give 
almost zero order drug release (Dhopeshwarkar and Zats, 1993). 
Xanthan Gum is also used in the production of topical formulations due to 
its shear thinning behaviour. It also has applications in the production of 
ophthalmic and vaginal dosage forms. 
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Xanthan Gum used in this study was a kind gift from A and E Connock 
perfumery and confectionary Ltd. (Fordingbridge, England). The batch 
number is 165558. 
 
 
2.1.2. Spray dried lactose: 
Spray dried lactose is a white or off-white powder, which is mainly 
odourless, and has a high aqueous solubility of 1 part in 4.63 parts of 
water (Kibbe 2000). It consists of spherical particles that contain a 
mixture of crystalline and amorphous lactose entities, containing α-
lactose and β-lactose moieties. It is usually produced by a process of 
spray drying in which a suspension of α-lactose monohydrate crystals, 
containing approximately 10-20% of dissolved lactose and 80-90% of 
suspended particles in the crystalline form is used.  
 
Spray dried lactose is used mainly as a diluent in the production of 
pharmaceutical tablets by direct compression, due to its good compaction 
properties. It had been reported that the compaction and flow properties 
of this type of lactose are highly affected by its particle size and the 
proportion of amorphous content in the particles (Vormans et al 1987). 
The spray dried lactose used in this study is Zeparox® which was 
supplied by Borculo Whey Products (Needsweg, Holland). The batch 
number is 642708. 
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2.1.3. Dibasic Calcium Phosphate Dihydrate (Emcompress®): 
Dibasic calcium phosphate dihydrate is a white odourless and tasteless 
powder or crystalline solid that is practically insoluble in ethanol, ether 
and water, but soluble in dilute acids. It is available in two particle size 
ranges, the finer of which (milled) is used mainly in wet granulation. The 
coarse grade is used in the direct compression of tablets due to its good 
flow behaviour and its desirable compaction properties; it deforms mainly 
by brittle fracture (De Boer et al 1978, Moreton 2006). The dibsaic 
calcium phosphate dihydrate used in this study is Emcompress®. It was 
supplied by JRS Pharma Ltd. (Surrey, UK). The batch number is 515H. 
 
 
2.1.4. Magnesium Stearate: 
Magnesium stearate is a very fine white cohesive powder with poor 
flowability (Allen and Luner, 2006). It consists of a mixture of magnesium 
salts of various fatty acids, predominantly stearic acid and palmitic acid, 
with minor proportions of other fatty acids. The powder is present in three 
degrees of hydration; trihydrate, dihydrate and anhydrate. It is practically 
insoluble in ethanol, ether and water (Allen and Luner, 2006). In the 
pharmaceutical industry magnesium stearate is mainly used as a 
lubricating agent in the formulation and production of tablets and 
capsules at concentrations between 0.25 and 5.00 % w/w (Allen and 
Luner 2006). The magnesium stearate used in this study was supplied by 
BDH chemical Ltd. (Pool, England). The batch number is 555174. 
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2.1.5. Orphenadrine Citrate: 
Orphenadrine Citrate is a cationic drug. It exists in the form of a white or 
almost white crystalline powder. It is sparingly soluble in water, with an 
aqueous solubility of 1 part in 70 parts of water. It has a molecular weight 
of 461.5 g/mol, and a melting point of 134°C to 138°C (Moffat et al 2004). 
Orphenadrine Citrate salt used in this study was supplied by Sigma-
Aldrich Company Ltd. (Chillingham, UK). The batch number is 048f0510. 
 
 
2.1.6. Orphenadrine Hydrochloride: 
Orphenadrine Hydrochloride is a cationic drug. It exists in the form of a 
white or almost white crystalline powder (BP 2007). It is freely soluble in 
water, with an aqueous solubility of 1 part in 1 part of water. It has a 
molecular weigth of 305.9 g/mol, and a melting point of about 156°C to 
157°C (Moffat et al 2004). Orphenadrine Hydrochloride used in this study 
has a purity ≥ 98%. It was supplied by Fluka Chemie GmbH, (Italy). The 
lot number is 1093843. 
 
The drug Orphenadrine has a pKa of 8.4, thus it is expected to have a 
higher solubility at lower pH values due to the ionisation of the drug. 
 
 
2.1.7. Distilled de-aerated water: 
The water used in this study, was distilled water, de-aerated using a 
bench dissolution media preparation unit (Copley Degasser, Copley 
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Scientific Ltd., Nottingham, UK). Media de-aeration was done at 37°C by 
subjecting the required volumes of distilled water to a constant vacuum 
with constant stirring. 
 
 
2.2. Methods: 
2.2.1. Particle size analysis: 
Particle size analysis for the powders used in the study was done using 
light microscopy. A small sample of each powder was placed on a glass 
slide, and dispersed in 2-3 drops of dispersion liquid. A set of dispersion 
liquids with refractive indices ranging from 1.40 to 1.70 were tested 
(Certified refractive index liquids, Calligen, USA), in order to acquire 
suitable contrast between the particles of each powder and the 
background. For spray dried lactose, Emcompress®, and Orphenadrine 
HCl, a dispersion liquid with a refractive index of 1.40 was used and for 
Xanthan Gum and Orphenadrine Citrate, a dispersion liquid with a 
refractive index of 1.70 was used. The powder sample was mixed 
thoroughly with the dispersion liquid to achieve maximum particle 
dispersion and minimize the presence of any powder agglomerates. A 
slide cover was introduced slowly on top of the dispersed powder to 
minimize the formation of any air bubbles. 
 
The particle size analysis was carried out using light microscopy 
(Olympus BH-2, Olympus Optical Co., Japan). An objective lens with a 
magnification power of 4X was used for the investigation of Xanthan 
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Gum, spray dried lactose, Emcompress® and Orphenadrine Citrate 
samples resulting in a total resolution of the combined microscope and 
image analysis system of 50X. For the investigation of Orphenadrine HCl 
an objective lens with a magnification power of 10X was used, resulting in 
a total resolution of 125X. Multiple pictures of the microscope field were 
acquired using a digital camera connected to the microscope (Axiocam 
MRC, Carl Zeiss GmbH, Göttingen, Germany).  The pictures were then 
automatically analysed using image analysis software (KS 400, Carl 
Zeiss GmbH, Göttingen, Germany). The software was initially calibrated 
using a graduated slide (S16 Stage Mic. 1mm/0.01 Div., Graticules 
Pyser-SGI Ltd, Kent, UK). Images of the powder systems were processed 
automatically. Initially a threshold was set to allow the clear visualisation 
of particle boundaries and to minimize the influence of background noise. 
A black and white image was produced and individual particles were then 
analysed for a set of three size parameters; particle projected area, 
particle minimum Feret diameter and particle maximum Feret diameter. A 
minimum of one thousand particles were analysed for each powder 
system.  
 
Prior to the final measurement process, each black and white image was 
subjected to manual processing to minimise the influence of artefacts; 
particles on the borders of the image, air bubbles, and regions in which 
agglomeration was apparent were marked and rejected from the analysis 
process. 
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2.2.2 Determination of the moisture content of the powders: 
The determination of powder moisture content was carried out using 
halogen moisture analysis which provided a rather fast and reliable 
procedure for moisture content determination. A powder sample of 4-5 g 
in weight was dispersed evenly on a flat aluminium tray. The tray was 
introduced into the heating chamber of a halogen moisture analyser (HG 
53 Halogen Moisture Analyser, Mettler Toledo GmbH, Switzerland). 
Sample heating was carried out at a temperature of 90°C for all powders 
apart from magnesium stearate which has a reported melting point of 
about 60°C, hence a heating temperature of 50°C was used for this 
powder. The moisture analyser had a built-in scale and the reduction in 
sample weight to 0.001 g was monitored at 30 seconds intervals. The 
analyser was programmed to switch off automatically when the reduction 
in sample weight was less than 1 mg every 140 seconds, which was 
considered as stable dry weight.  
 
 
2.2.3. Determination of the apparent density of the powders: 
Helium pycnomtery was used to determine the apparent powder density 
for each of the powders used in this study. A single chamber helium 
pycnometer was used (Multipycnometer, Quantachrome Corp., NY, 
USA). The pycnometer was initially switched on and allowed to warm up 
for thirty minutes. Helium was then introduced into the measurement 
chamber and allowed to purge for ten minutes. Calibration of the 
pycnometer was carried out using two small calibration spheres with a 
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volume of 1.078 cm3 each. Powder samples were accurately weighed 
and introduced in the pycnometer chamber for analysis.  Five different 
powder samples were analysed for each material used, and each sample 
was further analysed five times, the mean value of which was used in the 
calculation process. 
 
 
2.2.4. Calculation of tablet volumes: 
2.2.4.1. Round tablets: 
The volume of flat round tablets used in the study was calculated using 
Equation  2.1.  
 
trV t
2π=                                                                         Equation 2.1. 
 
where (Vt) is the volume of the tablet, (r) is the radius of the tablet and (t) 
is the height of the tablet. 
 
The volume of convex round tablets includes the volume of the cylindrical 
portion of the tablet which was calculated using Equation 2.1., and the 
volumes of the two convex caps of the tablet (see figure 2.1.), each of 
which was calculated using Equation 2.2.  
 
( )hRhVc −= 3
3
1 2
π                                                         Equation 2.2. 
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where (Vc) is the volume of the cap, (h) is the height of the cap and (R) is 
the radius of tablet curvature. 
 
 
 
 
 
 
 
 
 
Figure 2.1. Schematic representation of the dimensional parameters of 
round tablets, R: radius of curvature, W: height of cylindrical part of the 
tablet, h: height of tablet cap, r: tablet radius. 
 
 
2.2.4.2. Elongated tablets:  
The volume of flat elongated tablets was calculated using equation 2.3.. 
The volume of convex elongated tablets includes the volume of the flat 
box and the volumes of two curved segments (see Figure 2.2.) which in 
turn was calculated according to equation 2.4.. 
 
dlbV tt ××=                                                                                Equation 2.3. 
 
where (Vt) is the volume of the tablet, (b) is the tablet width, (lt) is the 
tablet length and (d) is the height of the tablet. 
r 
R 
  W h 
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                                                              Equation 2.4. 
 
where (Vce) is the volume of the curved segment, (b) is the tablet width 
and (a) is the height of the curved segment 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Schematic representation of the size parameters of elongated 
tablets, adapted from Newton et al (2000b), b: tablet width, d: height of 
rectangular tablet section, a: height of curved segment. 
 
 
 
2.2.5. Calculation of tablet densities and weights: 
Initially the densities of all tablets used in this study were calculated 
depending on the apparent densities of the powder mixtures used in 
tablet production, and the pre-determined porosities of the tablets 
(Equations 2.5. and 2.6.).  
 
b 
d 
a 
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∑ ×= powderpowdermix Xρρ                                                      Equation 2.5. 
 
 
mix
tab
ρ
ρ
ε =−1                                                                                      Equation 2.6. 
 
where (ρmix) is the powder mixture density, (ρpowder) is the density of the 
individual powders, (Xpowder) is the percentage fraction of each powder in 
the powder mix, (ρtab) is the tablet density and (ε) is the tablet porosity. 
 
The weights required for tablet productions were then calculated using 
the previously calculated values of tablet volume and tablet density 
(Equation 2.7.). 
                                                                                                                               
tabtabtab VW ρ×=                                                                             Equation 2.7. 
 
where (Wtab) is the weight of the tablet, (Vtab) is the volume of the tablet 
and (ρtab) is the density of the tablet. 
 
 
2.2.6. Production of tablets: 
Initially, powder mixing was carried out in a step-wise process; all 
formulation ingredients apart from magnesium stearate were accurately 
weighed, and pre-mixed in a Turbula® mixer (Turbula, Basel, 
Switzerland) for six minutes. The powder mixture was then passed 
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through a 250µm mesh to break up any powder agglomerates. Any large 
un-agglomerated particles remaining on the mesh were then returned to 
the mixture. Afterwards, the powder mixture was further mixed in the 
Turbula mixer for another six minutes, before adding the required amount 
of magnesium stearate which was mixed with the rest of the powders for 
a further three minutes. 
 
Tablet production was carried out using a process of direct compression. 
A single punch tablet press was used in the production of all tablets used 
in this study (F-press, Manesty Machines, Liverpool, England). For round 
tablets a die with an internal diameter of 12.5 mm was used. Four sets of 
punches with a progressively increasing face curvature ratio were used. 
All punches had a diameter of 12.5 mm. For elongated tablets, a die with 
a width of 10 mm and length of 25 mm was used. For the production of 
these tablets three sets of elongated punches were used with a width of 
10 mm, length of 25 mm and a progressively increasing face curvature. 
All dies and punch sets were produced by the same manufacturer  
(I Holland Ltd., Nottingham, England). 
 
Powder samples were accurately weighed depending on the calculated 
values of tablet weight. Each weighed sample was individually fed into 
the required die. The surface of the powder was then levelled using a 
small metal spatula, and the tablet was produced by manually operating 
the tablet press. 
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After ejection from the die, each tablet was accurately weighed to 0.0001 
g, and the dimensions of the tablet were measured to 0.001 mm using a 
digital micrometer (Mitutoyo digital micrometer, Mitutoyo, Kawasaki, 
Japan). The height of the cylindrical part of round convex tablets, and the 
length and box height of elongated tablets were measured to 0.01mm 
using a digital calliper (UPM digital calliper, United Precision Machine 
Inc., Shenzhen, China). Weight and dimension limits were applied as a 
quality control procedure, in order to maintain a narrow margin of 
variation in tablet properties. Only tablets with weight variation within       
± 0.01 g and dimensional variation within ± 0.01 mm from the theoretically 
calculated values were used in the study. 
 
After production, each batch of tablets was stored in an amber glass air-
tight container in a dark place at ambient conditions. Tablet storage was 
carried out for a minimum period of 14 days, to allow complete relaxation 
of tablets after the compaction process. 
 
 
2.2.7. Determination of tablet tensile strength; 
2.2.7.1. Round tablets: 
Prior to use, the weights and dimensions of all tablets were determined to 
0.0001 g and 0.001 mm respectively, and the height of the cylindrical part 
of convex tablets was measured to 0.01 mm. The breaking loads for 
round tablets were determined by subjecting the tablets to diametral 
loading between the two steel plates of a strength tester (CT 40, 
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Engineering Systems, Nottingham, UK).  The load was applied at a rate 
of 1 mm/min, and the load at which tablet failure occurred was recorded. 
Tablets were inspected for their failure patterns after retrieval, and only 
tablets with a diametral failure pattern were used for evaluation.  
 
The tensile strengths of flat round tablets were calculated using Equation 
2.8. which was proposed by Fell and Newton (1968, 1970). 
 
Dt
P
t
π
σ
2
=                                                                                             Equation 2.8. 
 
where (σt) is the diametral tensile strength of the tablet, (P) is the 
breaking load, (D) is the diameter of the tablet, (t) is the thickness of the 
tablet. 
 
The tensile strengths of convex round tablets were calculated using 
Equation 2.9., developed by Pitt et al (1988). 
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σ                               Equation 2.9. 
 
where (σt) is the diametral tensile strength of the tablet, (Ps) is the 
breaking load, (D) is the diameter of the tablet, (t) is the total height of the 
tablet and (W) is the height of the cylinder. 
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2.2.7.2. Elongated tablets: 
In a similar manner to round tablets, the weights and dimensions of 
elongated tablets were determined to 0.0001 g and 0.001 mm, 
respectively, and the length and box height of curved elongated tablets 
were measured to 0.01 mm. The flexural breaking load of the tablets was 
measured using a physical testing instrument (CT 5, Engineering 
Systems, Nottingham, UK) fitted with a 3 point bending device (Figure 
2.3.). The distance between the two lower rolls (a) was set at 16.5 mm, 
and the breaking load was applied at a rate of 1 mm/ min. The load at 
which tablet failure occurred was recorded using the peak hold facility of 
the strength tester. The failure patterns of the tablets were monitored 
after retrieval and only tablets in which the breaking was initiated at the 
centre of the lower surface were evaluated. 
 
 
 
 
 
 
 
Figure 2.3. Schematic illustration of the bending test to determine the 
fracture load of elongated tablets. 
 
 
The tensile strengths of flat faced elongated tablets were calculated using 
Equation 2.10. (Stanley and Newton, 1980). 
  l 
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3
bd
Fl
f =σ                                                                                         Equation 2.10. 
 
where (σf) is the flextural tensile strength of the tablet, (F) is the breaking 
load, (l) is the distance between the two lower rolls, (b) is the width of the 
tablet and (d) is the thickness of the tablet. 
 
The tensile strengths of curved elongated tablets were approximated 
using Equation 2.11. (Stanley and Newton, 1980). 
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σ                                                                   Equation 2.11. 
 
where (σf) is the flextural tensile strength of the tablet, (F) is the breaking 
load, (l) is the distance between the two lower rolls, (b) is the width of the 
tablet, (d) is the thickness of the tablet, (a) is the height of the curved 
segment and (A) is the area of the curved segment. 
 
 
2.2.8. Hydration studies: 
Hydration or “swelling” studies for all tablets used in this study were 
carried out using live in-situ image analysis. The settings for the hydration 
studies varied depending on the shape of the tablets used. 
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2.2.8.1. Hydration of round tablets: 
2.2.8.1.1. Axial swelling studies: 
The axial swelling of round tablets was monitored using an assembly 
consisting of a black and white camera (CCD-4 miniature video camera 
module, Rengo Co., Japan) with a zoom lens (18–108/2.5, Olympus 
Europe, Hamburg, Germany). The camera was connected to an image 
analyser (Seescan Solitaire 512, Seescan, Cambridge, UK). Three light 
sources were used to provide adequate illumination of the tablets. Two of 
these sources were placed at an angle of 45° on each side of the imaging 
stage (Highlight 3001, Olympus Optical Co. (Europe) GmbH, Hamburg, 
Germany). The third light source was placed on top of the stage (Halogen 
desk spotlight, Winsource Industries Ltd., Kln, Hong Kong). 
 
The software was initially calibrated for length using a graduated ruler 
which was placed inside a glass beaker containing the same hydration 
medium used in the study to eliminate any influence arising from these 
factors. Round tablets were initially measured for height to 0.001 mm 
using a digital micrometer (Mitutoyo digital micrometer, Mitutoyo, 
Kawasaki, Japan). Each tablet was then individually placed on a specially 
assembled holder equipped with a set of pins (Figure 2.4.). This 
assembly was chosen to allow full surface hydration of the tablets. Each 
tablet was then placed in a glass beaker containing distilled de-aerated 
water at 37±1°C.  The temperature of the hydration medium was 
maintained at 37°C by placing the beakers in a thermally controlled water 
bath (Unstirred water both, type JB6, Grants Instruments, Cambridge, 
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UK). At consecutive time intervals of 10, 20, 30, 40, 50, 60, 70, 80, 90, 
100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 
240, 255, 270, 285, 300, 315, 330, 345, 360,  375, 390, 405, 420, 435, 
450, 465, and 480 minutes, each beaker was taken out, placed on the 
imaging stage, and black and white images of the tablet were taken and 
analysed manually for tablet overall height, which was defined as the 
distance between the two pole points for curved tablets, and between the 
two centre points of the axial faces of flat tablets. The swelling studies 
were carried out for 480 minutes. 
 
 
 
 
 
  
  
Figure 2.4. Shematic representation of the pin-holder assembly used in 
the swelling studies of round tablets. 
 
 
The axial swelling indices of the hydrating tablets were calculated at the 
consecutive time intervals using equation 2.12. 
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where (SIa) is the tablet swelling index in the axial direction at time t, 
(height) and (height0) are the heights of the tablet at time t and at the 
beginning of the experiment, respectively. 
 
 
2.2.8.1.2. Radial swelling studies: 
The radial swelling of round tablets was monitored using an assembly 
similar to that used in axial swelling studies with some modifications.  
Tablets were measured for diameter to 0.001 mm using a digital 
micrometer (Mitutoyo digital micrometer, Mitutoyo, Kawasaki, Japan), and 
then individually placed on the previously mentioned pin holders. Tablets 
were then placed inside a glass vessel containing distilled de-aerated 
water maintained at 37±1°C by means of a thermally controlled water 
bath (Tempette Junior TE-8J, S.H. Scientific, Blyth, UK). The black and 
white camera was placed on top of the hydration apparatus, together with 
two top light sources (Highlight 3001, Olympus Optical Co. (Europe) 
GmbH, Hamburg, Germany). The internal surface of the hydration vessel 
was coated with matt black adhesive paper to maximise the contrast 
between the tablets and their background. This was further enhanced by 
tuning the threshold level of the analysis software. A calibration step for 
the software was initially carried out using a graduated ruler placed inside 
the hydration vessel. Then, at consecutive time intervals, i.e. at 5, 10, 15, 
20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 
110, 115, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 
240, 255, 270, 285, 300, 315, 330, 345, 360,  375, 390, 405, 420, 435, 
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450, 465, and 480 minutes, black and white images of each tablet were 
taken and automatically analysed for tablet Feret diameter, which was 
defined as the mean of thirty six measurements of tablet diameter around 
the circumference. Swelling studies were carried out for 480 minutes. 
 
The radial swelling indices of the hydrating tablets were calculated at 
consecutive time intervals using equation 2.13. 
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SI tr                                     Equation 2.13. 
 
where (SIr) is the tablet swelling index in the radial direction at time t, 
(diametert) and (diameter0) are the diameters of the tablet at time t and 
at the beginning of the experiment respectively. 
 
2.2.8.2. Hydration of elongated tablets: 
2.2.8.2.1. Height swelling studies: 
For the investigation of the axial swelling of elongated tablets, certain 
modifications were made to the system used for the investigation of the 
swelling of round tablets. Initially three measurements for tablet width 
were performed (two at the two ends of the tablet and one at the centre of 
the tablet) to 0.001 mm using a digital micrometer (Mitutoyo digital 
micrometer, Mitutoyo, Kawasaki, Japan). The mean value of the three 
readings was used for further evaluation. In order to accommodate for the 
change in tablet shape and possible difference in swelling patterns, each 
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tablet was placed on a modified pin holder, where a piece of coated mesh 
was placed on top of the pins to maintain tablet integrity during hydration. 
Tablets were then individually placed in transparent glass boxes 
containing distilled de-aerated water at 37°C, and temperature control 
was achieved by placing the beakers in a thermally controlled water bath 
(Unstirred water both, type JB6, Grants Instruments, Cambridge, UK) 
maintained at 37±1°C. 
 
At consecutive time intervals, i.e. at 10, 20, 30, 40, 50, 60, 70, 80, 90, 
100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 
240, 255, 270, 285, 300, 315, 330, 345, 360,  375, 390, 405, 420, 435, 
450, 465, and 480 minutes, each box was placed on the imaging stage, 
and tablet images were taken and manually analysed for tablet height. 
The mean of three measurements of tablet height, taken at the centre 
and both edges of the tablet, was used for tablet evaluation. 
 
The Swelling indices for tablet height at the consecutive time intervals 
were calculated using equation 2.14. 
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where (SIh) is the tablet height swelling index at time t, (height-mean) and 
(height0-mean) are the mean values of tablet height at time t and at the 
beginning of the experiment, respectively. 
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2.2.8.2.2. Width and length swelling studies:  
The width and length swelling of elongated tablets were investigated 
using an assembly similar to that used for round tablets. Tablets were 
initially measured for length to 0.01 mm using a digital calliper (UPM 
digital calliper, United Precision Machine Inc., Shenzhen, China), and for 
width to 0.001 mm using a digital micrometer (Mitutoyo digital 
micrometer, Mitutoyo, Kawasaki, Japan). Tablets were then placed 
individually into the hydration medium using the previously mentioned 
mesh holders. After calibration of the analysis software, the changes in 
tablet width and length were monitored at consecutive time intervals, i.e. 
at 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 
170, 180, 190, 200, 210, 220, 230, 240, 255, 270, 285, 300, 315, 330, 
345, 360,  375, 390, 405, 420, 435, 450, 465, and 480 minutes.  For 
tablet length, one manual measurement was recorded from the image. 
For tablet width, the mean of three measurements, taken at the centre 
and at both ends of the tablet, was used for tablet evaluation, as 
illustrated in Figure 2.5.  
 
Figure 2.5. Schematic illustration of the radial measurements performed 
on hydrating elongated tablets, W: width, L: length. 
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The swelling indices for tablet width and length at consecutive time 
intervals were calculated using equations 2.15. and 2.16. respectively. 
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where (SIw) is the tablet swelling index in the width direction at time t, 
(widtht-mean) and (width0-mean) are the widths of the tablet at time t and at 
the beginning of the experiment respectively. 
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where (SIl) is the tablet swelling index in the length direction at time t, 
(lengtht) and (length0) are the lengths of the tablet at time t and at the 
beginning of the experiment respectively. 
 
 
2.2.9. Characterisation of Xanthan Gum gel systems: 
2.2.9.1. Preparation of gel samples: 
Blank and drug containing Xanthan Gum gels were produced at three 
different concentrations of 2, 4 and 6% w/w. 25 grams of each gel was 
produced; initially, the weights of each formulation needed to make each 
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of the gel concentrations were calculated using equation 2.17., and are 
listed in Table 2.2. 
 
( )
p
wg
mix
X
WC
W
×
=                                                                   Equation 2.17 
 
where, (Wmix) is the weight of powder mix required, (Cg) is the required 
concentration of the gel, (Ww) is the weight of the aqeous powder 
dispersion used and (Xp) is the percentage fraction of the polymer in the 
powder mix. The percentage fraction of the polymer in each powder mix 
was based on the developed formulations, which is discussed in detail in 
Chapter 4.  
 
 
Formulation        Gel Concentration (w/w %) 
 2% 4% 6% 
A (Blank) 1.053 2.105 3.158 
B (Orphenadrine Citrate) 1.429 2.857 4.286 
C (Orphenadrine HCl) 1.429 2.857 4.286 
 
Table 2.1. Weights of blank and drug containing Xanthan Gum mixtures, 
in grams, used for the preparation of gels used in the rheological studies. 
 
 
 
Each accurately weighed sample was added to distilled de-aerated water 
at 37°C to obtain 25 grams of aqeous powder dispersion. The mixing was 
initially done using a magnetic stirrer equipped with a hot plate facility 
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which helped to maintain the gel temperature at 37°C. Stirring was 
carried out for 30 minutes. Gels that had a high viscosity hindered the 
movement of the stirrer after some time, thus stirring was continued 
manually using a glass rod. Gel storage was carried out at two stages. 
Initially, gels were placed in a thermally controlled water bath in sealed 
containers for 1 hour to enhance complete hydration, followed by storage 
at ambient conditions in air-tight amber glass containers for a further 24 
hours to allow complete hydration. 
 
 
2.2.9.2. Rheological studies: 
All rheological studies were carried out using a controlled stress 
rheometer (Bohlin Gemini 200, Malvern Instruments Ltd., Malvern, UK), 
equipped with a parallel serrated plate geometry with a diameter of 25 
mm, which was chosen to minimise gel sample slipping during 
measurements. The gap between the plates was set to 1 mm and all 
experiments were carried out at a constant temperature of 37°C.  Gel 
samples were introduced between the plates and allowed to stand for 15 
minutes to allow gel relaxation after sample handling, and to allow gel 
samples to equilibrate at the desired temperature. A solvent trap, and a 
plastic cover were used to enclose the plates and the sample, in order to 
maintain a humid atmosphere during measurements, and to prevent 
sample drying which could lead to the occurrence of artefacts. All 
rheological measurements were repeated three times using different 
samples. 
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2.2.9.2.1. Oscillation studies: 
Dynamic oscillatory measurements were performed on each gel sample. 
Initially stress “amplitude” sweeps were done between 0.01 and 100 Pa   
at a constant frequency of 1 Hz to determine the linear viscoelastic region 
for each sample. Values of strain and corresponding stress from the 
middle part of the linear viscoelastic region were employed to carry out 
frequency sweeps between 0.01 and 20 Hz to investigate to relationship 
between the oscillation frequency and the rheological properties of the 
sample, i.e. elastic modulus, viscous modulus, and the phase angle. 
 
 
2.2.9.2.2. Viscometric studies: 
The flow behaviour of each gel sample was investigated in a controlled 
rate mode, using rates between 0.01 and 10 Hz. In order to investigate 
the presence of thixotropic behaviour in the gel samples, flow rate values 
were increased to the maximum of 10 Hz and then decreased once again 
to the minimum of 0.01 Hz in order to elucidate the presence and 
magnitude of the hysteresis loop associated with thixotropic behaviour. 
 
In order to practically identify the yield stress of each gel sample studied, 
the rheometer was operated in the controlled stress mode, and the 
influence of changing the shear stress, between 0.1 and 100 Pa, on the 
values of gel strain and its instantaneous viscosity was monitored. The 
yield stress of each gel sample was automatically calculated depending 
on the deflection point observed in the curves. 
                                                                                                     Chapter 2 
 111
2.2.10. Dissolution studies: 
Preliminary studies indicated a significant absorbance exhibited by one of 
the excipients used in this study, which is Xanthan Gum. Thus it was 
necessary to construct calibration curves for all absorbing entities, i.e. the 
two drugs and Xanthan Gum. Two wavelengths were used for 
absorbance measurements using UV-spectrophotometry; 264 nm and 
244 nm. The choice of wavelengths and calculations for obtaining the 
contribution of both; drug and polymer, in the overall absorbance at each 
wavelength, are discussed in detail in Chapter 7.  
 
 
2.2.10.1. Construction of drug calibration curves: 
In order to define the relationship between drug absorbance values and 
drug concentration, a calibration curve was constructed for each drug at 
the two wavelengths of 264 nm and 244 nm. A stock solution with a 
concentration of 1000 µg/ml was prepared volumetrically for each drug 
individually. Then drug solutions with concentrations of 5, 10, 20, 40, 60, 
80, 100, 125, 150, 175, 200, 250, 300, 350, 400 and 450 µg/ml were 
prepared volumetrically using the stock solution. The absorbance of each 
solution was measured at both wavelengths of 264 nm and 244 nm using 
a double beam UV spectrophotometer (CE 594 Double Beam 
Spectrophotometer, Cecil Instruments, Cambridge, England). Two 
readings were recorded for each solution at each wavelength and the 
mean value was used for evaluation.  
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2.2.10.2. Construction of polymer calibration curves: 
Due to the significant absorbance from the polymer, two calibration 
curves were constructed for the polymer at the two specified 
wavelengths. Accurately weight amounts of the polymer of 5, 10, 20, 40, 
60, 80, 100, 125, 150, 175, 200, 250 and 300 mg were introduced 
individually into dissolution vessels of a paddle dissolution apparatus 
(Type DT6 R, Erweka Appartebau GmbH, Heusenstamm, Germany ) 
containing 1000 ml of distilled de-aerated water each. Polymer dissolution 
was enhanced by applying a paddle rotation speed of 150 rpm. After six 
hours, samples where withdrawn from each dissolution vessel through 
filter tips with a pore size of 20 µm. The absorbance of each sample was 
recorded twice at the two wavelengths of 264 nm and 244 nm using a 
double beam UV spectrophotometer (CE 594 Double Beam 
Spectrophotometer, Cecil Instruments, Cambridge, England). Polymer 
calibration studies were repeated twice and the combined results of the 
two runs were used for further evaluation. 
 
 
2.2.10.3. Tablet dissolution studies: 
Tablet dissolution was carried out using the British Pharmacopeia paddle 
apparatus (Type DT6 R, Erweka Appartebau GmbH, Heusenstamm, 
Germany). Tablets were introduced individually into dissolution vessels 
containing 900 ml of distilled de-aerated water each, maintained at  
37±1 °C. The paddle speed was set to 75 rpm. At specified time intervals 
of 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420, and 480 minutes, 
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10ml samples were withdrawn from each dissolution vessels through filter 
tips with a pore size of 20 µm. The absorbance of each sample was 
measured immediately at the two specified wavelengths of 264 nm and 
244 nm using a double beam UV spectrophotometer (CE 594 Double 
Beam Spectrophotometer, Cecil Instruments, Cambridge, England). 
 
For the dissolution studies of elongated tablets, a modification was 
introduced into the system. Tablets were individually placed on a purpose 
made sinker assembly (Figure 2.6.) in order to prevent the continuous 
collision between the tablets and the rotating paddles. Such an effect was 
caused by the nature of the size and shape of the tablets which caused 
the continuous rotation of the tablet immediately after insertion into the 
dissolution medium. 
 
 
 
 
 
 
 
 
Figure 2.6. Schematic illustration of the metal sinkers used for dissolution 
studies of elongated tablets. 
 
 
 
 
Tablet 
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2.2.11. Scanning electron microscopy: 
Scanning electron microscopy was used to get closer insight into the 
morphological and structural properties of the powders and tablets used 
in this study. All studies were carried out using the same scanning 
electron microscope (Hitachi S3000N Scanning Electron Microscope. 
Hitachi High-Tech Science Systems Corp., Japan) 
 
 
2.2.11.1. Scanning electron microscopy of powder samples. 
A small amount of each powders sample was dispersed on the surface of 
a double sided adhesive black paper, which was mounted on a small 
round metal stub. The samples were subjected to a brief air jet to remove 
any agglomeration of the powder. The powder samples were initially 
coated with a thin layer of gold palladium sputter (Polaron SC7620, 
Quoron Technologies, Newhaven, UK), and then introduced into the 
imaging chamber of the scanning electron microscope. The microscope 
was operated at a voltage of 5kV, and microscopic images of the powder 
were acquired at various magnification powers. 
 
 
2.2.11.2. Scanning electron microscopy of tablets. 
Two main features of the tablets were investigated using scanning 
electron microscopy, i.e. tablet surface and the fracture surface of the 
tablets after being subjected to diametral compression. Whole tablets 
were used for surface imaging and fractured tablets were used for 
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fracture surface imaging. The tablets were mounted on double sided 
black adhesive paper on round metal stubs, coated with a thin layer of 
gold palladium sputter (Polaron SC7620, Quoron Technologies, 
Newhaven, UK), and then introduced into the imaging chamber of the 
scanning electron microscope. The microscope was operated at a voltage 
of 20kV and tablet surfaces and fracture surfaces were imaged at various 
magnification powers.  
 
 
2.2.11.3. Scanning electron microscopy of hydrated tablets. 
For the microscopic imaging of the surface properties of hydrated tablets, 
tablets were initially allowed to hydrate adequately by placing them in a 
glass beaker containing distilled de-aerated water maintained at 37±1 °C 
by means of a thermally controlled water bath (Unstirred water both, type 
JB6, Grants Instruments, Cambridge, UK). Prior to imaging, tablets were 
removed from the hydration medium and wiped gently with an absorbing 
tissue to remove excess water from the surface. Each tablet was then 
placed on a round metal stub and placed on a cooling stage within the 
imaging chamber of the scanning electron microscope. The temperature 
of the cooling stage and the pressure within the imaging chamber were 
adjusted to keep the tablet at a stage very close to freezing without 
allowing ice formation, a special sample holder was used to maintain the 
sample at low temperatures (XVP Coolstage, Deben UK Ltd, Suffolk, 
UK). Images of the hydrated tablet surface were acquired at various 
magnification powers.  
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2.2.12. Thermal investigation of powders and dried gel samples: 
2.2.12.1. Preparation of dried gel samples: 
Gel samples were prepared at concentrations of 2, 4 and 6% w/w. Gels 
contained either pure Xanthan Gum or binary mixtures of Xanthan Gum 
and either of the two model drugs used in the study. The Xanthan Gum to 
drug ratio in drug containing mixtures was kept equivalent to their ratio in 
the formulations used elsewhere in the study.  
 
The use of binary polymer-drug mixtures instead of whole formulations 
was chosen to elucidate any potential interactions between the polymer 
and either of the two drugs.  
 
Gel preparation was carried out using a process identical to that 
described in section 2.2.9.1. The weights of pure Xanthan Gum powder 
and binary Xanthan Gum-drug mixtures used in the preparation of the 
various gels are listed in Table 2.2.  
 
Powder Mixture                              Gel Concentration (w/w %) 
 2% 4% 6% 
Blank Xanthan Gum 0.500 1.000 1.500 
Xanthan Gum + Orphenadrine Citrate 0.857 1.714 2.572 
Xanthan Gum + Orphenadrine HCl 0.857 1.714 2.572 
 
Table 2.2. Weights of pure and drug containing Xanthan Gum mixtures, 
in grams, used for the preparation of gels investigated by the thermal 
studies. 
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After 24 hours, gel samples were placed on flat trays and dried for three 
hours at 50°C, then stored in a silica gel desiccator for 7 days to complete 
the dehydration process prior to use.  
 
 
2.2.1.2.1. Thermal investigation: 
Thermal investigation of the powder and gel samples used in this study 
was carried out to further elucidate the physicochemical nature of these 
systems. All thermal studies were carried out using differential scanning 
calorimetery, employing a temperature modulated differential scanning 
calorimeter (TA Q1000, TA Instruments Ltd, Crawly, UK). Prior to use, the 
temperature modulated differential scanning calorimeter was calibrated 
for enthalpy using Indium and for heat capacity using sapphire. 
 
For the thermal investigation of the powder and dried gel samples, 
samples of 4-5mg were initially encapsulated in crimped Aluminium pans. 
The pans were introduced into the heating chamber of the differential 
scanning calorimeter, which was operated in the modulated mode, using 
Nitrogen as a purge gas at a flow rate of 50ml/min. Sample heating was 
carried out between 10°C and 230°C at a heating rate of 3°C/min. 
Temperature modulation during the heating cycle included an oscillation 
amplitude of 0.5 °C, and an oscillation period of 50 seconds. 
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2.2.13. Statistical analysis: 
Statistical analysis of the data used in this study was carried out using 
two available software packages; SPSS® 14.0 for Windows® (SPSS 
release 14.0.0. SPSS Inc., Chicago, USA), and Microsoft Excel for 
Microsoft Office XP® (Microsoft Office XP®, professional edition, Microsoft 
Corp., Washington, USA). 
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CHAPTER THREE 
  
3. Choice and characterisation of pharmaceutical 
materials 
3.1. Introduction: 
As has been discussed previously in chapter one, the physicochemical 
properties of the materials used in the formulation of hydrophilic matrix 
tablets have a major effect on the physical properties of the produced 
tablets and on their hydration behaviour. It was thus important to choose 
the appropriate pharmaceutical materials, which would help in fulfilling the 
main aims of this study. It was also important to thoroughly characterise 
the physicochemical properties of all materials used. Hence, the main 
aims of this part of the study were to choose the appropriate materials 
and to characterise the main physicochemical properties associated with 
them. This in turn could give further insight into the physical and hydration 
behaviour of the produced tablets. 
 
Another important aim, associated with this chapter, is attributed to the 
nature of some of the excipients used in this work. A material such as 
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spray dried lactose could exist in different polymorphic forms. Such 
variation, as will be discussed in this chapter, could have a significant 
influence on the properties of the produced tablets, and thus introduce 
undesired variables that may hinder the investigation of the main focus 
points of this study, which are the influence of tablet shape properties, 
and drug physicochemical properties.  It was hence important to 
characterise such properties and monitor them throughout the span of the 
study. 
 
 
3.2. Choice of Materials: 
3.2.1 Choice of polymer: 
The choice of the hydrophilic polymer used in this study, was done in 
accordance with one of the main aims of this study, which is the 
investigation of the possible ionic interaction between the matrix forming 
polymer and the drug incorporated into the formulation. Xanthan Gum, as 
was previously discussed, is an anionic polymer that has the potential of 
interacting with oppositely charged cationic drugs. Moreover, Xanthan 
Gum has an advantageous property, which is its ability to rapidly forming 
gel-like structures with high viscosities, even at low concentrations.  
 
3.2.2. Choice of model drugs: 
Two main factors influenced the choice of the two model drugs used in 
this study.  The first of which is directly related to the potential for ionic 
interaction between the drug and the hydrophilic polymer. A cationic drug 
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was required to introduce the possibility of interaction with the anionic 
Xanthan Gum. The other factor was drug solubility. Two drugs were 
required, with similar chemical structure but varying in solubility. The two 
cationic drugs, Orphenadrine Citrate and Orphenadrine Hydrochloride 
were thus chosen. The first is freely soluble in water with an aqueous 
solubility of 1 part in 1 part of water, whereas the latter is sparingly 
soluble in water with an aqueous solubility of 1 part in 70 parts of water. 
Thus, the influence of drug solubility on the hydration process and on the 
potential ionic interaction could be studied. 
 
The other excipients used in the study were chosen to facilitate the 
process of tablet production. Spray dried lactose and Emcompress® were 
used as diluents and magnesium stearate was used as a lubricant 
incorporated into the formulation. 
 
 
3.3. Results and discussion: 
3.3.1. Characterisation of particle size and morphological properties: 
The particle size of the active ingredients and excipients incorporated into 
hydrophilic matrix tablets is considered a major factor influencing the 
overall behaviour of the tablets (Tros de llarduya et al 1997, Sumathi et al 
2003, Dhopenshwarkar and Zats 1993). 
 
A combined microscopic technique was adopted in the characterisation of 
the particle size and morphological properties for all powders used in this 
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study. Light microscopy accompanied with automatic image analysis was 
used to characterise the particle size distribution of the powders. Three 
measured parameters were used to characterise the size of each particle, 
i.e. the particle projected area, its minimum Feret diameter and its 
maximum Feret diameter. One further parameter, the McCarthy 
elongation (McCarthy 1976) was used to characterise the two-
dimensional shape properties of the particles.  
 
 
                               Particle Feret diameter in the direction it is maximum. 
                               Particle Feret diameter in the direction it is minimum. 
 
Equation 3.1. McCarthy elongation (McCarthy, 1976). 
 
In conjunction with light microscopy, scanning electron microscopy was 
used to give a more detailed characterisation of the three-dimensional 
morphological properties of all powders. 
 
 
3.3.1.1. Orphenadrine Citrate: 
Size parameters for Orphenadrine Citrate Powder are shown below 
(Table 3.1.). The values indicate a powder with a rather fine particle size 
with median values of 19 µm for the maximum Feret diameter, 11 µm for 
the minimum Feret diameter and 125 µm2 for particle projected area.  
 
 
McCarthy =   
Elongation  
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Table 3.1. Particle size parameters for Orphenadrine Citrate powder. 
 
 
The cumulative undersize frequency curves for the minimum and 
maximum Feret diameters (Figure 3.1.) also indicate a rather narrow 
particle size distribution composed mainly of fine particles with a lower 
percentage of larger particles, which is reflected in the low mode values 
for each of the parameters. 
 
The two dimensional shape properties of the particles, in the form of the 
McCarthy elongation (Table 3.1.) and (Figure 3.2.) indicate the 
abundance of elongated particles in the powder system. This fact is made 
clearer in the SEM images (Figures 3.3. and 3.4.) which show the 
presence of large amounts of elongated rectangular shaped particles. 
 
Parameter 
Lower 
Quartile 
(25%) 
Median 
(50%) 
Upper 
Quartile 
(75%) 
Mode 
 
Maximum Feret 
diameter (µm) 
10 19 37 6 
Minimum Feret 
diameter (µm) 
6 11 22 3 
Area  (µm2) 35 125 450 8 
McCarthy 
Elongation 
1.43 1.67 2.00 1.81 
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Figure 3.1. Percentage cumulative undersize frequency curve for 
Orphenadrine Citrate powder, -■- minimum Feret diameter, -●-maximum 
Feret diameter. 
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Figure 3.2. Percentage cumulative undersize frequency curve of 
McCarthy elongation for Orphenadrine Citrate powder. 
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Figure 3.3.  SEM image of Orphenadrine Citrate powder (magn. 100x). 
 
 
 
 
Figure 3.4.  SEM image of Orphenadrine Citrate powder (magn. 500x). 
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3.3.1.2. Orphenadrine Hydrochloride: 
Size parameters associated with the drug Orphenadrine HCl (Table 3.2.) 
and (Figure 3.5.), indicate an even finer powder in comparison with 
Orphenadrine Citrate. The HCl form has median values of 4 µm, 6 µm, 
and 10 µm 2 for the minimum Feret diameter, maximum Feret Diameter 
and projected area, respectively. 
 
 
Table 3.2. Particle size parameters for Orphenadrine HCl powder. 
 
The cumulative undersize frequency curves for the minimum and 
maximum Feret values (Figure 3.5.) also indicate a much narrower 
particle size distribution as compared to Orphenadrine Citrate.  In terms 
of the shape properties, no great difference is observed between the 
values obtained for Orphenadrine HCl  (Table 3.2.) and (Figure 3.6.) and 
those obtained for Orphenadrine Citrate. This finding is supported by the 
SEM images obtained for Orphenadrine HCl (Figures 3.7. and 3.8.) which 
show the abundance of elongated particles in the powder system. 
However, the sizes of the particles are smaller than those of 
Orphenadrine Citrate. 
Parameter 
Lower 
Quartile 
(25%) 
Median 
(50%) 
Upper 
Quartile 
(75%) 
Mode 
 
Maximum Feret 
diameter (µm) 
3 6 10 3 
Minimum Feret 
diameter (µm) 
2 4 6 2 
Area  (µm2) 5 10 35 2 
McCarthy 
Elongation 
1.38 1.60 1.93 1.80 
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Figure 3.5. Percentage cumulative undersize frequency curve for 
Orphenadrine HCl powder, -■- minimum Feret diameter, -●-maximum 
Feret diameter. 
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Figure 3.6. Percentage cumulative undersize frequency curve of 
McCarthy elongation for Orphenadrine HCl powder. 
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Figure 3.7.  SEM image of Orphenadrine HCl powder (magn. 1000x). 
 
 
 
 
Figure 3.8.  SEM image of Orphenadrine HCl powder (magn. 3000x). 
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3.3.1.3. Xanthan Gum: 
Xanthan Gum is a microbiologically produced polymer, which is available 
in a number of size ranges (Singh 2006). The crucial role of the polymer 
in the mechanism of action of hydrophilic matrix systems, and the 
previously discussed influence of polymer particle size on this mechanism 
of action, makes it essential to give a thorough characterisation of the 
size and shape properties associated with this polymer. 
 
The size parameters and size distribution of Xanthan Gum powder (Table 
3.3) and (Figure 3.9.) indicate a powder with a large percentage of fine 
particles, with median values of 13 µm, 29 µm, and 190 µm2   for the 
minimum Feret diameter, maximum Feret diameter, and projected area, 
respectively. This is also supported by the low mode values associated 
with all three parameters. However, further observation of Figure 3.9. 
indicates the presence of wider size distribution as compared to the 
previous materials, with the presence of a certain percentage of large 
particles. 
 
In terms of shape properties, the two-dimensional results obtained for the 
McCarthy elongation for Xanthan Gum powder (Table 3.3) and (Figure 
3.10.), indicate the presence of particles with a higher degree of 
elongation, with a median value of 2.07.  Furthermore, the percentage 
cumulative undersize curve for this parameter (Figure 3.10.) shows a 
clear shift towards higher values as compared to those obtained for the 
other materials used in the study.  
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Further investigation of the morphological characteristics of Xanthan Gum 
powder system using SEM, (Figures 3.11. and 3.12.), revealed the 
presence of angular shaped particles in addition to some fibrous particles 
that are heavily elongated. 
 
Table 3.3. Particle size parameters for Xanthan Gum powder. 
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Figure 3.9. Percentage cumulative undersize frequency curve for 
Xanthan Gum powder, -■- minimum Feret diameter, -●-maximum Feret 
diameter. 
Parameter 
Lower 
Quartile 
(25%) 
Median 
(50%) 
Upper 
Quartile 
(75%) 
Mode 
 
Maximum Feret 
diameter (µm) 
18 29 48 9 
Minimum Feret 
diameter (µm) 
8 13 24 7 
Area  (µm2) 80 190 640 38 
McCarthy 
Elongation 
1.57 2.07 2.82 2.69 
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Figure 3.10. Percentage cumulative undersize frequency curve of 
McCarthy elongation for Xanthan Gum powder. 
 
 
 
Figure 3.11.  SEM image of Xanthan Gum powder (magn. 40x). 
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Figure 3.12.  SEM image of Xanthan Gum powder (magn. 200x). 
 
 
3.3.1.4. Spray Dried Lactose: 
As will be discussed later, spray dried lactose is the main diluent used in 
the formulation of tablets investigated in this study. Moreover, this diluent 
has a high aqueous solubility.  It is thus important to have a clear 
understanding of the particle size and shape properties of this material, 
as they could have a significant influence on the compaction and 
hydration behaviour of the tablets, and on the process of drug release. 
 
The size parameters of spray dried lactose are presented below (Table 
3.4.) and (Figure 3.13.).  The average particle size of the spray dried 
lactose batch used in this study is comparable to those reported 
elsewhere in literature where 40-60% of particles had a particle size of 
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less than 100 µm (Kibbe 2000). Further investigation of the size 
distribution of this batch reveals a rather wide particle size distribution 
with a high percentage of fines as well as large particles. This feature 
could in turn be attributed to the nature of spray dried lactose. It is 
composed of aggregates of α-lactose monohydrate produced by spray 
drying (Hutton et al 1972).  Spray dried lactose aggregates could have 
various sizes and they could also fragment into smaller particles during 
the preparation of the microscopy slide giving rise to a wide particle size 
distribution. 
 
Table 3.4. Particle size parameters for spray dried lactose powder. 
 
 
 
 
 
Parameter 
Lower 
Quartile 
(25%) 
Median 
(50%) 
Upper 
Quartile 
(75%) 
Mode 
 
Maximum Feret 
diameter (µm) 
17 60 130 16 
Minimum Feret 
diameter (µm) 
9 38 93 5 
Area  (µm2) 80 1160 7660 7 
McCarthy 
Elongation 
1.31 1.54 1.96 1.81 
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Figure 3.13. Percentage cumulative undersize frequency curve for Spray 
Dried Lactose powder, -■- minimum Feret diameter, -●-maximum Feret 
diameter. 
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Figure 3.14. Percentage cumulative undersize frequency curve of 
McCarthy elongation for spray dried lactose powder. 
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Figure 3.15.  SEM image of spray dried lactose powder (magn. 100x). 
 
 
 
 
Figure 3.16.  SEM image of spray dried lactose powder (magn. 500x). 
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The two-dimensional shape properties of spray dried lactose, (Table 3.4.) 
and (Figure. 3.14.) indicate the presence of some degree of elongation. 
The median value of McCarthy elongation is 1.54. However, in 
comparison to Xanthan Gum, the distribution of this elongation value 
associated with spray dried lactose (Figure. 3.14.) appears to be 
narrower. Such findings are further elucidated by the SEM images 
obtained for spray dried lactose (Figures 3.15. and 3.16.), which show the 
presence of rather spherical aggregated particles with some degree of 
elongation.  Elongated crystal shaped smaller particles are also present. 
 
 
3.3.1.5. Dibasic Calcium Phosphate Dihydrate (Emcompress ®): 
Particle size parameters and size distribution of Emcompress® powder 
are presented below (Table 3.5) and (Figure 3.17.), respectively. The low 
median values of particles size parameters, 13 µm, 24 µm, and 145 µm2    
for the minimum Feret diameter, maximum Feret diameter and area, 
respectively could be attributed to the presence of a large amount of  
 
 
Table 3.5. Particle size parameters for Emcompress® powder. 
Parameter 
Lower 
Quartile 
(25%) 
Median 
(50%) 
Upper 
Quartile 
(75%) 
Mode 
 
Maximum Feret 
diameter (µm) 
13 24 101 13 
Minimum Feret  
diameter (µm) 
6 13 63 5 
Area  (µm2) 45 145 4020 7 
McCarthy Elongation 1.42 1.70 2.27 1.42 
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Figure 3.17. Percentage cumulative undersize frequency curve for 
Emcompress®  powder, -■- minimum Feret diameter, -●-maximum Feret 
diameter. 
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Figure 3.18. Percentage cumulative undersize frequency curve of 
McCarthy elongation for Emcompress® powder. 
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Figure 3.19.  SEM image of Emcompress® powder (magn. 40x). 
 
 
 
 
Figure 3.20.  SEM image of Emcompress® powder (magn. 180x). 
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fine particles in the powder system. However, further investigation shows 
the presence of a wide particle size distribution (Figure 3.17). This is 
further supported by the considerable gap between the median values of 
all parameters and their upper quartile values (Table 3.5.). Such 
behaviour could originate from the fragmentation of the larger brittle 
Emcompress® particles into multiple smaller ones, giving rise to a system 
containing large fractions of coarse and fine particles. 
 
In terms of shape properties, the values of McCarthy elongation 
associated with Emcompress® powder indicate the presence of particles 
with some degree of elongation. The value distribution curve (Figure 
3.18) indicates a wider value distribution as compared to spray dried 
lactose.  SEM images (Figures 3.19. and 3.20.) give more clarity to this, 
as they illustrate the presence of coarse and fine particles of varying 
degrees of elongation in the system. 
 
 
3.3.1.6. Magnesium Stearate: 
Magnesium Stearate is a lubricant used in the production of 
pharmaceutical tablets. It has a very low particle size, hence it was not 
possible to use light microscopy to produce reliable particle size 
distribution measurements for this powder. SEM images of the powder  
(Figures 3.21 and 3.22.) revealed a range of fine crystal aggregates of 
varying sizes. 
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Figure 3.21. SEM image of magnesium stearate powder (magn. 1000x). 
 
 
 
 
Figure 3.22.  SEM image of magnesium stearate powder (magn. 3000 x). 
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3.3.2. Determination of the moisture content of the powders: 
The moisture content of pharmaceutical powders may have a significant 
influence on the compaction properties of the powders, and by that 
influencing the physical properties and behaviour of the produced tablets. 
 
The moisture contents of the drug and excipient powder systems used in 
this study were determined using halogen moisture analysis. The results 
are presented in Table 3.6. Sample heating was carried out at 90°C for all 
samples apart from magnesium stearate which undergoes a melting 
process above 50°C, thus the heating for this material was carried out at 
50°C The two drugs, Orphenadrine Citrate and Orphenadine HCl, 
contained minimal amount of moisture content with equal values of 0.1%. 
As for the excipients, Xanthan Gum contained the highest moisture 
content of 12.46% and this is in accordance with a previously reported 
reference value of ≤ 15% (Singh 2006). This behaviour could be 
attributed to the hydrophilic property of the polymer.  The other excipients 
exhibited lower and varying degrees of moisture content. The values for 
spray dried lactose and magnesium stearate were in accordance with 
reference values of ≤ 0.5% (Edge et al 2006), and ≤ 6% (Allen and Luner 
2006), respectively. 
 
As for Emcompress®, the measured value of 2.23% was considerably 
lower than the reference value reported in literature of 19.5-22% (Moreton 
2006). One explanation for this could lie in the particle size properties 
associated with this powder. The presence of a large amount of fine 
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particles in the powder system used in the study may have facilitated the 
process of moisture loss, due to the much greater surface area available 
in smaller particles. 
 
Powder 
Moisture Content 
(%) 
Heating 
temperature (°C) 
Orphenadrine Citrate 0.10 90 
Orphenadrine Hydrochloride 0.10 90 
Xanthan Gum 12.46 90 
Spray Dried Lactose 0.11 90 
Dibasic Calcium Phosphate 
Dihydrate (Emcompress ®) 
2.23 90 
Magnesium Stearate 1.03 50 
 
Table 3.6. Percentage moisture content of drug and excipient powders. 
 
 
3.3.3. Determination of the apparent densities of the powders: 
Determination of the apparent densities of all powders incorporated into 
the formulations used in this study was done using helium pycnometry. 
This is a rather non-destructive technique for obtaining the apparent 
density of pharmaceutical powders. 
 
This technique provides the closest measurements of the true volume of 
a material as it depends on the advantageous properties of helium 
molecules which are able to penetrate pores and surface structures as 
small as one Ångstrom, due to their small size.  
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Initially the apparent densities of all powders in their ambient state were 
determined. However, certain materials, such as hydrophilic polymers, 
may adsorb large amounts of moisture on their surface. This may lead to 
inaccurate determination of the apparent density using pycnometry. Thus, 
the determination of the apparent densities of all powder systems was 
repeated with samples that were subjected to loss on drying analysis, as 
the adsorbed moisture content of the samples would have been lost.  The 
apparent densities for all powders before and after drying are listed below 
(Table 3.7.). 
 
 
Powder 
APD 
Before drying 
APD 
After drying 
t-test 
p 
Orphenadrine Citrate 
1.245 
( 0.024)* 
1.225 
( 0.009)* 
0.146 
Orphenadrine Hydrochloride 
1.166 
( 0.027)* 
1.153 
( 0.016)* 
0.371 
Xanthan Gum 
1.542 
( 0.006)* 
1.552 
(0.008 )* 
0.048 
Spray Dried Lactose 
1.536 
( 0.006)* 
1.528 
( 0.004)* 
0.033 
Dibasic Calcium Phosphate Dihydrate 
(Emcompress ®) 
2.377 
( 0.015)* 
2.367 
( 0.017)* 
0.360 
Magnesium Stearate 
1.091 
( 0.021)* 
1.087 
( 0.014)* 
0.728 
 
Table 3.7. Apparent powder density of drug and excipient powders before 
and after drying. *Standard deviation (n = 5). p: significance; error 
probability to just reject the null hypothesis (significant if p<0.05). 
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All runs were performed with five replicates, and the significance of the 
difference in powder apparent density, before and after drying, was 
investigated using the independent sample t-test. 
 
Xanthan Gum was the only material to exhibit a significant but small 
increase in its determined apparent density after drying (p= 0.048). As for 
the other materials, they all exhibited a reduction in their determined 
apparent density after drying. The difference was significant with spray 
dried lactose (p= 0.033). The difference between the apparent densities 
of the four other materials, before and after drying was not significant. 
 
The behaviour of the powders, in terms of their density variation, could be 
clarified by the results of the moisture analysis studies. Xanthan Gum 
was the only powder with a considerable amount of moisture content. 
Water adsorbed on the surface of the particles may lead to errors in the 
determination of the apparent density. Picker and Mielck (1996), when 
working with pure hydrophilic polymer powders, used thermogravimertic 
analysis to determine the moisture content of the hydrophilic polymers 
maintained at different relative humidities. They suggested the use of a 
correction factor for the calculation of the apparent density of polymer 
powders when placed at equilibrium at various relative humidities, taking 
into account the influence of polymer bound water. However, this 
suggestion was made for pure polymer powders when placed at 
equilibrium at various relative humidities, but when the polymer is 
incorporated into multi-component formulations, and then compacted into 
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pharmaceutical tablets, its hydration properties may be affected which 
makes it difficult to determine its hydration characteristics. 
 
As for all the other powders used in this study, they contained low 
amounts of moisture, and thus, the heating process may have affected 
the structure of the powder particles. This effect, of course, varies from 
material to material depending on its properties. 
 
 
3.3.4. Thermal Characterisation of Spray Dried Lactose: 
As discussed previously, spray dried lactose is usually manufactured by 
spray drying a suspension of α-lactose monohydrate crystals. This 
technique results in a material that has varying percentages of crystalline 
and amorphous content. The amorphous form of lactose was reported to 
have several advantages such as better compaction properties (Sebhatu 
and Alderborn 1999) and higher aqueous solubility. However, certain 
disadvantages are also associated with this form, mainly its 
hygroscopicity (Vromans et al 1987), and low stability (Elamin et al 1995). 
Hence, it is crucial to determine the polymorphic behaviour of any spray 
dried lactose batch.  
 
The thermal behaviour of the spray dried lactose batch used in this study 
was investigated using Differential Scanning Calorimetry (DSC), which 
was considered a simple qualitative technique for identifying the type of 
hydrate present and content of the amorphous form of lactose. The 
results are presented below (Figure 3.23.)  
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Figure 3.23.  DSC thermogram of spray dried Lactose powder, heating 
rate 10°C/min, samples weight 5.1 mg.  
 
 
The thermogram of the spray dried lactose batch used in the study 
exhibited a typical thermal behaviour associated with crystalline α-lactose 
monohydrate, showing a dehydration endothermic peak at about 146°C 
and a melting endothermic peak at about 220°C. This behaviour could be 
attributed to the conversion of the unstable amorphous form of lactose 
into the more stable crystalline form during the storage period. 
As a quality control procedure the thermal investigation of the lactose 
batch was repeated at the start and the end of the study to monitor any 
change in behaviour. Similar results were obtained on both occasions, 
and thus it was possible to eliminate the potential influence of a change 
due to recrystallisation for this study. 
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3.4. General Discussion and Conclusions: 
The results presented in this Chapter showed a varying nature in the 
physicochemical properties of the materials used in this study. In terms of 
the physicochemical properties of the two drugs used, Orphenadrine HCl 
is characterised by having a very small particle size value with a narrow 
particle size distribution. Whereas, Orphenadrine Citrate has a larger 
particle size value, and to an extent, a broader particle size distribution. 
This difference may have an influence on the physical properties of the 
different formulations used in this study. It could significantly influence 
their compaction properties, and the properties of the produced tablets.  
Moreover, this size difference, in association with the difference in the 
aqueous solubility between the two drugs, may have a marked influence 
on the hydration behaviour of the tablets, and on the process of drug 
release from them. 
 
In terms of the polymer and the diluents used in this study, all of these 
materials exhibited rather broad particle size distributions. This was also 
accompanied by the presence of a large amount of fine particles.   
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CHAPTER FOUR 
 
4. Production and physical characterisation of tablets 
4.1 Introduction: 
The influence of tablet properties, in terms of face curvature and porosity, 
on tablet physical behaviour, had been studied before using other types 
of pharmaceutical tablets. It was reported that these variables have a 
significant influence on the structural properties within the tablet, and on 
tablet tensile strength (Pitt et al 1989, 1990, Newton et al 2000a, 2000b, 
Djemai et al 2005). Such variables, and their subsequent influence on 
tablet properties, could have clear and major manifestations in hydrophilic 
matrix tablets, which undergo a hydration process initiated by water 
diffusion into the tablet and manifested by tablet swelling and expansion, 
all of which could be greatly affected by variation in tablet structural 
features. 
 
It was hence the aim of this chapter to investigate fully the influence of 
such variables on the physical properties associated with the tablets used 
in this study. It was also attempted to clarify any observed variations 
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further using microscopic imaging techniques of the tablet structure. 
Another aim of this chapter was to elucidate how the influence of tablet 
face curvature, and that of tablet overall porosity, on the physical 
properties of the tablet vary when changing the nature of the formulation 
used in tablet production. 
 
 
4.2. Choice of tablet parameters: 
The choice of the particular tablet shapes used in this study was done to 
in order to have a representative model of the various degrees of tablet 
face curvature used normally in the pharmaceutical industry.  Moreover, 
this selection was done to gain insight into the behaviour of tablets with a 
considerable variation in the nature of their structural properties.  
 
4.2.1. Round tablets: 
Four different degrees of tablet face curvature ratio were used for round 
tablets, as illustrated below (Figure 4.1.) and (Table 4.1). Moreover, the 
internal structural properties of all tablets were varied by using three 
different degrees of tablet overall porosity, i.e. 12.5%, 15% and 17.5%.  
Attempts to press tablets with the higher degrees of face curvature ratios 
of 1 and 1.43 at a lower porosity of 10% were not successful. Thus three 
degrees of tablet overall porosity were used. 
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Figure 4.1: Schematic representation of the shape parameters of round 
tablets. R: radius of curvature, D: diameter. 
 
 
 
Tablet Curvature Radius of Curvature (mm) Face Curvature Ratio (R/D) 
Flat 0.00 0.00 
Shallow 6.25 0.50 
Unity 12.5 1.00 
Coating 17.88 1.43 
  
Table 4.1. Face curvature ratios of round tablets used. All tablets had a 
constant diameter of 12.5mm. 
 
 
4.2.2. Elongated tablets: 
Elongated tablets were used with three different degrees of curved 
segment height “a” of 0 mm “flat”, 1 mm and 2 mm (Figure 4.2.). In terms 
   
        Unity        Flat       Shallow     Coating 
R 
 D 
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of tablet porosity, it was not possible to produce elongated tablets with 
curved segment height of 2 mm at a porosity of 12.5%, thus, an upward 
shift in porosity values was undertaken resulting in three different degrees 
of tablet overall porosity of 15%, 17.5% and 20%. 
 
 
 
 
 
 
 
 
Figure 4.2. Schematic representation of shape parameters of elongated 
tablets, adapted from Newton et al (2000b). 
 
A detailed description of the volume and shape parameters associated 
with all tablets used in this study are reported in the appendix. 
 
4.3. Choice of formulations and tablet production: 
A step wise experimental approach was adopted in the choice of the 
formulations used in this study. After initial selection of the hydrophilic 
polymer and drug substances, formulation development was carried out 
in parallel with tablet production. The main aim of this was to produce 
tablets with varying degrees of porosity, and sufficient physical strength to 
allow handling. 
 
a 
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Multiple formulations were initially investigated, in which the contents of 
the diluents were varied. However, the three formulations listed in Table 
4.2. were chosen because they allowed the production of tablets with the 
desired porosities and also with sufficient strength for handling. 
 
 
Table 4.2.  Percentage contents of formulations used in tablet production. 
 
Another factor taken into consideration during the process of formulation 
development was to keep the polymer content higher than that of the 
drug. This was sought to maintain a sufficient amount of the polymer for 
hydration in the presence of any interaction with the drug. 
 
The apparent powder densities for the three formulation mixtures used in 
the study are presented below (Table 4.3.). Apart from Xanthan Gum, for 
all materials, the values for apparent powder density used were those 
obtained prior to subjecting the materials to loss on drying analysis, in 
order to avoid any influence cause by the possible changes in material 
Formulation 
Ingredients 
Formulation percentage content 
A B C 
Xanthan Gum 47.5 35.0 35.0 
Spray Dried Lactose 47.5 35.0 35.0 
Dibasic Calcium Phosphate Dihydrate 4.0 4.0 4.0 
Magnesium Stearate 1.0 1.0 1.0 
Orphenadrine Citrate 0.0 25.0 0.0 
Orphenadrine HCl 0.0 0.0 25.0 
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structure during the heating process. In the case of Xanthan Gum, the 
value used was that obtained for the dried Xanthan Gum sample. Once 
again this was done due to the high moisture content associated with the 
polymer powder.  
 
 
Formulation Apparent powder mixture density (g/cm3) 
A 1.573 
B 1.498 
C 1.479 
 
Table 4.3. Apparent powder mixture densities of formulations used in 
tablet production. 
 
A detailed description of the weight parameters associated with all the 
tablets used in the study is reported in the appendix.  
 
 
 
4.4. Results and discussion: 
4.4.1. Determination of the tensile strength of round tablets: 
The tensile strength values of round tablets formulated with the three 
formulations used in this study are presented in Figures 4.3. to 4.5. The 
results are presented as a function of tablet face curvature.  It is clearly 
evident from the figures that the influence of tablet structural properties; 
i.e. tablet face curvature and tablet porosity, on tablet tensile strength 
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values changes with the change in tablet formulation. For blank Xanthan 
Gum tablets (Figure 4.3.), increasing tablet face curvature ratio from 0 to 
0.5, resulted in a drop in tablet tensile strength. Further increase in tablet 
face curvature ratio resulted in a progressive increase in tablet tensile 
strength, and this effect was observed in tablets produce at all three 
degrees of tablet overall porosity. A clear drop in tablet tensile strength 
was observed with the progressive increase in tablet overall porosity from 
12.5% to 17.5%, and this influence was observed with all face curvature 
ratios.  
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Figure 4.3. Tensile strength of round blank Xanthan Gum tablets. 
-▲-  Porosity 12.5%,  -●- Porosity 15%, -■-,  Porosity 17.5%, (n = 6). 
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Figure 4.4. Tensile strength of round Xanthan Gum tablets with 
Orphenadrine Citrate. -▲-  Porosity 12.5%,  -●- Porosity 15%, -■-,  
Porosity 17.5%, (n = 6). 
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Figure 4.5. Tensile strength of round Xanthan Gum tablets with 
Orphenadrine HCl. -▲-  Porosity 12.5%,  -●- Porosity 15%, -■-,  Porosity 
17.5%, (n = 6). 
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Inclusion of either of the two drugs used in this study resulted in a clear 
change in tablet tensile strength values. For tablets containing the drug 
Orphenadrine Citrate (Figure 4.4.), a clear drop in tablet tensile strength 
was observed with the increase in tablet overall porosity from 12.5% to 
17.5%. The influence of tablet face curvature ratio was different in 
comparison to blank tablets. Increasing tablet face curvature ratio from 0 
to 0.5 resulted in a decrease in tablet tensile strength. Further increase in 
tablet face curvature ratio had a varying influence on tablet tensile 
strength for tablets produced at different overall porosity values. Tablets 
containing the drug Orphenadrine HCl (Figure 4.5.) exhibited a similar 
pattern in relation to the influence of tablet overall porosity. A clear drop in 
tablet tensile strength values was observed with the progressive increase 
in tablet overall porosity from 12.5% to 17.5%. This influence was also 
consistent with all face curvature ratios.  The influence of tablet face 
curvature ratio was once again highly dependent on tablet overall 
porosity. For tablets produced at the two lower porosities of 12.5% and 
15%, a progressive increase in tablet tensile strength was observed with 
the progressive increase in tablet face curvature ratio from 0 to 1. This 
was followed by a drop in tablet tensile strength upon further increase in 
tablet face curvature ratio from 1 to 1.43. For tablets produced at the 
higher overall porosity of 17.5%, a decrease in tablet tensile strength was 
observed upon increase in tablet face curvature ratio from 0 to 0.5. This 
was followed by a progressive increase in tablet tensile strength with 
further increase in tablet face curvature ratio from 0.5 to 1.43.  
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4.4.2. Statistical analysis of tensile strength values of round tablets: 
The variation of tablet tensile strength values among the three 
formulations used in this study, and the clear influence of this variable on 
the effects induced by the changes in tablet face curvature and porosity, 
necessitated further elucidation of the differences between the tensile 
strength values obtained for the various tablets studied.  
 
This statistical comparison of the tensile strength values of round tablets 
used in this study was accomplished by the use of analysis of variance 
(ANOVA) which is one of the powerful statistical analysis methods used 
in the comparison of the means of two or more groups of samples. The 
principle of this analysis depends on the comparison between the 
variability between the different groups with the variability within each of 
the separate groups through the use of the F-ratio which is calculated by  
dividing the variance between groups by that within the groups. The 
larger the F-ratio, the more indication of the presence of variability 
between groups (Pallant 2005). The computer calculates the precise error 
probability at which the Null hypothesis can just be rejected. If the value 
of the calculated error probability is equal to or less than a threshold of 
0.05, then this can be accepted as significant difference. 
 
For the analysis of the tensile strength values of round tablets used in this 
study, a multiple process of variance analysis was adopted. Initially, two-
way ANOVA, which requires the presence of two independent 
categorising factors or variables under investigation, was carried out for 
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each formulation separately to investigate the significance of any effect 
induced by the change of tablet face curvature and porosity on tablet 
tensile strength. Further elucidation of the results was accomplished by a 
series of one-way ANOVAs, which were carried out for each value of 
overall porosity separately. This was done to investigate the influence of 
tablet face curvature on tablet strength and how this effect changes with 
changes in tablet overall porosity.  
 
4.4.2.1. Round blank Xanthan Gum tablets: 
The results of the two-way ANOVA for the tensile strength values of 
round blank Xanthan Gum tablets are shown in Table 4.4. The results 
indicate a significant influence of tablet overall porosity on tablet tensile 
strength with an F ratio of 790.185 corresponding to a p value of less than 
0.001. A significant influence was also observed for tablet face curvature 
ratio with an F ratio of 199.287 corresponding to a p value of less than 
0.001. The influence of tablet overall porosity seems to be more 
significant. This is indicated by the higher F ratio. However, and more 
importantly, the interaction product between tablet overall porosity and 
tablet face curvature ratio also has a significant influence on tablet tensile 
strength with an F ratio of 10.232 corresponding to a p value of less than 
0.001. Such interaction is clearly evident in Figure. 4.3.; the magnitude of 
the difference between the tensile strength values for tablet with different 
face curvature ratios seems to decrease with the progressive increase in 
tablet overall porosity.  
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In order to give a clear picture for the interaction between tablet porosity 
and tablet face curvature ratio, one-way ANOVA was carried out for each 
of the three values of tablet overall porosity separately, to investigate the 
differences between tablets with different face curvature ratios. The 
results (Table 4.5.) indicate that tablet face curvature ratio had a 
significant influence on the tensile strength of tablets with all three overall 
porosity values.  
 
 
Variable df             F       p 
Porosity 2 790.185 < 0.001 
Curvature 3 199.287 < 0.001 
Porosity*Curvature 6 10.232 < 0.001 
 
Table 4.4. Results of the two-way ANOVA for the tensile strength of 
round blank Xanthan Gum tablets. 
 
 
 
Porosity df            F           p 
12.5% 3 77.033 < 0.001 
15.0% 3 100.098 < 0.001 
17.5% 3 32.221 < 0.001 
 
Table 4.5. Results for the one-way ANOVA for the tensile strength of 
round blank Xanthan Gum tablets, with different face curvature ratios. 
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Further insight into the significant effect as a result of the change in tablet 
face curvature ratio on tablet tensile strength (Table 4.5.) was 
accomplished by post hoc analysis using the Sheffé test, the use of which 
was justified due to the high significance associated with the studied 
variable; i.e. tablet face curvature ratio.  
 
The results for the post hoc analysis for tablets produced at overall 
porosity values of 12.5%, 15% and 17.5% are listed in Tables 4.6. to 4.8.  
 
 
 
 
 
 
 
Table 4.6. Results for the Sheffé post-hoc analysis test for round blank 
Xanthan Gum tablets, porosity 12.5%. 
 
 
 
 
 
 
 
 
Table 4.7. Results for the Sheffé post-hoc analysis test for round blank 
Xanthan Gum tablets, porosity 15.0%. 
  
Curvature N 
Subset 
1 2 3 
0.5 6 .43381   
1 6  .64580  
0 6   .73980 
1.43 6   .77275 
Sig.   1.000 1.000 .623 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
Curvature N 
Subset 
1 2 3 
0.5 6 .25724   
1 6  .43866  
1.43 6   .52172 
0 6   .52998 
Sig.   1.000 1.000 .975 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
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Table 4.8. Results for the Sheffé post-hoc analysis test for round blank 
Xanthan Gum tablets, porosity 17.5%. 
 
 
The outcome of the Sheffé analysis groups the mean tensile strength 
values for the different levels of the studied variable into progressive 
subsets; the values grouped into the same subset are considered to have 
no significant difference between them. However, those grouped into 
different subsets are considered significantly different. The results for 
tablets with an overall porosity of 12.5% (Table 4.6.) show three different 
subsets. Tablets with a face curvature ratio of 0.5 have the lowest tensile 
strength value, followed by tablets with a face curvature ratio of 1. The 
highest tensile strength values were obtained with tablets with a face 
curvature ratio of 0 and 1.43, and these values are statistically similar. A 
similar pattern is obtained with tablets having an overall porosity of 15%. 
However, further increase in tablet overall porosity resulted in two 
subsets only. Tablets with a face curvature ratio of 0.5 had a mean tensile 
strength value that is significantly lower than tablets produced at the three 
other levels of face curvature ratio which were statistically similar. 
 
Curvature N 
Subset 
1 2 
0.5 6 .15943  
1 6  .25353 
1.43 6  .29754 
0 6  .29878 
Sig.   1.000 .083 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
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4.4.2.2. Round Xanthan Gum tablets with Orphenadrine Citrate: 
The results of the two-way ANOVA for the tensile strength of round 
Xanthan Gum tablets with Orphenadrine Citrate (Table 4.9.) indicated a 
highly significant influence of tablet overall porosity on tablet tensile 
strength with an F ratio of 964.245 corresponding to a p value of less than 
0.001. A significant influence was also observed for tablet face curvature 
ratio with an F ratio of 53.418 corresponding to a p value of less than 
0.001. Moreover, similar to the blank tablets, the interaction between the 
two variables; tablet overall porosity and face curvature ratio, had a 
significant influence on tablet tensile strength with an F ratio of 5.499 
corresponding to a p value of less than 0.001.  
 
The results of the one-way ANOVA for tablets with the three degrees of 
overall porosity are listed in Table 4.10. and they indicate a significant 
effect induced by the change in tablet face curvature on tablet tensile 
strength, for all degrees of tablet overall porosity. 
 
Variable df              F        p 
Porosity 2 964.245 < 0.001 
Curvature 3 53.418 < 0.001 
Porosity*Curvature 6 5.499 < 0.001 
 
Table 4.9. Results of the two-way ANOVA for the tensile strength of 
round Xanthan Gum tablets with Orphenadrine Citrate. 
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Porosity df            F           p 
12.5% 3 18.935 < 0.001 
15.0% 3 23.327 < 0.001 
17.5% 3 30.748 < 0.001 
 
Table 4.10. Results for the one-way ANOVA for the tensile strength of 
round Xanthan Gum tablets with Orphenadrine Citrate, with different face 
curvature ratios. 
 
The results of the post hoc Sheffé analysis for tablets with overall 
porosities of 12.5% and 15% (Tables 4.11. and 4.12.) show a similar 
pattern; two subsets were obtained, the first of which contained the mean 
strength values for tablets with face curvature ratios of 0, 0.5 and 1. Thus, 
these values are considered statistically similar. A significantly higher 
strength value was obtained with tablets having a face curvature ratio of 
1.43, which is placed in a separate subset.  
 
Upon further increase in tablet overall porosity a different outcome was 
obtained (Table 4.13.); the output of the Sheffé test had three subsets, 
the first contained the mean strength values for tablets with face 
curvature ratios of 0.5. The second contained those of tablets with a face 
curvature ratio of 1, and the third contained the mean strength values for 
tablets with face curvature ratios of 0 and 1.43. These values were 
statistically similar, and significantly higher than the values obtained for 
tablets with face curvature ratios of 0.5 and 1. 
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Table 4.11. Results for the Sheffé post-hoc analysis test for round 
Xanthan Gum tablets with Orphenadrine Citrate, porosity 12.5%. 
 
 
 
 
 
 
 
Table 4.12. Results for the Sheffé post-hoc analysis test for round 
Xanthan Gum tablets with Orphenadrine Citrate, porosity 15.0%. 
 
 
 
 
 
 
 
 
Table 4.13. Results for the Sheffé post-hoc analysis test for round 
Xanthan Gum tablets with Orphenadrine Citrate, porosity 17.5%. 
 
Curvature N 
Subset 
1 2 
1 6 .36859  
0.5 6 .37442  
0 6 .39398  
1.43 6  .51487 
Sig.   .667 1.000 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
 
Curvature N 
Subset 
1 2 
0.5 6 .62818  
0 6 .65900  
1 6 .69150  
1.43 6  .82238 
Sig.   .192 1.000 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
Curvature N 
Subset 
1 2 3 
0.5 6 .19220     
1 6   .23096   
0 6     .27860 
1.43 6     .28848 
Sig.   1.000 1.000 .860 
Means for groups in homogeneous subsets are displayed. 
Sheffe test uses Harmonic Mean Sample Size = 6.000. 
Alpha = .05. 
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4.4.2.3. Round Xanthan Gum tablets with Orphenadrine HCl: 
The results for the two-way ANOVA for round Xanthan Gum tablets with 
Orphenadrine HCl are listed in Table 4.14. The results are somewhat 
similar to those obtained for tablets made using the two other 
formulations; tablet overall porosity had a highly significant influence on 
tablet tensile strength with an F ratio of 602.155 corresponding to a p 
value of less than 0.001. A significant influence was also obtained for the 
variable “tablet face curvature ratio”, but with a lower value for the F ratio 
of 20.321 corresponding to a p value of less than 0.001. The interaction 
between the two previous variables had also a significant influence on 
tablet tensile strength with an F ratio of 6.191 corresponding to a p value 
of less than 0.001.  
 
Variable df               F       p 
Porosity 2 602.155 < 0.001 
Curvature 3 20.321 < 0.001 
Porosity*Curvature 6 6.191 < 0.001 
 
Table 4.14. Results for the two-way ANOVA for the tensile strength of 
round Xanthan Gum tablets with Orphenadrine HCl. 
 
 
One-way ANOVA was also carried out for tablets with different degrees of 
overall porosity. The results (Table 4.15.) indicate a significant effect of 
tablet face curvature ratio on tablet tensile strength at all three levels of 
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tablet overall porosity. The results of the Sheffé analysis for these tablets 
are shown in Tables 4.16. to 4.18. 
 
Porosity df            F           p 
12.5% 3 13.658 < 0.001 
15.0% 3 7.764 0.001 
17.5% 3 6.641 0.003 
 
Table 4.15. Results for the one-way ANOVA for the tensile strength of 
round Xanthan Gum tablets with Orphenadrine HCl, with different face 
curvature ratios. 
 
 
 
 
 
 
 
Table 4.16. Results for the Sheffé post-hoc analysis test for round 
Xanthan Gum tablets with Orphenadrine HCl, porosity 12.5%. 
 
 
 
 
 
 
 
Table 4.17. Results for the Sheffé post-hoc analysis test for round 
Xanthan Gum tablets with Orphenadrine HCl, porosity 15.0%. 
Curvature N 
Subset 
1 2 
1.43 6 .71615  
0 6 .73812  
0.5 6 .77093  
1 6  .92932 
Sig.   .544 1.000 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
Curvature N 
Subset 
1 2 
0 6 .46114   
0.5 6 .47651   
1.43 6 .48051   
1 6   .57255 
Sig.   .902 1.000 
Means for groups in homogeneous subsets are displayed. 
Sheffe test uses Harmonic Mean Sample Size = 6.000. 
Alpha = .05. 
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Table 4.18. Results for the Sheffé post-hoc analysis test for round 
Xanthan Gum tablets with Orphenadrine HCl, porosity 17.5%. 
 
A similar trend is noted in the Sheffé output of tablets with overall porosity 
of 12.5% and 15%. Two Subsets are present, the first of which contained 
the statistically similar mean strength values for tablets with face 
curvature ratios of 0, 0.5 and 1.43. The second subset contained the 
mean tensile strength value for tablets with a face curvature ratio of 1. 
This value was significantly higher than the values obtained with all other 
tablets. Two subsets were also present in the Sheffé output for tablets 
with an overall porosity of 17.5%, the first of which contained the mean 
strength values for tablets with a face curvature ratio of 0.5 and 0. The 
second subset contained the mean strength values for tablets with face 
curvature ratios of 0, 1, and 1.43. Such result indicate that the only 
statistically significance difference occurred between the tensile strength 
values of tablets with face curvature ratios of 0.5 and those with ratios of 
1, and 1.43 which were significantly higher. No statistically significant 
differences were noted between the tensile strength values of flat tablets 
and those of tablets with any of the other face curvature ratios. 
Curvature N 
Subset 
1 2 
0.5 6 .24893   
0 6 .29907 .29907 
1 6   .31337 
1.43 6   .33410 
Sig.   .130 .400 
Means for groups in homogeneous subsets are displayed. 
Sheffe test uses Harmonic Mean Sample Size = 6.000. 
Alpha = .05. 
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The results of the statistical analysis for the tensile strength values of 
round tablets indicated some similar trends where both tablet overall 
porosity and to a lesser extent tablet face curvature ratio had a significant 
influence on tablet tensile strength. Moreover, the interaction between 
these two variables had a significant influence on tablet tensile strength. 
Further investigation of this interaction clearly demonstrated that round 
tablets produced at similar overall porosity values but with different face 
curvature ratios, vary in their tensile strength values. Such findings are in 
agreement with previous work carried out using other pharmaceutical 
materials (Newton et al 2000a). This behaviour could be attributed to the 
greater importance associated with the actual pore shape and size on the 
tensile strength of tablets, when compared to the importance associated 
with the overall porosity of the tablets (Rice 1993). Producing tablets 
using punches with varying degrees of face curvature could lead to 
different patterns of powder movement and densification within the tablet 
(Eiliazadeh et al 2003, 2004). This in turn could lead to different patterns 
of density and hence porosity distribution within tablets having different 
degrees of face curvature.  
 
Tablet failure upon being subjected to diametral compression is highly 
associated with the formation of cracks in the tablet structure. Tablet 
pores, although not considered as being part of flaws in the structure of 
the tablet, form the starting point for crack formation and propagation 
(Rice 1984). Thus, the actual shape and size of the individual pores could 
have a clear influence on tablet tensile strength. 
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In terms of the influence of the type of formulation on the tensile strength 
of round tablets, it becomes evident from monitoring the tensile strength 
values associated with the various round tablets (Figures 4.3. to 4.5.) that 
the change in tablet tensile strength upon changing the face curvature 
ratio of the tablet and the tablet overall porosity, is highly influenced by 
the change in the formulation used in the production of the tablets. Such 
variation arises mainly from the change in the physical properties of the 
powders incorporated into the different formulations. Such changes, 
especially the change in powder particle size and compaction properties, 
would lead to significant changes in the internal structure of the tablet.  
 
 
4.4.3. Determination of the tensile strength of elongated tablets: 
The tensile strength values for blank and drug containing elongated 
tablets are presented in Figures (4.6. to 4.8.). Values are presented as a 
function of tablet curved segment height.  Once again, it is clearly 
evident, that a change in tablet formulation caused a clear variation in the 
tensile strength values obtained for the different tablets. Upon inspection 
of the results obtained for blank Xanthan Gum tablets (Figure 4.6.), it was 
evident that increasing the height of the curved segment in the tablet from 
0 to 2mm resulted in a progressive increase in tablet tensile strength. A 
clear drop in tensile strength values was observed with the increase in 
tablet overall porosity from 15% to 20% progressively. Furthermore, the 
extent of increase in tablet tensile strength as a function of the increase in 
curved segment height varied between the different degrees of tablet 
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overall porosity, and seemed to flatten with the increase in tablet overall 
porosity. 
 
Tablets containing the drug Orphenadrine Citrate (Figure 4.7.) exhibited a 
somewhat different behaviour; an increase in tablet tensile strength was 
observed upon increase of curved segment height from 0 to 1 mm. 
Further increase in curved segment height from 1mm to 2 mm resulted in 
a minimal increase in tablet tensile strength in comparison to blank 
tablets. The effect of tablet overall porosity was also evident in these 
tablets; a drop in tablet tensile strength was found as a result of the 
progressive increase in tablet overall porosity from 15% to 20%.  
 
Tablets containing the drug Orphenadrine HCl (Figure 4.8.) exhibited a 
clear drop in tablet tensile strength with the progressive increase in tablet 
overall porosity. In terms of the effect associated with the height of the 
curved segment in the tablet, increasing this height from 0 to 2 mm 
resulted in a progressive increase in tablet tensile strength. Moreover, 
this effect also varied with the variation in tablet overall porosity.  
 
Tablets containing the drug Orphenadrine HCl had tensile strength values 
that were consistently higher than those obtained with blank tablets and 
tablets containing the drug Orphenadrine Citrate. Such effect could be 
caused by the different nature of the internal structure of tablets produced 
using the three different formulations.  
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Figure 4.6. Tensile strength of elongated blank Xanthan Gum tablets. 
-▲-  Porosity 15%,  -●- Porosity 17.5%, -■-,  Porosity 20%, (n = 6). 
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Figure 4.7. Tensile strength of elongated Xanthan Gum tablets with 
Orphenadrine Citrate. -▲-  Porosity 15%,  -●- Porosity 17.5%, -■-,  
Porosity 20%, (n = 6). 
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Figure 4.8. Tensile strength of elongated Xanthan Gum tablets with 
Orphenadrine HCl. -▲-  Porosity 15%,  -●- Porosity 17.5%, -■-,  Porosity 
20%, (n = 6). 
 
 
The results obtained in this study are in agreement with previously 
reported work, which indicated an increase in the tensile strength of 
elongated tablets with progressive increase in the height of the curved 
segment of the tablet, and a progressive decrease in tablet tensile 
strength values with increased tablet porosity (Newton et al 2000b). 
 
4.4.4. Statistical analysis of tensile strength values of elongated 
tablets: 
In a similar manner to round tablets, the tensile strength values for 
elongated tablets were subjected to statistical analysis comprising a 
combination of two-way and one-way ANOVA, in order to clearly 
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elucidate the influence of tablet properties, in terms of curvature height 
and overall porosity, on the tensile strength of tablets produced using the 
three formulations used in this study.  
 
4.4.4.1. Elongated blank Xanthan Gum tablets: 
The results of the two-way ANOVA for elongated blank Xanthan Gum 
tablets are shown in Table 4.17. They indicate a significant influence as a 
result of the change in tablet porosity on tablet tensile strength with an F 
ratio of 434.771 corresponding to a p value of less than 0.001. The 
influence of tablet curvature height on tablet tensile strength was also 
significant with an F ratio of 715.335 corresponding to a p value of less 
than 0.001. The magnitude of the influence associated with the change in 
tablet face curvature seems to be higher than that associated with tablet 
overall porosity, which is apparent from the value of the F ratio associated 
with each of them. More importantly, the interaction between the two 
previous variables also had a significant influence on the tensile strength 
of tablets.  
 
Variable df               F        p 
Porosity 2 434.771 < 0.001 
Curvature 2 715.335 < 0.001 
Porosity*Curvature 4 83.609 < 0.001 
 
Table 4.19. Results for the two-way ANOVA for the tensile strength of 
elongated blank Xanthan Gum tablets. 
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Further investigation of the significant interaction between tablet overall 
porosity and tablet curvature height was accomplished by a series of one-
way ANOVA to elucidate the influence of changing tablet curvature height 
on tablet tensile strength. Separate investigations were carried out for 
tablets with the three degrees of overall porosity, the results of which are 
reported in Table 4.18. The values of the F ratio and the corresponding p 
value for each porosity level revealed a significant influence of tablet 
curvature height on tablet tensile strength values. 
 
Porosity df            F           p 
15.0% 2 523.821 < 0.001 
17.5% 2 238.906 < 0.001 
20.0% 2 57.437 < 0.001 
 
Table 4.20. Results for the one-way ANOVA for the tensile strength of 
elongated blank Xanthan Gum tablets, with different curvature heights. 
 
 
In a manner, similar to that used with round tablets, post hoc Sheffé 
analysis was carried out to point out the significant differences between 
the degrees of tablet curvature height at all porosity levels. For tablets 
with overall porosities of 15% and 17.5%, a similar pattern was observed 
in the output of the Sheffé analysis. Three different subsets were 
obtained, containing the mean values of tablet tensile strength associated 
with the three different degrees of tablet curvature height progressively. 
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This indicates a significant increase in tablet tensile strength with the 
progressive increase in curvature height from 0 to 2 mm. 
 
For tablets with an overall porosity of 20%, the output of the Sheffé 
analysis indicated two different subsets, the first of which contained the 
mean value for the tensile strength of flat tablets. The second subset 
contained the mean values for the tensile strength of tablets with the two 
higher degrees of curvature height of 1 and 2 mm. these statistically 
similar strength values are significantly higher that the strength value of 
flat tablets. 
 
 
 
 
 
 
 
Table 4.21. Results for the Sheffé post-hoc analysis test for elongated 
blank Xanthan Gum tablets, porosity 15.0%. 
 
 
 
 
 
 
 
Table 4.22. Results for the Sheffé post-hoc analysis test for elongated 
blank Xanthan Gum tablets, porosity 17.5%. 
Curvature N 
Subset 
1 2 3 
0 6 1.16900     
1 6   2.21983   
2 6     3.84517 
Sig.   1.000 1.000 1.000 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
 
Curvature N 
Subset 
1 2 3 
0 6 .84117     
1 6   1.90950   
2 6     2.62900 
Sig.   1.000 1.000 1.000 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
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Table 4.23. Results for the Sheffé post-hoc analysis test for elongated 
blank Xanthan Gum tablets, porosity 20.0%. 
 
 
4.4.4.2. Elongated Xanthan Gum tablets with Orphenadrine Citrate: 
The results of the two-way ANOVA for elongated Xanthan Gum tablets 
with Orphenadrine Citrate are listed in Table 4.22. They indicate a 
significant influence of tablet overall porosity on tablet tensile strength 
with an F ratio of 390.319 corresponding to a p value of less than 0.001. 
The influence of tablet curvature height was also significant, with an F 
ratio of 205.358 corresponding to a p value of less than 0.001. In contrast 
to the blank elongated tablets, the magnitude of the influence associated 
with tablet overall porosity was higher than that associated with tablet 
curvature height and this is apparent from the higher F ratio. 
 
Variable df              F        p 
Porosity 2 390.319 < 0.001 
Curvature 2 205.358 < 0.001 
Porosity*Curvature 4 6.389 < 0.001 
 
Table 4.24. Results for the two-way ANOVA for the tensile strength of 
elongated Xanthan Gum tablets with Orphenadrine Citrate. 
Curvature N 
Subset 
1 2 
0 6 .62783   
1 6   1.20250 
2 6   1.35800 
Sig.   1.000 .130 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
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Once again, one-way ANOVA for all three levels of tablet overall porosity 
revealed a significant influence as a result of the change in tablet 
curvature height on the tensile strength values, as noted from the values 
of the F ratio and the corresponding p values in Table 4.23.  
 
Porosity df            F           p 
15.0% 2 74.353 < 0.001 
17.5% 2 62.489 < 0.001 
20.0% 2 91.798 < 0.001 
 
Table 4.25. Results for the one factorial ANOVA for the tensile strength of 
elongated Xanthan Gum tablets with Orphenadrine Citrate, with different 
curvature heights. 
 
 
Post hoc analysis for the tensile strength values of these tablets indicated 
that at the lower porosity of 15% (Table 4.24.) the output of the Sheffé 
analysis contained two subsets, the first containing the mean strength 
value for flat tablets. However, the second subset contained the 
significantly higher mean strength values for tablets with curvature height 
of 1 and 2 mm. 
 
The two higher overall porosities of 17.5% and 20% resulted in three 
significantly different subsets (Tables 4.25. and 4.26.), containing the 
mean strength values for tablets with the three degrees of curvature 
height progressively. 
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Table 4.26. Results for the Sheffé post-hoc analysis test for elongated 
Xanthan Gum tablets with Orphenadrine Citrate, porosity 15.0%. 
 
 
 
 
 
 
 
Table 4.27. Results for the Sheffé post-hoc analysis test for elongated 
Xanthan Gum tablets with Orphenadrine Citrate, porosity 17.5%. 
 
 
 
 
 
 
 
 
Table 4.28. Results for the Sheffé post-hoc analysis test for elongated 
Xanthan Gum tablets with Orphenadrine Citrate, porosity 20.0%. 
 
 
 
 
Curvature N 
Subset 
1 2 
0 6 1.67915   
1 6   2.73293 
2 6   2.88537 
Sig.   1.000 .391 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
 
Curvature N 
Subset 
1 2 3 
0 6 1.01843     
1 6   1.74697   
2 6     1.99505 
Sig.   1.000 1.000 1.000 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
Curvature N 
Subset 
1 2 3 
0 6 .61168     
1 6   1.04858   
2 6     1.40257 
Sig.   1.000 1.000 1.000 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
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4.4.4.3. Elongated Xanthan Gum tablets with Orphenadrine HCl: 
The results for the two-way ANOVA for elongated Xanthan Gum tablets 
with Orphenadrine HCl are listed in Table 4.27. A significant influence 
induced by the change in both tablet overall porosity and tablet curvature 
height was noted. The magnitude of such influence seems to be similar 
for both variables with an F ratio of 369.703 corresponding to a p value of 
less than 0.001 for tablet overall porosity, and an F ratio of 356.139 
corresponding to a p value of less than 0.001 for tablet curvature height. 
Furthermore, in a manner consistent with all previous observations, the 
interaction between the two previous variables had a significant influence 
on tablet tensile strength with an F ratio of 19.788 corresponding to a p 
value of less than 0.001. 
 
One-way ANOVA for tablets produced at the three levels of overall 
porosity revealed a significant influence as a result of the change in tablet 
curvature height on tablet tensile strength, as noted by the F ratios and 
the corresponding p values in Table 4.28. 
 
Post hoc Sheffé analysis revealed a similar trend in tablets produced at 
all three degrees of overall porosity (Tables 4.29. to 4.31.). Each output 
contained three significantly different progressive subsets, containing the 
mean strength values for tablets with the three degrees of curvature 
height progressively. 
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Variable df                   F           p 
Porosity 2 369.703 < 0.001 
Curvature 2 356.139 < 0.001 
Porosity*Curvature 4 19.788 < 0.001 
 
Table 4.29. Results for the two-way ANOVA for the tensile strength of 
elongated Xanthan Gum tablets with Orphenadrine HCl. 
 
 
 
Porosity df            F           p 
15.0% 2 155.767 < 0.001 
17.5% 2 118.365 < 0.001 
20.0% 2 89.285 < 0.001 
 
Table 4.30. Results for the one-way ANOVA for the tensile strength of 
elongated Xanthan Gum tablets with Orphenadrine HCl, with different 
curvature heights 
 
 
 
 
 
 
 
Table 4.31. Results for the Sheffé post-hoc analysis test for elongated 
Xanthan Gum tablets with Orphenadrine HCl, porosity 15.0%. 
 
Curvature N 
Subset 
1 2 3 
0 6 2.40703     
1 6   3.55237   
2 6     4.90348 
Sig.   1.000 1.000 1.000 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
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Table 4.32. Results for the Sheffé post-hoc analysis test for elongated 
Xanthan Gum tablets with Orphenadrine HCl, porosity 17.5%. 
 
 
 
 
 
 
 
 
Table 4.33. Results for the Sheffé post-hoc analysis test for elongated 
Xanthan Gum tablets with Orphenadrine HCl, porosity 20.0%. 
 
 
All the one-way and two-way ANOVA processes carried out during the 
statistical analysis of tensile strength data for both round and elongated 
tablets were preceded by a check for the homogeneity of variance 
between the studied samples in each test. The homogeneity of variance 
is a prerequisite for parametric comparisons of mean values. The test for 
it was accomplished using the Levene test, and the results indicated a 
homogeneity in variances of the samples used in most of the ANOVA 
tests. Some exceptions were noted, in which the results of the Levene 
Curvature N 
Subset 
1 2 3 
0 6 1.86850     
1 6   2.93310   
2 6     3.47282 
Sig.   1.000 1.000 1.000 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
Curvature N 
Subset 
1 2 3 
0 6 1.20225     
1 6   1.93808   
2 6     2.35647 
Sig.   1.000 1.000 1.000 
Means for groups in homogenous subsets are displayed.  
Sheffe test uses Harmonic Mean Sample Size = 6.000.  
Alpha = 0.05. 
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test indicated a significant difference between the variances of the 
studied samples. However, the use of ANOVA was justified in all cases 
for two reasons; initially, the F ratio is sufficiently robust to differences in 
sample variance when the sizes of the studied samples are equal 
(Stevens 1996), which is the case in this work. A uniform sample size of 
six tablets was adopted for all tests. Secondly, and more importantly, the 
influence level of the studied variables, in the cases were differences in 
sample variance were reported, was highly significant, with p values of 
less than 0.001. Thus clear differences were noted between the different 
samples. A list of the outputs of the ANOVA tests used in this work is 
included in the appendix. 
 
In a manner similar to that observed with round tablets, the results of the 
tensile strength experiments conducted on elongated tablets (Figures 4.6. 
to 4.8.) clearly indicate a profound influence of the type of formulation 
used in tablet production on the effects exerted by the two dosage form 
related variables, i.e. tablet face curvature and tablet overall porosity. 
 
 
4.4.5. Microscopic examination of tablet structure: 
Scanning electron microscopy was used to give further insight into the 
structural features associated with the various types of tablets used in this 
study. The results obtained from the tensile strength determination 
studies indicated a large variation in the behaviour of the tablets 
produced using the three different formulations used in this study. This 
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variation, as was previously mentioned, could be related to the variation 
in the internal structural features of the tablets. Moreover, the overall 
appearance of the produced tablets was significantly different especially 
among the three formulations used. It was thus important to further 
investigate such variations, as they could influence tablet properties and 
behaviour. 
 
4.4.5.1. Tablet Surface: 
The nature of the surface properties associated with hydrophilic matrix 
tablets could have a significant influence on the initial phases of tablet 
hydration and drug release. Hence it was crucial to identify any variations 
in such properties between the various tablets used in this study.   
 
Scanning electron microscopic images of the surface of blank and drug 
containing round flat tablets are presented in Figures 4.9. to 4.14. Closer 
inspection of the images reveals some variations in the surface structural  
properties associated with each formulation. Blank Xanthan Gum tablets 
(Figures 4.9. and 4.10.) could be characterised by having a rather rough 
surface due to the presence of large un-fragmented Xanthan Gum 
particles.  Tablets containing the drug Orphenadrine Citrate had a less 
rough surface when compared to blank tablets (Figure 4.11.). Closer 
inspection of these tablets revealed a more compacted surface (Figure 
4.12.).  As for tablets containing the drug Orphenadrine HCl, the surface 
of these tablets was much smoother in comparison to tablets produced 
using the two other formulations (Figure 4.13.). Closer inspection of the  
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Figure 4.9. SEM images of the surface of flat round blank Xanthan Gum 
tablets with porosity of 15% (magn. 50X). 
 
 
Figure 4.10. SEM images of the surface of flat round blank Xanthan Gum 
tablets with porosity of 15% (magn. 1000X). 
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Figure 4.11. SEM images of the surface of flat round Orphenadrine 
Citrate tablets with porosity of 15% (magn. 50X). 
 
 
 
Figure 4.12. SEM images of the surface of flat round Orphenadrine 
Citrate tablets with porosity of 15% (magn. 1000X). 
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Figure 4.13. SEM images of the surface of flat round Orphenadrine HCl 
tablets with porosity of 15% (magn. 50X). 
 
 
 
 
Figure 4.14. SEM images of the surface of flat round Orphenadrine HCl 
tablets with porosity of 15% (magn. 1000X). 
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surface of these tablets (Figure 4.14.), revealed the presence of a large 
number of fine particles with a high degree of compaction. Such an effect 
could be related to the previously reported fine particle size associated 
with this drug. 
 
Fine cracks were noticed in tablets produced using all three formulations. 
However, the extent of the presence of such cracks was larger in blank 
tablets and tablets containing the drug Orphenadrine Citrate, with fewer 
cracks noticed in tablets containing the drug Orphenadrine HCl. 
 
 
4.4.5.2. Tablet fracture surface: 
The structural patterns associated with the fracture surface of the tablet 
could give an insight into the different fracture behaviours associated with 
the different tablets.  Scanning electron microscopic images of the 
fracture surfaces of round convex tablets with a face curvature ratio of 
1.43 are presented in Figures 4.15. to 4.20. 
 
Initial comparison of tablets produced using the three different 
formulations at a low magnification power did not reveal significant 
differences between the tablets (Figures 4.15., 4.17. and 4.19.). Closer 
inspection of the fracture surface of blank Xanthan Gum tablets (Figure 
4.16.) revealed the presence of a compacted structure composed mainly 
of large particles.  
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A rather similar pattern was observed upon the inspection of the fracture 
surface in tablets containing the drug Orphenadrine Citrate (Figure 4.18.). 
In these tablets, a somewhat higher degree of compaction could be 
observed, with the presence of some fine particles. However, for tablets 
containing the drug Orphenadrine HCl, a significantly different fracture 
surface was observed (Figure 4.20.). The surface was highly compacted 
with the presence of a large number of fine particles. This pattern, once 
again, could be attributed to the fine particle size of the drug. 
 
The varying nature of the fracture surface properties associated with the 
three different formulations gives a clear insight into the change in the 
internal structure of the tablets. Such change, in turn, may have lead to 
the different tensile strength values obtained for tablets produced using 
the different formulations.  
 
Upon comparing the surface and internal structural properties associated 
with flat and highly convex round tablets using scanning electron 
microscopy, minimal differences were observed. Thus, this technique was 
not useful in investigating this aspect with the formulations used in this 
study. 
 
                                                                                                     Chapter 4 
 189
 
Figure 4.15. SEM images of the fracture surface of round blank Xanthan 
Gum tablets with porosity of 15% (magn. 100X). 
 
 
 
Figure 4.16. SEM images of the fracture surface of round blank Xanthan 
Gum tablets with porosity of 15% (magn. 2000X). 
                                                                                                     Chapter 4 
 190
 
Figure 4.17. SEM images of the fracture surface of  round Orphenadrine 
Citrate tablets with porosity of 15% (magn. 100X). 
 
 
 
Figure 4.18. SEM images of the fracture surface of round Orphenadrine 
Citrate tablets with porosity of 15% (magn. 2000X). 
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Figure 4.19. SEM images of the fracture surface of round Orphenadrine 
HCl tablets with porosity of 15% (magn. 100X). 
 
 
 
Figure 4.20. SEM images of the fracture surface of round Orphenadrine 
HCl tablets with porosity of 15% (magn. 2000X). 
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4.5. General discussion and conclusions: 
The results of this chapter gave an insight into the influence of variables 
associated with the dosage form and with the physicochemical properties 
of the drugs, on the mechanical properties of hydrophilic matrix tablets. 
Changes in tablet shape and tablet overall porosity had a significant 
influence on tablet tensile strength values. This was attributed mainly to 
changes in the internal structure of the tablet, i.e. due to variation in the 
density distribution within the different tablets, and the possibility of crack 
formation after the compaction process. Such changes in tablet structural 
properties, could have a clear influence on the process of water ingress 
and diffusion into hydrophilic matrix tablets, and subsequently affect the 
swelling and expansion of such tablets.  
 
The nature of the previously mentioned influences, which are caused by 
the change in tablet properties, varied among the three different 
formulations used in the production of tablets. This outcome was further 
clarified by scanning electron microscopy, which indicated a clear 
difference in the internal structural features, between tablets produced 
using the three formulations.  Differences were also apparent in the 
external surface features of the tablets. This in turn could influence the 
initial hydration and drug release behaviour associated with the tablets. 
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CHAPTER FIVE 
  
5. Tablet hydration studies 
5.1. Introduction: 
Monitoring the hydration patterns associated with hydrophilic matrix 
tablets constitutes an indispensable part in the investigation of such 
tablets. The hydration of hydrophilic matrix tablets leads to the activation 
of multiple processes that are crucial in their overall function. Most 
importantly is the formation of the gel layer on the outer surface of the 
tablet, this is due to the relaxation and swelling of the polymer chains 
upon contact with the hydration medium. The gel layer forms the main 
barrier to water ingress into the tablet, and subsequently drug release 
from within it. However, other changes may also occur within the internal 
structure of the tablet upon introduction into the hydration medium, such 
as the expansion of the dry core of the tablet. These changes may affect 
the overall function and integrity of the tablet. 
 
It was thus the objective of this part of the work to thoroughly investigate 
the hydration patterns associated with the various tablets used in this 
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study. The initial objective is to compare the influence of formulation 
change on the hydration behaviour of the various hydrophilic matrix 
tablets under study.  
 
Furthermore, the results obtained in chapter four of this study indicated 
that the variables associated with the dosage form; i.e. tablet, have a 
major influence on the physical properties of the dry tablet. This was 
attributed to the change in the internal structural properties of the tablet, 
caused by the variation in tablet face curvature and overall porosity.  It 
was hence a further objective of this part of the work to monitor the 
influence of such variables on the hydration behaviour of the investigated 
tablets, and to observe any influence they may have on the structural 
properties and integrity of the tablets during the hydration process. 
 
 
5.2. Choice of swelling investigation method: 
As previously discussed in chapter one, several methods have been 
reported in the literature as techniques to investigate the swelling of 
hydrophilic matrix tablets. In this study it was decided to monitor the 
dimensional expansion of the different tablets using image analysis. Such 
technique provided an advantage of providing the ability to monitor the 
expansion of the tablets in the different directions. Moreover it allowed the 
investigation and comparison of the influence of the studied variables, in 
terms of dosage form and formulation properties, on the various 
dimensional changes occurring within the different tablets. This type of 
investigation and comparison was highly desired in our study, as the 
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changes in tablet properties, especially the change of tablet face 
curvature ratio, may cause a change in the internal structure of the tablet. 
It was thus important to investigate the influence of such change on the 
expansion of the tablets in the various directions. Another advantage of 
such technique is the ability to investigate the hydration of the tablets 
intensively and in-situ, thus eliminating any artefacts that may be caused 
by the extraction of the tablets from the hydration medium prior to the 
imaging process. 
 
The results are reported in the form of the percentage swelling indices of 
the tablets in the various dimensions. Such values would relate the 
hydration dimensions of the various tablets to their dry state dimensions 
(values reported in the appendix), thus giving a clear indication of the 
extent of tablet hydration and expansion.  Moreover, the normalisation of 
the dimensional values of the tablets is required if tablets with different 
dimensions in the dry state are to be compred. 
 
 
5.3. Results and Discussion: 
5.3.1. Hydration of Round tablets: 
5.3.1.1. Axial swelling studies: 
The axial swelling profiles of blank and drug containing round Xanthan 
Gum tablets with all four degrees of tablet face curvature ratio are 
presented in Figures 5.1 to 5.3 respectively. The swelling profiles of 
tablets produced at the three levels of tablet overall porosity were highly 
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super-imposable, thus only the profiles for tablets with overall porosity of 
12.5% are presented in the figures for clarity. A detailed list of the 
swelling profiles of all other tablets is presented in the appendix.  
For blank round Xanthan Gum tablets (Figure 5.1), immediate tablet 
hydration was initiated upon introduction of all tablets into the hydration 
medium. A uniform gel layer was clearly apparent within the first five 
minutes of tablet hydration. Tablet swelling was very rapid in the initial 
phase of hydration and gradually slowed down with progressive 
hydration. Such observations can be attributed to the progressive nature 
of gel layer formation on the outer surface of the tablets. Progressive 
polymer hydration leads to the thickening of the gel layer which forms a 
barrier to further water ingress into the dosage form, thus slowing down 
the process of tablet swelling. Another aspect of tablet overall expansion 
in the initial phase of hydration could be correlated with the expansion of 
the dry core within the tablet structure upon introduction into the hydration 
medium. Such observations were previously examined within tablets 
produced with HPMC using nuclear magnetic imaging. They were 
attributed to the relaxation of the stresses within the tablet structure upon 
hydration (Rajabi-siahboomi et al 1994). 
 
A clear change in tablet hydration behaviour was caused upon 
introduction of either of the two model drugs used in this study. For 
tablets containing the drug Orphenadrine Citrate (Figure 5.2), the 
hydration process was initiated with a very rapid and marked erosion 
process, which was visually apparent. However, within the first ten 
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minutes of tablet hydration, a uniform gel layer was clearly visible on the 
surface of the tablets. Tablet swelling was rapid in the initial hydration 
phase and slowed down with progressive hydration. In comparison with 
blank Xanthan Gum tablets, the swelling of tablets containing the drug 
Orphenadrine Citrate was much slower. This could be indicative of the 
diminished ability of the polymer chains to fully hydrate and swell.  
 
The addition of the drug Orphenadrine HCl seems to have had the most 
detrimental influence on table swelling. The axial swelling profiles of such 
tablets are presented in Figure 5.3. Upon introduction into the hydration 
medium these tablets exhibited a marked and prolonged erosion process. 
Only a highly irregular gel layer was apparent on the surface of such 
tablets within the first two hours of hydration. Moreover, crack formation 
was apparent within the gel layer on the sides of such tablets. Cracks 
were noted on the sides of tablets with all four degrees of face curvature 
ratio. However, the extent of crack formation and enlargement 
progressively increased with the increase in tablet face curvature ratio; 
clearly visible deep cracks were formed on the sides of tablets with face 
curvature degrees of 1 and 1.43. Such behaviour could be highly 
correlated with the previously discussed process of tablet core expansion; 
the gel layer formed within tablets containing the drug Orphenadrine HCl 
seems to be too weak to withstand any potential expansion of the dry 
core of the tablet upon introduction into the hydration medium. The extent 
of any potential expansion in the dry core of the hydrating tablets would 
be greater in tablets with higher degrees of face curvature ratio due to the  
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Figure 5.1. Axial swelling profiles of round blank Xanthan Gum tablets, 
porosity 12.5%. -♦-(R/D= 0), -■-(R/D=0.5), -▲-(R/D=1), -●-(R/D=1.43), 
(n=6). 
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Figure 5.2. Axial swelling profiles of round Xanthan Gum tablets with 
Orphenadrine Citrate, porosity 12.5%. -♦-(R/D= 0), -■-(R/D=0.5), -▲-
(R/D=1), -●-(R/D=1.43), (n=6). 
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Figure 5.3. Axial swelling profiles of round Xanthan Gum tablets with 
Orphenadrine HCl, porosity 12.5%. -♦-(R/D= 0), -■-(R/D=0.5), -▲-
(R/D=1), -●-(R/D=1.43), (n=6). 
 
higher densification process occurring within the edges of such tablets 
during compaction.  Crack formation was also evident in tablets produced 
at al three levels of tablet overall porosity. No differences were observed 
between tablets produced at al three porosities. 
 
Upon further hydration of all tablets containing the drug Orphenadrine 
HCl, a gradual formation of a uniform gel layer was apparent on the 
surface of the tablets, and within the cracks formed on the sides of such 
tablets, leading to the enhancement of tablet swelling. Such behaviour 
was more marked in tablets with the lower degrees of face curvature ratio 
of 0 and 0.5 in which tablet swelling became much faster with progressive 
hydration. This pattern of tablet swelling behaviour indicates that 
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progressive release of the drug from the internal environment of the tablet 
seemed to restore the ability of the polymer to hydrate freely. 
 
5.3.1.2. Statistical comparison of the axial swelling profiles of round 
tablets: 
An intensive technique was required to compare the swelling profiles of 
the tablets used in this study due to the multiple number of variables 
affecting the swelling behaviour of the tablets, and due to the complex 
hydration patterns associated with such tablets, especially those tablets 
containing the drug Orphenadrine HCl, in which the extent of tablet 
swelling was clearly different during the various phases of the hydration 
process. Such hydration patterns make it inappropriate to represent the 
whole hydration process in single numerical parameters. A combined 
statistical approach was used to gain thorough understanding of the 
swelling patterns associated with the studied tablets, and to compare 
such behaviour between the different tablets. The method comprised of 
the use of analysis of variance (ANOVA), which was previously discussed 
in Chapter 4, in addition to multivariate analysis of variance (MANOVA).  
 
Multivariate analysis of Variance (MANOVA) could be regarded as an 
extension of the previously discussed ANOVA (Chapter 4). MANOVA 
adopts a similar analysis method to ANOVA. However, the main 
difference is the presence of two or more dependent variables under 
investigation, in contrast to the single dependent variable investigated in 
ANOVA.  MANOVA requires the presence of some kind of relationship 
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between the multiple dependent variables, and it adopts the principle of 
matrix algebra as a numerical basis for calculations (Podczeck 2003).  
It could thus be seen that a potential practical advantage of MANOVA 
over ANOVA is its ability to investigate the entire range of dependent 
variables under investigation simultaneously. In this study these are the 
multiple swelling indices of the tablets. Thus MANOVA could facilitate the 
comparison of the entire swelling profiles of the tablets.  
 
Observing the axial swelling patterns associated with the tablets 
produced using the different formulations (Figures 5.1. to 5.3.) makes it 
evident that changing the type of formulation used in the production of the 
different tablets has a major effect on their axial swelling. Thus, and in 
order to investigate the influence of dosage form variables in terms of 
face curvature and overall porosity on the hydration patterns of tablets, 
and to compare any changes in such influence upon changing tablet 
formulation, statistical analysis was carried out for each of the three 
formulations separately. 
 
Initially MANOVA was employed to investigate the influence of tablet face 
curvature ratio and tablet overall porosity on the whole swelling profile. 
Then multiple ANOVAs were carried out at different time points 
representing the different phases of tablet swelling, in order to further 
elucidate the results of the MANOVA investigation, and to investigate the 
influence of tablet face curvature ratio and overall porosity on tablet 
swelling, and possible changes in such influence with time.  
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MANOVA results for the axial swelling profiles of tablets produced using 
the three different formulations are listed in Tablet 5.1. Upon investigating 
the influence of tablet face curvature and overall porosity on the overall 
axial swelling of blank round Xanthan Gum tablets, it becomes apparent 
that the degree of tablet face curvature is the only variable with significant 
influence on tablet overall axial swelling; with a Hotelling’s trace value of 
1127.901, (approximated F value of 184.850) corresponding to a p value 
of less than 0.001. The influence of tablet overall porosity, and that of the 
interaction between the degree of tablet face curvature and tablet overall 
porosity on tablet overall axial swelling are not significant as their p 
values are considerably higher than the set significance level of 0.05. A 
similar pattern is observed with tablets containing the drug Orpneadrine 
Citrate, in which the degree of tablet face curvature is the only factor with 
significant influence on tablet overall axial swelling with a Hotelling’s trace 
value of 634.948, (approximated F value of 104.061) corresponding to a p 
value of less than 0.001.  
 
A somewhat different result is noted with tablets containing the drug 
Orphenadrine HCL, as the MANOVA results for such tablets show a 
significant influence on tablet overall axial swelling associated with both 
dosage form variables; i.e. tablet face curvature ratio and tablet overall 
porosity with significance values lower than the set value of 0.05. 
Moreover the interaction between both factors seems to have a 
significant influence on tablet overall axial swelling. However, upon 
comparing the F values associated with the three variables, it becomes 
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clear that the main variable influencing tablet swelling is the ratio of tablet 
face curvature with an F value of 126.939; this value is considerably 
higher than the F values associated with tablet overall porosity and the 
interaction between the tablet face curvature ratio and overall porosity, 
which were 2.342 and 1.400 respectively. It could thus be concluded that 
although the influence of these two variables on tablet overall axial 
swelling is significant, the swelling process as such is dominated by the 
tablet face curvature ratio. 
 
 
Tablet 
type 
Variable 
Hotelling’s 
Trace 
value 
 
F 
 
 
Hypothesis 
df 
Error 
df 
p 
 
 Porosity 3.900 0.975 80.000 40.000 0.549 
Blank Curvature 1127.901 184.850 120.000 59.000 < 0.001 
 Porosity*Curvature 9.106 0.734 240.000 116.000 0.976 
 Porosity 5.403 1.351 80.000 40.000 0.149 
Citrate Curvature 634.948 104.061 120.000 59.000 < 0.001 
 Porosity*Curvature 12.102 0.975 240.000 116.000 0.570 
 Porosity 9.367 2.342 80.000 40.000 0.002 
HCl Curvature 774.541 126.939 120.000 59.000 < 0.001 
 Porosity*Curvature 17.377 1.400 240.000 116.000 0.021 
 
Table 5.1. MANOVA results for the axial swelling of round Xanthan Gum 
tablets. 
 
The results of the two -way ANOVA investigation for blank round Xanthan 
Gum tablets are presented in Table 5.2.  The results clearly indicate that 
the only variable with significant influence on tablet axial hydration at the 
three chosen time points is the ratio of tablet face curvature as noted from 
the significance values which are consistently lower that the set p value of 
0.05.  
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Further insight into the differences between the different degrees of tablet 
face curvature ratio was accomplished by the use of the post hoc Sheffé 
test, the use of which was justified due to the significance associated with 
this variable. As previously mentioned in chapter four, the output of the 
Sheffé test arranges the different levels of the studied variable in 
progressively increasing subsets. The values falling within the same 
subset are statistically similar and at the same time significantly different 
from the values falling into other subsets. The results of the Sheffé test 
for blank Xanthan Gum tablets indicated that at all three time points there 
was a significant difference between all four degrees of tablet face 
curvature ratio. The highest axial swelling was consistently associated 
with flat tablets with a face curvature ratio of 0 and it became 
progressively and significantly lower with the progressive increase in 
tablet face curvature ratio. A list of the Sheffé test results obtained with 
the different tablets is reported in the appendix. 
 
The results of the two -way ANOVA investigation for tablets containing 
the two drugs are presented in Tables 5.3. and 5.4 respectively. The 
results for tablets containing both drugs are similar to those  
obtained with the blank tablets in which tablet face curvature ratio is the 
only variable with significant influence on the axial swelling of tablets at 
the three time points investigated.  
 
 
 
                                                                                                     Chapter 5 
 205
Swelling 
time (min) 
Variable df F p 
 Porosity 2 0.067 0.935 
120 Curvature 3 4279.126 < 0.001 
 Porosity*Curvature 6 0.767 0.599 
 Porosity 2 0.483 0.619 
240 Curvature 3 3908.144 < 0.001 
 Porosity*Curvature 6 0.365 0.898 
 Porosity 2 0.084 0.919 
480 Curvature 3 3741.397 < 0.001 
 Porosity*Curvature 6 0.124 0.993 
 
Table 5.2. Two -way ANOVA results for the axial swelling of round blank 
Xanthan Gum tablets. 
 
 
 
 
Swelling 
time (min) 
Variable df F p 
 Porosity 2 0.142 0.868 
120 Curvature 3 960.009 < 0.001 
 Porosity*Curvature 6 0.156 0.987 
 Porosity 2 0.092 0.913 
240 Curvature 3 1244.918 < 0.001 
 Porosity*Curvature 6 0.055 0.999 
 Porosity 2 0.200 0.820 
480 Curvature 3 1940.624 < 0.001 
 Porosity*Curvature 6 0.282 0.943 
 
Table 5.3. Two -way ANOVA results for the axial swelling of round 
Xanthan Gum tablets with Orphenadrine Citrate. 
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Swelling 
time (min) 
Variable df F p 
 Porosity 2 0.290 0.750 
120 Curvature 3 1093.480 < 0.001 
 Porosity*Curvature 6 1.039 0.409 
 Porosity 2 0.166 0.847 
240 Curvature 3 1221.310 < 0.001 
 Porosity*Curvature 6 2.003 0.079 
 Porosity 2 0.293 0.747 
480 Curvature 3 1703.988 < 0.001 
 Porosity*Curvature 6 0.208 0.973 
 
Table 5.4. Two -way ANOVA results for the axial swelling of round 
Xanthan Gum tablets with Orphenadrine HCl. 
 
 
 
Post hoc analysis for the significant variable “tablet face curvature ratio” 
for both drugs indicated a pattern similar to that observed with blank 
tablets. A significant influence was noted between all four degrees of 
tablet face curvature ratio at al three time points investigated. The highest 
axial swelling was noted with flat tablets with a face curvature ratio of 0, 
and the values progressively and significantly decreased with the 
increase in tablet face curvature ratio.  
 
The two -way ANOVA results for tablets containing the drug 
Orphenadrine HCl indicated that there was no significant influence on 
tablet axial swelling associated with tablet overall porosity and the 
interaction product at al three time points investigated. However, the 
results for the MANOVA investigation conducted on the same tablets 
indicated a somewhat significant influence associated with these 
variables. Two factors should be taken into consideration upon comparing 
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such results. Initially, MANOVA investigates the overall swelling profile 
rather than single time points. More importantly, and as noted previously 
in Table 5.1., the magnitude of the influence associated with these two 
variables are much smaller than that associated with tablet face curvature 
ratio. Thus it could be concluded that the influence of tablet overall 
porosity on the axial swelling of such tablets is rather marginal.  
 
5.3.1.3. Radial swelling studies: 
The radial swelling profiles of blank and drug containing round Xanthan 
Gum tablets with all four degrees of face curvature ratio and an overall 
porosity of 12.5% are presented in Figures 5.4 to 5.6., respectively. Upon 
comparing the swelling profiles of blank and drug containing tablets, a 
pattern similar to that observed with the axial swelling profiles of the 
tablets was found. Blank Xanthan Gum tablets (Figure 5.4.) exhibited a 
gradual swelling process with the formation of a uniform gel layer on the 
surface of the tablet. The swelling of such tablets was more pronounced 
in the initial phase of tablet hydration.  
 
Upon introduction of either of the two model drugs used in the study a 
clear drop in the swelling ability of all tablets was observed. Tablets 
containing the drug Orphenadrine Citrate (Figure 5.5.) exhibited a rapid 
erosion process, followed by the formation of a uniform gel layer, and 
progressive tablet swelling, at a slower rate in comparison with blank 
tablets. Tablets containing the drug Orphenadrine HCl (Figure 5.6.) 
underwent prolonged erosion immediately after introduction into the 
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hydration medium with the formation of an irregular gel layer on the 
surface. Crack formation was apparent on the radial faces of tablets with 
all four degrees of face curvature ratios and all degrees of tablet overall 
porosity. However, the extent of crack formation and propagation on the 
radial faces of all tablets was less evident than that observed on the axial 
sides of the tablets. Moreover, an increase in the swelling ability of the 
tablets was apparent in the later stages of the hydration process, in a 
manner similar to that observed during the axial swelling studies. This 
was particularly evident within flat tablets in which drug release is 
expected to be faster. This is due to the smaller size of such tablets which 
results in faster hydration and drug release, resulting in the enhanced 
ability of the polymer to hydrate and swell. 
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Figure 5.4. Radial swelling profiles of round blank Xanthan Gum tablets, 
porosity 12.5%. -♦-(R/D= 0), -■-(R/D=0.5), -▲-(R/D=1), -●-(R/D=1.43), 
(n=6). 
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Figure 5.5. Radial swelling profiles of round Xanthan Gum tablets with 
Orphenadrine Citrate, porosity 12.5%. -♦-(R/D= 0), -■-(R/D=0.5), -▲-
(R/D=1), -●-(R/D=1.43), (n=6). 
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Figure 5.6. Radial swelling profiles of round Xanthan Gum tablets with 
Orphenadrine HCl, porosity 12.5%. -♦-(R/D= 0), -■-(R/D=0.5), -▲-
(R/D=1), -●-(R/D=1.43), (n=6). 
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5.3.1.4. Statistical comparison of the radial swelling profiles of 
round tablets: 
 
The results for the MANOVA investigation of the overall radial swelling of 
blank and drug containing round Xanthan Gum tablets are presented in 
Table 5.5. They indicate a more complex process in comparison to the 
axial swelling of the tablets.  A similar pattern is noted with all three types 
of tablets in which both dosage form associated variables; i.e. tablet face 
curvature ratio and tablet overall porosity seem to have a significant 
influence on the overall radial swelling of tablets which is indicated by 
their p values which are consistently lower than the threshold value of 
0.05. Moreover, the interaction between the two variables is also 
significant for all three types of tablets, and this indicates that the 
influence caused by one of the two variables is different at the different 
levels of the other variable. 
 
However, upon comparison of the F values associated with both variables 
and their interaction product, it becomes clearly evident that the F values 
associated with the tablet face curvature ratio are consistently and 
considerably higher than those associated with tablet overall porosity and 
the interaction product between both variables. This is indicating that 
tablet face curvature ratio is the main factor affecting the overall tablet 
radial swelling with minor influence caused by the change in tablet 
porosity. 
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Tablet 
type 
Variable 
Hotelling’s 
Trace 
value 
 
F 
 
 
Hypothesis 
df 
Error 
df 
p 
 
 Porosity 57.312 4.409 104.000 16.000 0.001 
Blank Curvature 2904.465 142.741 156.000 23.000 < 0.001 
 Porosity*Curvature 140.842 3.310 312.000 44.000 < 0.001 
 Porosity 47.837 3.680 104.000 16.000 0.002 
Citrate Curvature 411.942 20.245 156.000 23.000 < 0.001 
 Porosity*Curvature 182.928 4.300 312.000 44.000 < 0.001 
 Porosity 35.361 2.720 104.000 16.000 0.013 
HCl Curvature 2340.954 115.047 156.000 23.000 < 0.001 
 Porosity*Curvature 126.379 2.970 312.000 44.000 < 0.001 
 
Table 5.5. MANOVA results for the radial swelling of round Xanthan Gum 
tablets. 
 
 
Further investigation of the radial swelling behaviour of all tablets at the 
different time intervals was accomplished using multiple two-way ANOVA 
investigations, the results of which are presented in Tables 5.6. to 5.8. 
The results for round blank Xanthan Gum tablets (Table 5.6.) indicate that 
both dosage form variables have a significant influence on the radial 
swelling of blank tablets at all three time points. Moreover, the interaction 
between both variables also has a significant influence on tablet radial 
swelling. However, and as noted previously, the effect of tablet face 
curvature seems to be the main factor affecting tablet swelling as 
indicated by the high F values, as compared to the lower F value 
associated with tablet overall porosity and the interaction product. 
 
In order to elucidate the nature of the interaction between the two 
associated dosage form variables, follow up studies were carried out 
using one-way ANOVA to investigate the influence of tablet face 
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curvature ratio at each of the three levels of tablet overall porosity 
separately. As before, this was followed by post-hoc analysis using the 
Sheffé test to elucidate the differences between the various levels of 
tablet face curvature ratio. A complete list of the Sheffé test results is 
reported in the appendix.  
 
 
Swelling 
time (min) 
Variable df F p 
 Porosity 2 28.749 < 0.001 
120 Curvature 3 262.822 < 0.001 
 Porosity*Curvature 6 4.760 < 0.001 
 Porosity 2 62.144 < 0.001 
240 Curvature 3 1711.333 < 0.001 
 Porosity*Curvature 6 7.486 < 0.001 
 Porosity 2 115.826 < 0.001 
480 Curvature 3 4069.848 < 0.001 
 Porosity*Curvature 6 10.165 < 0.001 
 
Table 5.6. Two -way ANOVA results for the radial swelling of round blank 
Xanthan Gum tablets. 
 
 
Swelling 
time (min) 
Variable df F p 
 Porosity 2 3.219 0.047 
120 Curvature 3 72.129 < 0.001 
 Porosity*Curvature 6 1.470 0.204 
 Porosity 2 5.958 0.004 
240 Curvature 3 131.949 < 0.001 
 Porosity*Curvature 6 1.223 0.307 
 Porosity 2 2.261 0.113 
480 Curvature 3 220.450 < 0.001 
 Porosity*Curvature 6 1.226 0.306 
 
Table 5.7. Two -way ANOVA results for the radial swelling of round 
Xanthan Gum tablets with Orphenadrine Citrate. 
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Swelling 
time (min) 
Variable df F p 
 Porosity 2 5.969 0.004 
120 Curvature 3 31.065 < 0.001 
 Porosity*Curvature 6 2.557 0.028 
 Porosity 2 0.192 0.826 
240 Curvature 3 67.817 < 0.001 
 Porosity*Curvature 6 3.371 0.006 
 Porosity 2 2.421 0.097 
480 Curvature 3 1184.646 < 0.001 
 Porosity*Curvature 6 1.404 0.228 
 
Table 5.8. Two -way ANOVA results for the radial swelling of round 
Xanthan Gum tablets with Orphenadrine HCl. 
 
 
 
Upon comparing the different degrees of tablet face curvature it was 
clearly apparent that flat tablets had consistently higher swelling indices 
in comparison with the other tablets. Such behaviour could be attributed 
to the faster hydration process occurring in tablets with lower degrees of 
tablet face curvature ratio. The differences between tablets with higher 
degrees of tablet face curvature were initially smaller in magnitude, and 
had slight variations with the change in tablet overall porosity. With 
progressive hydration clear differences became apparent between the 
different tablets. This is evident from the increase in the F value 
associated with this variable with the progressive increase in time.  Clear 
differences were apparent between all four degrees of tablet face 
curvature ratio at 480 minutes. 
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The results of the two-way ANOVA analysis for the radial swelling of 
round Xanthan Gum tablets with Orphenadrine Citrate (Table 5.7.) 
indicate a significant influence associated with tablet face curvature ratio 
at all three time points as indicated by the p values. The effect of tablet 
overall porosity seems to be significant at the first two time points only as 
indicated by the p values. No significant effect is noted with the 
interaction product between the two associated dosage form variables, 
which indicates the independence of the effect caused by each factor. 
Thus, the effect of each factor has to be interpreted separately. 
 
The results of the Sheffé test for tablet face curvature ratio showed that, 
initially at 120 minutes, tablets with the two lower degrees of face 
curvature had similar swelling indices that were significantly higher than 
those associated with tablets with higher degrees of face curvature. With 
further hydration, tablet swelling became inversely related to the degree  
of tablet face curvature. Finally, clear differences were noted between all 
four degrees of tablet face curvature ratio at 480 minutes. A similar 
pattern to that noted with blank tablets is observed with the time 
dependent increase in the F value associated with the degree of tablet 
face curvature ratio. 
 
In terms of tablet porosity, the use of the Sheffé test was only justified at 
the two initial time points due to the significance level associated with this 
variable at these two points. Initially at 120 minutes, the only significant 
difference was noted between tablets with an overall porosity of 17.5% 
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and those with an overall porosity of 12.5%, with the former having higher 
radial swelling indices. At 240 minutes the radial swelling indices of 
tablets with an overall porosity of 17.5% were significantly higher than 
those associated with tablet produced at the two lower levels of overall 
porosity of 12.5% and 15% which were statistically similar. 
 
The results of the two-way ANOVA investigation of round Xanthan Gum 
tablets with Orphenadrine HCl (Table 5.8.) indicate a more complex and 
time dependent pattern. Initially at 120 minutes both associated dosage 
form variables seem to have a significant influence on the radial swelling 
of the tablets in addition to a significant influence caused by the 
interaction product of both variables. At 240 minutes only the degree of 
tablet face curvature ratio seems to have a significant effect on tablet 
radial swelling. However, the interaction between this variable and tablet 
overall porosity is also significant. At 480 minutes the only significant 
influence factor is the degree of tablet face curvature ratio. 
 
Once again one-way ANOVA investigations were carried out at each level 
of tablet overall porosity when the interaction product between the two 
dosage form associated variables was significant. Moreover post hoc 
analysis using the Sheffé test was carried out for the degree of face 
curvature ratio. Initially, slight variation in the radial swelling indices of 
tablets with the four degrees of face curvature was noted. Furthermore, 
small differences were observed between tablets having different overall 
porosities. The differences between the radial swelling indices of the 
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tablets increased progressively with time. This is clearly evident from the 
increase of the in the F value.  
 
Ultimately at 480 minutes the results of the Sheffé test indicated the 
presence of three different subsets, the highest of which contained the 
mean radial swelling index of flat tablets. The middle subset contained 
the mean radial swelling index of tablets with a face curvature ratio of 0.5. 
The lowest subset contained the mean swelling indices of tablets with 
face curvature ratios of 1 and 1.43.  The lack of significant difference 
between the swelling indices of tablets with the two higher degrees of 
tablet face curvature could be highly correlated with the previously noted 
crack formation which was much more evident in highly convex tablets 
with a face curvature ratio of 1.43. Such behaviour could have led to 
extensive water penetration into the internal structure of the tablets 
leading to an increase in the rate of tablet hydration. 
 
Upon close observation of the swelling profiles associated with the 
different tablets (Figures 5.1 to 5.3) and (Figures 5.4. to 5.6.), it becomes 
evident that the differences between the swelling profiles of tablets 
produced at the different degrees of face curvature became less 
pronounced upon inclusion of either of the two model drugs used in this 
study. Such behaviour is also evident upon comparing the F values 
associated with tablet face curvature ratio that were obtained during the 
various statistical investigations; the F values obtained with blank tablets 
are consistently higher than those obtained with either drugs indicating a 
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more pronounce influence of this factor on the swelling patterns of blank 
Xanthan Gum tablets in comparison to drug containing tablets. 
 
 
5.3.2. Hydration of elongated tablets: 
5.3.2.1. Height swelling studies: 
The results for the height swelling investigation of blank and drug 
containing elongated Xanthan Gum tablets are presented in the form of 
their time dependent swelling profiles (Figures 5.7. to 5.9.). A pattern 
similar to that obtained with the axial swelling studies conducted on round 
tablets can be observed; for blank elongated Xanthan Gum tablets 
(Figure 5.7.) a steady swelling process was initiated immediately after 
introducing the tablets into the hydration medium. The overall expansion 
process was faster in the early stages of tablet hydration and slowed 
down progressively with time. Such behaviour could be associated with 
the reasons previously mentioned in section 5.3.1.1. of this chapter; i.e. 
the progressive thickening of the gel layer and its retarding effect on 
water penetration, and the possible expansion of the dry tablet core in the 
early stages of hydration.  
 
Tablets containing the drug Orphenadrine Citrate (Figure 5.8.) exhibited a 
slow and steady swelling process which was initiated after a short erosion 
process. However, elongated Xanthan Gum tablets containing the drug 
Orphenadine HCl (Figure 5.9.) underwent a profound and lengthy erosion 
process initially. With progressive hydration, a steady formation of a 
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uniform gel layer was observed in these tablets. This later behaviour was 
more profound in flat tablets which underwent significant swelling in the 
later stages of the hydration process. 
 
Crack formation, which was a noticeable in round Xanthan Gum tablets 
with Orphenadrine HCl, was also clearly visible in elongated tablets with 
the same drug; this behaviour was also more profound in the early 
hydration stages and in tablets with higher face curvature degrees, in 
which larger cracks were formed.  
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Figure 5.7. Height swelling profiles of elongated blank Xanthan Gum 
tablets, porosity 15.0%. -♦-(curvature 0 mm), -■-(curvature 1 mm), -▲-
(curvature 2 mm), (n=3). 
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Figure 5.8. Height swelling profiles of elongated Xanthan Gum tablets 
with Orphenadrine Citrate, porosity 15.0%. -♦-(curvature 0 mm), -■-
(curvature 1 mm), -▲-(curvature 2 mm), (n=3). 
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Figure 5.9. Height swelling profiles of elongated Xanthan Gum tablets 
with Orphenadrine HCl, porosity 15.0%. -♦-(curvature 0 mm), -■-
(curvature 1 mm), -▲-(curvature 2 mm), (n=3). 
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5.3.2.2. Statistical comparison of the height swelling profiles of 
elongated tablets: 
 
 
The statistical comparison of the various swelling profiles investigated 
during the hydration of blank and drug containing Xanthan Gum 
elongated tablets was accomplished using the use of analysis of variance 
(ANOVA) at three time points within the swelling profile. In a manner 
similar to that conducted in the investigation of round tablets, the three 
time points were chosen to represent the progressive hydration stages of 
the tablets. The use of multivariate analysis of variance (MANOVA) in the 
statistical comparison of the swelling profiles of elongated tablets was not 
feasible. Such observation could be explained in terms of the properties 
of these statistical methods. Two of the assumptions usually required for 
both univariate and multivariate techniques for the analysis of variance 
are normal distribution of the observations and variance homogeneity 
between the studied samples.  As it was discussed in Chapter 4, the F 
ratio employed by ANOVA is robust to small deviations in the requirement 
of variance homogeneity, particularly when the size of the studied 
samples is equal (Stevens 1996).  In the case of MANOVA, there is also 
a certain robustness of the statistical parameters to small violations of the 
assumptions. However, other factors can exacerbate such effects, 
mainly, the larger number of dependent variables studied together, and 
the actual size of the studied samples in relation to the number of the 
dependent variables studied, which was smaller in the case of elongated 
tablets. Thus, the use of ANOVA at multiple time points within the 
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swelling profiles was regarded as a preferred and more robust technique 
for the investigation of the swelling behaviour of such tablets. 
 
The results of the two-way ANOVA investigations conducted on the 
height swelling profiles of the various elongated tablets  at the three time 
points of 120, 240 and 480 minutes are presented in Tables 5.9. to 5.11.. 
A similar pattern is observed with tablets produced using all three 
formulations; the only factor to have a significant influence on the height 
swelling process of the tablets is the degree of tablet face curvature. This 
is clearly noticeable by observing the F ratios associated with this factor 
and the corresponding p values which are consistently lower that the 
significance threshold value of 0.05. On the other hand, the influence 
associated with tablet overall porosity is clearly not significant at all three 
time points and this is indicated by the p values associated with this factor 
which are considerably higher than the threshold of 0.05. A similar trend 
of lack of significance is also associated with the interaction product 
between tablet face curvature and overall porosity. It could be thus 
concluded that for elongated Xanthan Gum tablets used in this study, the 
only factor influencing the height swelling process is the degree of tablet 
face curvature. 
 
To clarify the differences between the different degrees of tablet face 
curvature, and in a similar manner to that conducted with round tablets, 
post hoc Sheffé analysis was conducted for tablets produced using each 
of the three formulations separately. A similar pattern was observed with 
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all three formulations in which statistically significant differences were 
observed between all three degrees of tablet face curvature in terms of 
their height swelling indices. The swelling indices were highest for flat 
tablets and progressively and significantly decreased with the increase in 
tablet face curvature. A complete list of the results of the Sheffé analysis 
is reported in the appendix.  
 
 
Swelling 
time (min) 
Variable df F p 
 Porosity 2 0.071 0.931 
120 Curvature 2 7427.030 < 0.001 
 Porosity*Curvature 4 0.559 0.696 
 Porosity 2 0.372 0.695 
240 Curvature 2 5765.231 < 0.001 
 Porosity*Curvature 4 0.195 0.938 
 Porosity 2 0.453 0.643 
480 Curvature 2 16153.070 < 0.001 
 Porosity*Curvature 4 0.315 0.864 
 
Table 5.9. Two -way ANOVA results for the height swelling of elongated 
blank Xanthan Gum tablets. 
 
Swelling 
time (min) 
Variable df F p 
 Porosity 2 0.034 0.966 
120 Curvature 2 1795.489 < 0.001 
 Porosity*Curvature 4 0.665 0.624 
 Porosity 2 0.023 0.978 
240 Curvature 2 2936.629 < 0.001 
 Porosity*Curvature 4 0.458 0.765 
 Porosity 2 0.030 0.970 
480 Curvature 2 5100.527 < 0.001 
 Porosity*Curvature 4 0.265 0.896 
 
Table 5.10. Two -way ANOVA results for the height swelling of elongated 
Xanthan Gum tablets with Orphenadrine Citrate. 
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Swelling 
time (min) 
Variable df F p 
 Porosity 2 0.188 0.830 
120 Curvature 2 1928.126 < 0.001 
 Porosity*Curvature 4 0.732 0.582 
 Porosity 2 1.068 0.364 
240 Curvature 2 3044.582 < 0.001 
 Porosity*Curvature 4 1.462 0.255 
 Porosity 2 0.002 0.998 
480 Curvature 2 17128.276 < 0.001 
 Porosity*Curvature 4 0.412 0.798 
 
Table 5.11. Two -way ANOVA results for the height swelling of elongated 
Xanthan Gum tablets with Orphenadrine HCl. 
 
 
 
 
5.3.2.3. Width and length swelling studies: 
The width and length swelling profiles for blank and drug containing 
Xanthan Gum tablets are listed in Figures 5.10. to 5.12. and Figures 5.13. 
to 5.15. respectively. For blank and Orphenadrine Citrate containing 
tablets a steady swelling process was the most apparent feature noted. 
This was preceded by a short erosive period in Orphenadrine Citrate 
containing tablets, which also underwent a slower swelling process in 
comparison to blank tablets. For Orphenadrine HCl containing tablets 
(Figures 5.12. and 5.15.) the previously noted lengthy erosive process 
was apparent, and it was proceeded with a gradual retrieval of the 
swelling ability of the tablets. Crack formation was observed on the radial 
faces of Orphenadrine HCl containing tablets. However, and in a manner 
similar to that observed with round tablets, the nature of such cracks was 
less profound than that noted on the sides of the tablets. 
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Figure 5.10. Width swelling profiles of elongated blank Xanthan Gum 
tablets, porosity 15.0%. -♦-(curvature 0 mm), -■-(curvature 1 mm), -▲-
(curvature 2 mm), (n=3). 
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Figure 5.11. Width swelling profiles of elongated Xanthan Gum tablets 
with Orphenadrine Citrate, porosity 15.0%. -♦-(curvature 0 mm), -■-
(curvature 1 mm), -▲-(curvature 2 mm), (n=3). 
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Figure 5.12. Width swelling profiles of elongated Xanthan Gum tablets 
with Orphenadrine HCl, porosity 15.0%. -♦-(curvature 0 mm), -■-
(curvature 1 mm), -▲-(curvature 2 mm), (n=3). 
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Figure 5.13. Length swelling profiles of elongated blank Xanthan Gum 
tablets, porosity 15.0%. -♦-(curvature 0 mm), -■-(curvature 1 mm), -▲-
(curvature 2 mm), (n=3). 
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Figure 5.14. Length swelling profiles of elongated Xanthan Gum tablets 
with Orphenadrine Citrate, porosity 15.0%. -♦-(curvature 0 mm), -■-
(curvature 1 mm), -▲-(curvature 2 mm), (n=3). 
 
 
0
20
40
60
80
100
120
140
160
0 100 200 300 400 500 600
Time (min)
L
e
n
g
th
 S
w
e
ll
in
g
 I
n
d
e
x
 (
%
)
 
 
Figure 5.15. Length swelling profiles of elongated Xanthan Gum tablets 
with Orphenadrine HCl, porosity 15.0%. -♦-(curvature 0 mm), -■-
(curvature 1 mm), -▲-(curvature 2 mm), (n=3). 
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5.3.2.4. Statistical comparison of the width swelling profiles of 
elongated tablets: 
 
The results of the two-way ANOVA investigations conducted on the width 
swelling profiles of blank and drug containing elongated Xanthan Gum 
tablets are presented in Tables 5.12. to 5.14., respectively. For blank 
tablets (Table 5.12.)  a significant influence on the width swelling of the 
elongated tablets was noted with both studied factors, i.e. tablet face 
curvature degree and overall porosity. Moreover, a significant interaction 
was noted between both factors 
 
In order to further clarify such significant interaction observed between 
the two main factors, multiple one-way ANOVAs were conducted for each 
degree of tablet overall porosity separately to examine the effect 
associated with tablet face curvature degree. Furthermore, every 
investigation was followed by post hoc analysis using the Sheffé test. It 
was noted that the width swelling indices of flat tablets were significantly 
higher than those of tablets with the two higher degrees of face curvature 
which were statistically similar. A similar pattern was observed with 
tablets produced at all three overall porosity values, with only small 
differences between tablets having different porosities. A similar result 
was obtained with the two-way ANOVA investigation at 240 minutes. 
However, the results of the Sheffé test indicated the presence of 
significant differences between all three levels of tablet face curvature; 
flat tablets had the highest swelling indices, and the decrease in the 
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values was statistically significant with the increase in tablet face 
curvature ratio.  
 
At 480 minutes, only the two main factors had a significant influence on 
tablet width swelling. No significant interaction was noted between the 
factors, and thus the influence of each factor has to be interpreted 
seperately. The results of the Sheffé test indicated a pattern similar to 
that observed at 240 minutes with regards to the influence of tablet face 
curvature, i.e. significant difference between all three values of face 
curvature. As for tablet porosity the only significant difference was 
observed between tablets with an overall porosity of 15% and those with 
an overall porosity of 20%, and even between those two types of tablets, 
the difference in the values of width swelling indices were very small. 
 
 
Swelling 
time (min) 
Variable df F p 
 Porosity 2 5.819 0.011 
120 Curvature 2 151.055 < 0.001 
 Porosity*Curvature 4 10.789 < 0.001 
 Porosity 2 12.534 < 0.001 
240 Curvature 2 485.572 < 0.001 
 Porosity*Curvature 4 5.142 
0.006 
 
 Porosity 2 5.973 0.010 
480 Curvature 2 1158.775 < 0.001 
 Porosity*Curvature 4 1.800 0.173 
 
Table 5.12. Two -way ANOVA results for the width swelling of elongated 
blank Xanthan Gum tablets. 
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Two-way ANOVA investigation of the width swelling profiles of 
Orphenadrine Citrate containing tablets (Table 5.13.) indicated a uniform 
pattern at all three time points investigated in which the only factor to  
exert a significant influence on the width swelling of the elongated tablets 
is actually the degree of tablet face curvature, as indicated by the p 
values associated with this factor. No significant influence was associated 
with tablet overall porosity, and no significant interaction was observed 
between the two main factors, i.e. the degree of tablet face curvature and 
tablet overall porosity. The results of the Sheffé test indicated a 
statistically significant difference between all three degrees of tablet face 
curvature, with the values associated with flat tablets being highest. The 
same pattern of behaviour was noted at all three time points. 
 
 
Swelling 
time (min) 
Variable df F p 
 Porosity 2 0.864 0.438 
120 Curvature 2 73.554 < 0.001 
 Porosity*Curvature 4 0.671 0.620 
 Porosity 2 1.639 0.222 
240 Curvature 2 129.849 < 0.001 
 Porosity*Curvature 4 0.694 0.606 
 Porosity 2 0.916 0.418 
480 Curvature 2 214.254 < 0.001 
 Porosity*Curvature 4 0.678 0.616 
 
Table 5.13. Two -way ANOVA results for the width swelling of elongated 
Xanthan Gum tablets with Orphenadrine Citrate. 
 
 
A similar pattern was observed with elongated tablets containing the drug 
Orphenadrine HCl (Table 5.14.) with the degree of tablet face curvature 
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being the only factor to exert a significant influence on the width swelling 
of tablets, and a significant difference being present between all three 
levels of tablet face curvature 
 
Swelling 
time (min) 
Variable df F p 
 Porosity 2 0.117 0.890 
120 Curvature 2 25.464 < 0.001 
 Porosity*Curvature 4 0.456 0.767 
 Porosity 2 1.865 0.184 
240 Curvature 2 39.410 < 0.001 
 Porosity*Curvature 4 0.352 0.839 
 Porosity 2 0.955 0.403 
480 Curvature 2 511.604 < 0.001 
 Porosity*Curvature 4 0.300 0.874 
 
Table 5.14. Two -way ANOVA results for the width swelling of elongated 
Xanthan Gum tablets with Orphenadrine HCl. 
 
 
 
5.3.2.5. Statistical comparison of the length swelling profiles of 
elongated tablets: 
 
The results of the two-way ANOVA investigations conducted on the 
length swelling indices of blank and drug containing elongated Xanthan 
Gum tablets are listed in Tables 5.15. to 5.17., respectively.  For blank 
Xanthan Gum tablets (Table 5.15.), initially at 120 minutes, both studied 
factors, i.e. degree of tablet face curvature and tablet overall porosity had 
a significant influence on tablet length swelling indices. Moreover, the 
interaction between the two factors was significant.  With further hydration 
at 240 minutes only the degree of tablet face curvature had a significant 
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influence on tablet length swelling, but a significant interaction was noted 
between this factor and the overall porosity of the tablets. At 480 minutes 
the influence of the degree of tablet face curvature on tablet length 
swelling continued to be significant. However, no significance was 
associated with tablet overall porosity or the interaction between both of 
the previous factors. 
 
After conducting one-way ANOVA to investigate the influence of tablet 
face curvature at each level of tablet overall porosity and performing post 
hoc analysis using the Sheffé test. A pattern similar to that observed with 
tablet width swelling indices was noted, where initially at 120 minutes the 
swelling indices of flat tablets where significantly higher than those 
associated with tablets with the two higher degrees of face curvature 
which were statistically similar. With further hydration at 240 minutes and 
480 minutes a significant difference was noted between the swelling 
indices of tablets with all three degrees of tablet face curvature with those 
associated with flat tablets being highest. 
 
For tablets containing both drugs (Tables 5.16. and 5.17.) a significant 
influence on tablet length swelling was only noted with the degree of 
tablet face curvature at all three time points investigated. The results of 
the Sheffé test conducted for the significant factor; i.e. tablet face 
curvature degree, indicated that for elongated tablets containing the drug 
Orphenadrine Citrate, at all three time points, the length swelling indices 
of flat tablets were significantly higher than those of tablets with higher 
degrees of face curvature. However, no statistically significant differences 
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were observed between the two higher degrees of tablet face curvature, 
i.e. 1 mm and 2 mm. Such patterns could be explained in terms of the 
higher hydration potential associated with flat tablets due to their lower 
volume.  
 
As for tablets containing the drug Orphenadrine HCl, initially at 120 
minutes and 240 minutes significant differences were observed between 
the length swelling indices of tablets produced at all three levels of tablet 
face curvature, with those associated with flat tablets being highest. With 
further hydration at 480 minutes the only significant difference was noted 
between the length swelling indices of flat tablets and those of tablets 
with higher degrees of face curvature. However, no significant difference 
was noted between the two higher degrees of face curvature of 1 and 2 
mm. 
 
Swelling 
time (min) 
Variable df F p 
 Porosity 2 14.848 < 0.001 
120 Curvature 2 305.048 < 0.001 
 Porosity*Curvature 4 14.390 < 0.001 
 Porosity 2 3.417 0.055 
240 Curvature 2 1480.830 < 0.001 
 Porosity*Curvature 4 5.961 0.003 
 Porosity 2 0.711 0.504 
480 Curvature 2 2154.859 < 0.001 
 Porosity*Curvature 4 0.709 0.596 
 
Table 5.15. Two -way ANOVA results for the length swelling of elongated 
blank Xanthan Gum tablets. 
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Swelling 
time (min) 
Variable df F p 
 Porosity 2 2.061 0.156 
120 Curvature 2 96.852 < 0.001 
 Porosity*Curvature 4 0.893 0.488 
 Porosity 2 0.072 0.931 
240 Curvature 2 179.731 < 0.001 
 Porosity*Curvature 4 1.311 0.304 
 Porosity 2 0.851 0.444 
480 Curvature 2 88.093 < 0.001 
 Porosity*Curvature 4 0.265 0.897 
 
Table 5.16. Two -way ANOVA results for the length swelling of elongated 
Xanthan Gum tablets with Orphenadrine Citrate. 
 
 
 
Swelling 
time (min) 
Variable df F p 
 Porosity 2 2.418 0.117 
120 Curvature 2 137.858 < 0.001 
 Porosity*Curvature 4 0.856 0.509 
 Porosity 2 1.654 0.219 
240 Curvature 2 153.082 < 0.001 
 Porosity*Curvature 4 1.748 0.183 
 Porosity 2 0.025 0.975 
480 Curvature 2 242.951 < 0.001 
 Porosity*Curvature 4 0.266 0.896 
 
Table 5.27. Two -way ANOVA results for the length swelling of elongated 
Xanthan Gum tablets with Orphenadrine HCl. 
 
 
 
 
In a manner similar to that observed with round tablets, and upon 
comparing the differences between the various swelling profiles 
associated with blank and drug containing elongated Xanthan Gum 
tablets, it becomes clear that the differences in the swelling ability of 
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tablets produced with the different degrees of face curvature is more 
profound within blank tablets in comparison to drug containing tablets. 
This can also be noted by looking at the higher values of the F ratios 
associated with the factor of tablet face curvature degree in blank 
elongated tablets in comparison to drug containing ones. 
 
 
 
5.3.3. Microscopic examination of hydrated tablets: 
 
The results of the swelling studies of both round and elongated tablets 
indicated a clear difference in the swelling ability of tablets produced 
using the three different formulations used in this study. Most noticeable 
was the lower swelling ability of tablets containing either of the two model 
drugs in comparison with the blank tablets. This was particularly 
noticeable in tablets containing the drug Orphenadrine HCl in which a 
highly irregular gel layer was formed in the initial phase of tablet 
hydration. The formation of the gel layer due to polymer swelling is 
considered the main factor contributing to the overall expansion of 
hydrophilic matrix tablets during the span of the hydration process. It was 
thus necessary to get further insight into the structural properties of the 
gel layer formed on the surface of tablets produced using all three 
formulations. This was accomplished by microscopic imaging of the gel 
layer formed on the hydrated surface of the different tablets. 
 
Dosage form variables in terms of shape, curvature and porosity were 
kept constant during this part of the work to eliminate any differences 
cause by them; round tablets with a face Curvature ratio of 0 and overall 
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tablet porosity of 15% were used in this part to focus on the differences 
caused by the change in the formulation used. 
 
The gel layer formed on the radial face of blank and drug containing 
Xanthan Gum tablets are shown in Figures 5.16. to 5.18., respectively.  
The gel layer formed on the radial face of blank Xanthan Gum tablets 
(Figure 5.16.) appears to be porous in general. However, the size and 
shape distribution of the pores apparent on the surface is clearly wide; 
pores of various sizes and shapes are clearly seen.   
 
The gel layer formed on the radial surface of tablets containing the drug 
Orphenadrine Citrate (Figure 5.17.) appears to be denser in comparison 
to the other tablets, indicating a change in the hydration properties of the  
system. However, pores of varying sizes and shapes are also visible on 
the surface of the gel layer.  
 
Examination of the gel layer formed on the radial surface of tablets 
containing the drug Orphenadrine HCl during the initial phase of tablet 
hydration (Figure 5.18.) revealed a structure that is more porous in 
comparison to the other tablets. A greater number of large pores are seen 
in the structure of the gel layer. 
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Figure 5.16. SEM image of the surface of a hydrated round blank 
Xanthan Gum tablet (R/D = 0, porosity 15%, magn. 45X). 
 
 
 
Figure 5.17. SEM image of the surface of a hydrated round Xanthan 
Gum tablet with Orphenadrine Citrate (R/D = 0, Porosity 15%, magn. 
45X). 
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Figure 5.18. SEM image of the surface of a hydrated round Xanthan 
Gum tablet with Orphenadrine HCl (R/D = 0, porosity 15%, magn. 45X). 
 
 
5.4 General discussion and conclusions: 
The results of this chapter indicated that changing the shape parameters 
of Xanthan Gum hydrophilic matrix tablets had a mixed effect on the 
swelling and expansion ability of both round and elongated tablets. The 
influence of changing the degree of tablet face curvature on tablet 
swelling ability was much more profound than that associated with the 
change in tablet overall porosity within the range of porosities 
investigated in this study.  
 
Another important observation was that the nature of the effect 
associated with tablet face curvature varied between tablets produced 
using the three different formulations investigated in this study. Moreover, 
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the influence associated with tablet overall porosity clearly changed in 
terms of both; its significance, and its potential interaction with the 
influence associated with the degree of tablet face curvature, with the 
change of the formulation used in tablet production.  
 
Such observations indicated that the process of tablet swelling and 
expansion was dually governed by the nature of formulation used in tablet 
production and the degree of face curvature of the produced tablets, with 
minimal influence exerted by tablet overall porosity.  
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CHAPTER SIX 
 
6. Characterisation of Xanthan Gum gel systems: 
6.1. Introduction:  
The results of tablet hydration studies indicated a clear influence of the 
type of formulation used in tablet production on the hydration and swelling 
patterns of the produced tablets. Moreover, the nature of the hydration 
behaviour, especially for tablets containing the drug Orphenadrine HCl, 
appeared to be time dependent, with multiple stages observed in the 
hydration process of such tablets. Thus it was crucial to further 
investigate the hydration patterns associated with the various tablets, and 
furthermore, to characterise the properties associated with the gel layer 
formed within such tablets. 
 
The overall aim of this part of the work was to give further insight into the 
nature of the gel layer formed within the hydrating matrix tablets used in 
this study, by means of rheological and thermal studies. 
 
Rheological studies, which enable the investigation of the structural and 
flow properties of gel systems, were used to characterise the properties 
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of Xanthan Gum hydrated gel systems. Gels which mimic in their 
concentration and content the outer region in the gel layer of a hydrating 
hydrophilic matrix tablet were used. Two main types of rheological studies 
were employed in this investigation. Initially, oscillation studies were 
used. During these studies the gel samples were subjected to small 
sinusoidal oscillating stresses without destroying the gel structure, in 
order to determine the viscous “liquid” and elastic “solid” properties of the 
gels. The second step comprised the use of viscometric studies in which 
the gel structure was destroyed by applying larger rotational stresses. 
This allowed the determination of the flow properties of the gel systems.  
 
Thermal investigations were carried out using modulated differential 
scanning calorimetry which provided some insight into the physico-
chemical properties of the gel layer formed on the surface of the studied 
tablets. 
 
 
6.2. Results and discussion: 
6.2.1. Rheological studies: 
Clear differences were visually observed in the properties of gels 
prepared using the different formulations used in this study. Gels 
prepared using the blank Xanthan Gum formulation, and gels prepared 
using the formulations containing the drug Orphenadrine Citrate, were 
highly viscous. Moreover, the apparent viscosity of these gels increased 
with increased gel concentration. However, gels prepared using the 
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formulation containing the drug Orphenadrine HCl exhibited a rather 
different behaviour; at a concentration of 2% w/w, such gels had a 
consistency similar to that with blank and Orphenadrine Citrate containing 
gels prepared at the same concentration. Upon increase in gel 
concentration, a marked drop in gel structure was clearly visible; gels 
containing Orphenadrine HCl prepared at a concentration of 4% w/w had 
the consistency of a weak slurry system. Further increase in gel 
concentration to 6% w/w resulted in a much more significant drop in gel 
structure resulting in highly sedimenting particulate suspensions. 
Moreover, no gel formation or increase in viscosity was observed with 
time, even after continuous stirring for 30 minutes and storage for 24 
hours.  These gel systems, i.e. systems prepared at a concentration of 
6% w/w using the formulation containing the drug orphenadrine HCl, did 
not give consistent rheological measurements. This may be due to their 
high sedimentation rate which resulted in the occurrence of artefacts in 
the results. Thus no rheological measurements are reported for these.  
 
6.2.1.1. Oscillation studies: 
Initially, strain amplitude sweeps were carried out on all gel systems to 
determine the linear viscoelastic region (LVR) for each gel sample. Within 
this region the shear strain or deformation within a material is directly 
proportional to the applied shear stress. The relationship between the 
shear stress and shear strain was monitored using two parameters, the 
elastic modulus (G’) and the viscous modulus (G”). These parameters are 
the two components of the overall complex modulus (G*) which is the 
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mathematical parameter describing the relationship obtained by dividing 
the shear stress by the corresponding shear strain (Barnes et al 1996). 
The elastic, or storage, modulus (G’) reflects the part of the shear stress 
which is said to be in phase with the shear strain under sinusoidal 
conditions divided by the corresponding strain (Barnes et al 1996). This 
parameter is associated with the solid nature of the material. The viscous, 
or loss, modulus (G”) is an imaginary part of the complex modulus 
(Barnes et al 1996). This parameter in turn is associated with the liquid 
nature of the material. 
 
The results of the amplitude sweeps for the various gel systems 
investigated are shown in Figures 6.1. to 6.4. For blank Xanthan Gum 
gels, and gels containing the drug Orphenadrine Citrate, rather broad 
linear viscoelastic regions were detected for gels prepared at the three 
concentrations studied, covering most of the strain amplitude range 
studied. Moreover, the values of the elastic modulus (G’) for these gels 
are consistently higher than the values for the viscous or loss modulus 
(G”), indicating the presence of a rather solid structure. Such behaviour 
could be attributed to the ability of these systems to form a stable and 
consistent three dimensional gel network. Deflection points in the curves 
representing both the elastic (G’) and viscous (G”) moduli, are only 
apparent at higher amplitude values indicating the loss of gel structure at 
high amplitudes. Upon comparison between the values of elastic (G’) and 
viscous (G”) moduli for gels prepared using the same formulation but at 
different concentrations, a clear increase is observed in the values of both 
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moduli upon increase in gel concentration. The increase in moduli values 
is more apparent upon increase in gel concentration from 2% w/w to 4% 
w/w, with smaller increase upon further increase in gel concentration to 
6% w/w. Such behaviour became more apparent in gel systems 
containing the drug Orphenadrine Citrate. 
 
As for gel systems containing the drug Orphenadrine HCl, and as 
previously mentioned, a rather opposite behaviour was apparent in the 
results of the amplitude sweeps; gels prepared at a concentration of 2% 
w/w exhibited a broad linear viscoelastic region (LVR), in which the 
values of the elastic modulus (G’) are consistently higher than those of 
the viscous modulus (G”). This is comparable to the results obtained for 
gels prepared at the same concentration using the two other formulations.  
 
 
 
Figure 6.1. Amplitude sweep of blank Xanthan Gum gels. Red signs 
indicate the elastic modulus (G’), and blue signs indicate the viscous 
modulus (G”). (O) 2% w/w gel, (∆) 4% w/w gel, and (+) 6% gel. 
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Figure 6.2. Amplitude sweep of Xanthan Gum gels with Orphenadrine 
Citrate. Red signs indicate the elastic modulus (G’), and blue signs 
indicate the viscous modulus (G”). (O) 2% w/w gel, (∆) 4% w/w gel, and 
(+) 6% gel. 
 
 
 
 
Figure 6.3. Amplitude sweep of 2% w/w Xanthan Gum gel with 
Orphenadrine HCl. Red signs indicate the elastic modulus (G’), and blue 
signs indicate the viscous modulus (G”). 
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Figure 6.4. Amplitude sweep of 4% w/w Xanthan Gum gel with 
Orphenadrine HCl. Red signs indicate the elastic modulus (G’), and blue 
signs indicate the viscous modulus (G”). 
 
 
However, upon increase in the concentration of the gel system a sharp 
drop in the values of both elastic (G’) and viscous (G”) moduli was 
apparent and a much smaller linear viscoelastic region was obtained. 
This is consistent with the visual observation of this gel system which had 
the consistency of pourable slurry. Within the linear viscoleastic region 
the values of the elastic modulus (G’) are consistently higher than those 
of the viscous modulus (G”) but the magnitude of the difference between 
these values is much smaller than for the other gel systems investigated. 
Moreover, the breakdown in gel structure occurred at lower values of 
amplitude. 
 
Strain amplitude values obtained from the middle point of the linear 
viscoelastic region (LVR) for each of the gel systems investigated. 
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Together with the corresponding stress values, these values were used to 
obtain a dynamic spectrum for the rheological behaviour of the various 
gel systems across a frequency range between 0.01 and 10 Hz. For all 
gels a strain value of 0.01 was used in the frequency sweep investigation. 
One exception was the 4% w/w gel system containing the drug 
Orphenadrine HCl, where a strain value of 0.005 was used due to the 
previously mentioned nature of the linear viscoelastic region associated 
with such samples. 
 
The influence of oscillation frequency on the values of both, elastic (G’) 
and viscous (G”) moduli for the various gel systems investigated in this 
study are shown in Figures 6.5. to 6.7. Once again, certain trends are 
apparent in the behaviour of the various gel systems. For blank Xanthan 
Gum gels the results of the frequency sweeps show values of the elastic 
modulus (G’) that are consistently higher than those for the viscous 
modulus (G”). The difference between the values of both moduli is clearly 
apparent, and is within the range of one order of magnitude. No 
crossover point is detected within the frequency range investigated, and 
this is apparent for gels prepared at all concentrations. Moreover, the 
values of both moduli seem to have a certain degree of frequency 
dependence, with higher values obtained at higher values of oscillation 
frequency. This behaviour of frequency dependence is more apparent in 
the values of the elastic modulus (G’). Such behaviour is in agreement 
with previously published work that investigated the dynamic rheological 
behaviour of Xanthan Gum gels prepared at such higher concentrations; 
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Talukdar et al (1996) characterised Xanthan Gum gels prepared at 
concentrations of 4% and 7% w/w, and they reported similar finding 
where the values of the elastic modulus (G’) were consistently higher 
than those of the viscous modulus (G”) across a wide range of oscillation 
frequencies. This behaviour associated with Xanthan Gum was 
previously associated with the ability of this polysaccharide to form weak 
three dimensional gel structures. This was apparent at moderate gel 
concentration of 0.5%, 1% and higher. However, loss of this behaviour 
was apparent at lower concentration values (Lim et al 1984, Rochefort 
and Middleman 1987).  
 
Inclusion of the two drugs into the Xanthan Gum gel systems seems to 
have a different effect on the dynamic rheological properties of such 
systems. Gels containing the drug Orphenadrine Citrate exhibit a 
dynamic behaviour similar to that obtained with blank Xanthan Gum gel 
systems, in which the values of the elastic modulus (G’) are consistently 
higher that those of the viscous modulus (G”) throughout the frequency 
range investigated with slight frequency dependence observed in the 
values of both moduli; higher values were apparent at higher fruequency 
especially for the values of the elastic modulus (G’). No crossover point 
was apparent with the gels prepared at any of the concentrations 
investigated, and the values of both moduli progressively increased with 
increased gel concentration. Such systems could be defined with respect 
to previously published criteria as having weak-gel structures, where the 
elastic modulus (G’) is much larger than the viscous modulus (G”). Slight 
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frequency dependence is observed in the values of the moduli (Ross 
Murphy and Shatwell 1993). 
 
Inclusion of the drug Orphenadrine HCl had a different effect. This was 
mainly apparent in the effect associated with the increase in gel 
concentration. Gels with a concentration of 2% w/w exhibited a behaviour 
similar to that observed with blank and Orpheadrine Citrate containing 2% 
w/w gels; a slight frequency dependence was observed, and the values of 
elastic Modulus (G’) were consistently higher than those of the viscous 
modulus (G”). Furthermore, no crossover point was detected within the 
investigated frequency range. 
 
 
 
Figure 6.5. Influence of frequency on the elastic modulus (G’), and 
Viscous modulus (G”) of blank Xanthan Gum gels. (O) 2% w/w gel, (∆) 
4% w/w gel, and (+) 6% gel. 
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Figure 6.6. Influence of frequency on the elastic modulus (G’), and 
Viscous modulus (G”) of Xanthan Gum gels with Orphenadrine Citrate. 
(O) 2% w/w gel, (∆) 4% w/w gel, and (+) 6% gel. 
 
 
 
 
 
Figure 6.7. Influence of frequency on the elastic modulus (G’), and 
Viscous modulus (G”) of Xanthan Gum gels with Orphenadrine HCl. (O) 
2% w/w gel, (∆) 4% w/w gel. 
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On the other hand, gels with a concentration of 4% w/w exhibited much 
lower values for both the elastic (G’), and viscous (G”) moduli. The 
frequency dependence of the moduli values for these gels were much 
more apparent than those of all other gel systems investigated; values 
were clearly higher at higher frequencies. However, within the range of 
oscillation frequencies investigated, no crossover point was apparent, 
especially at the lower frequency values, which is usually associated with 
the phase transition between polymer gel and polymer solution. Such 
behaviour indicates that even at such consistency, a three dimensional 
gel structure was still apparent in the system. 
 
More insight into the structural features associated with the various gel 
systems investigated could be attained by observing the effect of 
oscillation frequency on the phase angle, or phase lag, values associated 
with the gel systems. These values represent the phase difference, or 
lag, between the stress and strain waves within a material during 
sinusoidal oscillation. A material with a pure elastic “solid” behaviour 
would produce a phase lag of 0°, whereas a material with a pure viscous 
“liquid” behaviour would produce a phase lag of 90° (Marriott 2002).  
 
The effect of oscillation frequency on the phase angle of the various gel 
systems studied is presented in Figures 6.8. to 6.10.  For blank Xanthan 
Gum gels (Figure 6.8), slightly higher phase angle values were observed 
at lower oscillation frequency values. This was apparent with gel systems 
prepared at all three concentrations of 2%, 4% and 6% w/w. Moreover, 
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the values of the phase angle seem to undergo a slight decrease with the 
increase in gel concentration. However, changes in the values of phase 
angle observed in these gel systems and the change in such values with 
frequency and concentration seem to be minimal with phase angle values 
ranging between about 9.0° and 13.0° for all samples. Thus, all blank 
Xanthan Gum gels investigated could be considered as having a solid gel 
structure due to the low phase angle values associated with these 
systems. A somewhat similar observation was apparent with gel systems 
containing the drug Orphenadrine Citrate (Figure 6.9), where similar 
variations in phase angle values where observed with changes in 
oscillation frequency and gel concentration. One irregular observation 
was noted with 6% w/w gel systems containing Orphenadrine Citrate in 
which phase angle values were slightly higher than those obtained with 
gels prepared at concentrations of 2% w/w and 4% w/w, which usually 
indicates a more liquid like structure. However, the differences between 
phase angle values at different oscillation frequencies and gel 
concentrations were once again minimal and ranged between 9.0° and 
13.5°.  
 
Gels prepared at a concentration of 2% w/w and containing the drug 
Orphenadrine HCl (Figure 6.10), had slightly higher phase angle values 
when compared to blank and Orphenadrine Citrate containing gels with 
similar concentration. They exhibited phase angle values ranging 
between 11.5 ° to 15.3° across the frequency range investigated. 
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Figure 6.8. Influence of frequency on the phase angle (δ) of blank 
Xanthan Gum gels. (O) 2% w/w gel, (∆) 4% w/w gel, and (+) 6% gel. 
 
 
 
 
 
 
Figure 6.9. Influence of frequency on the phase angle (δ) of Xanthan 
Gum gels with Orphenadrine Citrate. (O) 2% w/w gel, (∆) 4% w/w gel, 
and (+) 6% gel. 
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Figure 6.10. Influence of frequency on the phase angle (δ) of Xanthan 
Gum gels with Orphenadrine HCl. (O) 2% w/w gel, (∆) 4% w/w gel. 
 
However, the most apparent liquid-like behaviour was noted with the 4% 
w/w gel systems containing Orphenadrine HCl. These weak gel systems 
or slurries had phase angle values clearly higher than those obtained with 
2% gel systems containing Orphenadrine HCl, indicating a more liquid 
like behaviour of the system. Slight variations were also apparent in the 
values of the phase angle for these systems with changes of the 
oscillation frequency, with values ranging between 25.0° and 28.5°.  
 
The overall observation from oscillatory rheological studies indicates the 
formation of a weak three dimensional network, or gel structure, in blank 
Xanthan Gum, and Orphenadrine Citrate containing systems. The 
intensity or strength of such network is increased with the increase in the 
concentration of the gel system. Inclusion of the drug Orphenadrine HCl 
into the gel system seems to have a somewhat concentration dependent 
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effect; at the lower gel concentration of 2% w/w, the behaviour of 
Orphenadrine HCl containing gel systems was similar to that with blank 
Xanthan Gum and Orphenadrine Citrate containing systems. However, at 
higher concentrations, the influence of orphenadrine HCl seems to be 
more drastic resulting in a clear drop in the consistency of the gel 
structure. 
 
6.2.1.2. Viscometric studies: 
Viscometric studies were carried out on all gel systems. Such studies 
provide an insight into the behaviour of a gel at the point of breakdown of 
the structural consistency and beyond. Thus, the results of these studies 
would give an important comparison between the flow behaviour of all gel 
systems studied. Such behaviour could be directly related to the erosion 
process occurring on the outer surface of a hydrating hydrophilic matrix 
tablet.  
 
Polymer particles usually undergo a continuous process of hydration 
within the gel layer of a hydrating matrix tablet. After reaching a certain 
concentration polymer chains usually break away and erode into the 
surrounding hydration medium. However, pharmaceutical tablets, 
including hydrophilic matrix ones, mostly contain a combination of soluble 
and in-soluble excipients in addition to the active ingredient. All of these 
materials could have a marked effect on the structural properties of the 
gel layer, either directly or by interacting with each other or with the 
polymer, leading in some cases to particle erosion from the outer region 
of the gel layer. Thus, viscometric studies would help in elucidating the 
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erosion and flow behaviour associated with the gel layer in the various 
tablets used in this study. 
 
6.2.1.2.1. Investigating the flow behaviour of Xanthan Gum gels: 
The influence of shear rate on the apparent viscosity (η) of blank and 
drug containing Xanthan Gum gels are documented below (Figures 6.11. 
to 6.13.).  For blank Xanthan Gum gels a clear shear thinning behaviour 
is observed with gels prepared at all three concentrations (Figure 6.11.), 
which means a decrease in the apparent gel viscosity (η) with the 
increase in shear rate. Such an effect could be attributed mainly to the 
structural features of Xanthan Gum in the hydrated state; at lower shear 
rate values, Xanthan Gum molecules in their helical structures tend to 
aggregate and interact together by means of hydrogen bonding, whereas 
at higher values of shear rate the structural integrity of Xanthan Gum 
molecules is damaged and hydrogen bonds are broken and polymer 
molecules align in the shear direction leading to a drop in apparent 
viscosity. Similar trends were reported with gum solutions of lower 
concentrations (Rochefort and Middleman 1987, Zats and Knapp 1984). 
 
An increase in the apparent viscosity (η) of blank Xanthan Gum gels is 
observed with the increase in gel concentration. Such behaviour could 
also be attributed to the structural properties of the hydrated Xanthan 
Gum molecules; increased gel concentration leads to the increase of 
hydrated Xanthan Gum molecules available for hydrogen bonding, thus 
increasing the rigidity of the system and giving rise to higher values of  
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Figure 6.11. Influence of shear rate (ý) on the apparent viscosity (η) of 
blank Xanthan Gum gels. (O) 2% w/w gel, (∆) 4% w/w gel, and (+) 6% 
gel. 
 
 
 
 
 
Figure 6.12. Influence of shear rate (ý) on the apparent viscosity (η) of 
Xanthan Gum gels with Orphenadrine Citrate. (O) 2% w/w gel, (∆) 4% 
w/w gel, and (+) 6% gel. 
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Figure 6.13. Influence of shear rate (ý) on the apparent viscosity (η) of 
Xanthan Gum gels with Orphenadrine HCl. (O) 2% w/w gel, (∆) 4% w/w 
gel. 
 
apparent viscosity (η). The difference in the values of apparent viscosity 
(η) is more obvious between gels prepared at the lower concentration of 
2% w/w and the ones prepared at the two higher concentratins of 4% and 
6% w/w.  
 
Incorporating the drug orphenadrine Citrate into the Xanthan Gum gels 
resulted in a similar shear thinning behaviour (Figure 6.12.). Moreover, 
the influence of increasing the concentration of the gel is similar to that 
observed with blank Xanthan Gum gels, where a progressive increase in 
gel apparent viscosity (η) was observed with the increase in gel 
concentration. A slightly smaller difference was observed between the 
apparent viscosity (η) of gels prepared at concentrations of 4% and 6% 
w/w, as compared to blank Xanthan Gum gels. 
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Incorporating the drug Orphenadrine HCl into Xanthan Gum gels resulted 
in a concentration dependent effect (Figure 6.13.); at the lower gel 
concentration of 2% w/w, the profile of apparent gel viscosity (η) with 
shear rate was similar to those of blank and Orphenadrine Citrate 
containing gels. Upon further increase in gel concentration to 4% w/w, a 
clear drop in gel apparent viscosity (η) was noted. Such behaviour is in 
agreement with the results of the dynamic oscillatory studies conducted 
on these gels. This behaviour could arise from the inability of the Xanthan 
Gum molecules to fully hydrate and interact by hydrogen bonding leading 
to the formation of a weaker three dimensional network of gel structure. 
However, the presence of a shear thinning behaviour associated with 
such system (Figure 6.13) indicates that some kind of structural integrity 
is still found in the system, which indicates that the influence of the drug 
had not diminished the ability of Xanthan Gum molecules to interact and 
form a three dimensional network. 
 
The dependence of the shear stress on the shear rate for blank and drug 
containing Xanthan Gum gels is shown in the flow curves of such 
systems (Figures 6.14. to 6.16.). For blank Xanthan Gum gels (Figure 
6.14.), two main features are apparent from the flow curves associated 
with the gels. Initially, it is clear that all gels exhibit some kind of yield 
stress which is the minimum stress or force required to break the gel 
structure, as the values of the shear stress are consistently higher than 
zero at the lower values of shear rate. The value of the yield stress 
becomes progressively higher with the increase in gel concentration. 
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Figure 6.14. Flow Curves of blank Xanthan Gum gels. (ý) is shear rate, 
and (σ) is shear stress. (O) 2% w/w gel, (∆) 4% w/w gel, and (+) 6% gel. 
 
 
 
 
 
 
Figure 6.15. Flow Curves of Xanthan Gum gels with Orphenadrine 
Citrate. (ý) is shear rate, and (σ) is shear stress. (O) 2% w/w gel, (∆) 4% 
w/w gel, and (+) 6% gel. 
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Figure 6.16. Flow Curves of Xanthan Gum gels with Orphenadrine HCl. 
(ý) is shear rate, and (σ) is shear stress. (O) 2% w/w gel, (∆) 4% w/w gel. 
 
This effect, once again is related to the interaction between the hydrated 
Xanthan Gum molecules and the need to apply a certain level of stress to 
break such interactions. 
 
Another aspect that becomes clear from the flow curves of blank Xanthan 
Gum gels, is the thixotropic behaviour associated with such systems. 
Thixotropy could be defined as the decrease in the apparent viscosity, of 
the gel systems in this study, under constant shear stress or shear rate 
which is followed by a process of gradual recovery when such shear 
stress or shear rate is removed. Moreover this effect is time dependent 
(Barnes et al 1996). In the case of gels, Thixotropy could be indicative of 
the breakdown of the gel structure upon application of stress over time, 
and the consecutive rebuilding or reformation of gel structure upon 
removal of the affecting stress.  
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Quantitative insight into the magnitude of thixotropic behaviour was 
accomplished by integrating the area of the “hysteresis loop” which is the 
area between the “up” and “down” segments of the flow curve. The 
results of the thixotropic behaviour of all blank and drug containing gel 
systems are listed in Table 6.1. For Blank Xanthan Gum gels, an increase 
in thixotropy is observed with the increase in gel concentration. This could 
be attributed to the larger number of hydrogen bonding interactions in the 
structural network of gels with higher concentrations, which, upon 
destruction, would cause a more apparent drop in gel structural integrity. 
Moreover, such systems would require more time to rebuild their 
structural networks after the removal of the affecting stress. 
 
Gels containing the drug Orphenadrine Citrate (Figure 6.15.) exhibited a 
similar behaviour in terms of the presence of a yield stress value. 
However, such gels exhibited a higher degree of thixotropic behaviour as 
compared to blank Xanthan Gum gels (Table 6.1.). Such change in 
behaviour could be attributed to a number of factors. Initially, 
Orphenadrine Citrate has an aqueous solubility of 1 in 70 of water(Moffat 
et al 2004). Thus a certain fraction of drug particles could remain 
suspended within the gel network formed by Xanthan Gum leading to a 
change in the rigidity of the network. Secondly, upon dissolution, 
Orphenadrine is a cationic drug and has the potential to interact with the 
anionic Xanthan Gum. Such interaction could lead to the formation of a 
complex with limited or low aqueous solubility, which in turn could 
influence the properties of the gel network. A pattern, similar to that 
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obtained with blank Xanthan Gum gels, is apparent in terms of the 
influence of gel concentration on the thixotropic behaviour; gels produced 
at higher concentrations had higher degrees of thixotopic behaviour 
(Table 6.1.). 
 
 
                              Gel Concentraion (%w/w) 
Gel Type 2% 4% 6% 
Blank Xanthan Gum 
21.785 
(2.805) 
74.466 
(2.215) 
144.323 
(1.422) 
Xanthan Gum with Orphenadrine Citrate 
32.235 
(2.017) 
101.919 
(4.125) 
155.950 
(8.788) 
Xanthan Gum with Orphenadrine HCl 
8.376 
(3.700) 
1.626 
(0.647) 
n.d. 
n.d. 
 
Table 6.1. Thixotopy values for blank and drug containing Xanthan Gum 
gels, (SD) n=3. (n.d.: not determined, see section 6.2.1.). 
 
 
Gels containing the drug Orphenadrine HCl exhibited consistently lower 
values of thixotropic behaviour as compared to blank and Orphenadrine 
Citrate containing gels. Moreover, and in agreement with the results of 
dynamic studies, a drop in the degree of thixotropic behaviour was 
observed with the increase of gel concentration from 2% w/w to 4% w/w, 
which is attributed to the lower degree of structural integrity and 
interaction. In terms of yield stress values, Orphenadrine HCl containing 
gels at a concentration of 2% w/w exhibited a certain degree of yield 
stress similar to that exhibited by blank gels. However, gels with a 
concentration of 4%, seem to exhibit a diminishing value of yield stress. 
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In order to further elucidate the influence of gel concentration on the 
extent of thixotropic behaviour associated with the various gels, analysis 
of variance (ANOVA) was carried out to determine the presence and 
nature of any significant effect of concentration on thixotropic behaviour.  
 
For blank Xanthan Gum gels, analysis of variance (ANOVA) indicated a 
significant influence of the concentration of the gel on its thixotropic 
behaviour (F= 2298.469, p < 0.001). Post hoc analysis was carried out 
using the Sheffé test to elucidate the difference between the three levels 
of gel concentration. The results of the analysis are shown below (Table 
6.2.) and they indicate a significant difference between all thee levels of 
gel concentration in terms of the extent of their thixotropic behaviour.  
 
 
 
 
 
 
 
 
Table 6.2. Post hoc analysis results for thixotopy values of blank Xanthan 
Gum gels. (The values reported are the mean thixotropy values, and the 
classification into different subsets is used to indicate significant 
differences between mean values). 
 
 
 
  
Scheffe  
Conc N 
Subset 
1 2 3 
2% 3 21.78533     
4% 3   74.46633   
6% 3     144.32333 
Sig.   1.000 1.000 1.000 
*Alpha = .05. 
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A similar pattern was noted with Orphenadrine Citrate containing gels; the 
result of the analysis of variance (ANOVA) indicated a significant effect of 
the change of gel concentration on the extent of their thixotopic behaviour 
(F= 352.148, p < 0.001). Post hoc analysis, using the Sheffé test (Table 
6.3.), indicated a significant difference between all thee levels of gel 
concentration in terms of the extent of their thixotropic behaviour.  
 
 
 
 
 
 
 
 
 
 
Table 6.3. Post hoc analysis results for thixotopy values of Xanthan Gum 
gels with Orphenadrine Citrate, (see table 6.2. for further explanation). 
 
 
For gels containing the drug Orphenadrine HCL, only two levels of gel 
concentration were investigated, hence, the independent sample t-test 
method was used to elucidate the presence of any significant difference 
between the values of thixotropic behaviour associated with the two 
concentrations. The results indicated that no significant difference was 
found between the values of the thixotropic behaviour associated with the 
two concentrations (t= 3.113, p= 0.083.). 
 
 
  
Scheffe  
Conc N 
Subset 
1 2 3 
2% 3 32.23467     
4% 3   101.91933   
6% 3     155.95000 
Sig.   1.000 1.000 1.000 
* Alpha = .05. 
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6.2.1.2.2. Determination of the yield stress of Xanthan Gum gels. 
An experimental approach was adopted for the determination of the yield 
stress values associated with the various gels used in this study. This 
method includes the application of progressively increasing shear stress 
values on the samples, with continuous monitoring of the strain and the 
instantaneous viscosity within the samples. Upon reaching the yield value 
of the sample, a clear deflection is noted in the values of both monitored 
variables due to the destruction of the structural integrity of the gel 
system. This method provided a rather practical and reliable method for 
the determination of the actual yield stress values associated with gel 
samples. 
 
The results of yield stress determination studies for blank and drug 
containing Xanthan Gum gels are presented in Figures 6.17 to 6.20. and 
in Table 6.4. For blank Xanthan Gum gels (Figure 6.17.) and (Table 6.4.) 
a progressive increase in the yield stress values is observed with the 
increase in gel concentration.  
 
A rather similar pattern is observed with gels containing the drug 
Orphenadrine Citrate (Figure 6.18.) and (Table 6.4.). At the two lower 
concentrations of 2% and 4% w/w, such gels exhibited yield stress values 
higher than those exhibited by blank Xanthan Gum gels with similar 
concentration. However, a different observation was noted for the yield 
stress at higher concentration. After an initial increase in the yield stress 
values, a drop is observed in these values with further increase in gel 
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concentration to 6% w/w. This behaviour could be attributed to the 
possible presence of undissolved free drug particles or drug-polymer 
complex particles within the gel structure which could enhance gel 
breakage and lower the yield value when present at higher 
concentrations. 
 
Gels with a concentration of 2% w/w and containing the drug 
Orphenadrine HCl (Figure 6.19.) and (Table 6.4.), exhibited yield stress 
values similar to those obtained with blank Xanthan Gum gels. Further 
increase in gel concentration to 4% w/w, (Figure 6.20.) and (Table 6.4.), 
resulted in a marked drop in yield stress values. 
 
 
 
 
Figure 6.17. Yield stress determination for blank Xanthan Gum gels. (σ) 
is the shear stress, blue curves are the strain (У), and red curves are the 
instantaneous viscosity (ηi). (O) 2% w/w gel, (∆) 4% w/w gel, and (+) 6% 
gel. 
                                                                                                     Chapter 6 
 267
 
 
Figure 6.18. Yield stress determination for Xanthan Gum gels with 
Orphenadrine Citrate. (σ) is the shear stress, blue curves are the strain 
(У), and red curves are the instantaneous viscosity (ηi). (O) 2% w/w gel, 
(∆) 4% w/w gel, and (+) 6% gel. 
 
 
 
 
Figure 6.19. Yield stress determination for 2% w/w Xanthan Gum gels 
with Orphenadrine HCl. (σ) is the shear stress, blue curves are the strain 
(У), and red curves are the instantaneous viscosity (ηi). 
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Figure 6.20. Yield stress determination for 4% w/w Xanthan Gum gels 
with Orphenadrine HCl. (σ) is the shear stress, blue curves are the strain 
(У), and red curves are the instantaneous viscosity (ηi). 
 
 
 
 
 
                              Gel Concentraion (%w/w) 
Gel Type 2% 4% 6% 
Blank Xanthan Gum 
20.199 
(2.366) 
42.456 
(2.366) 
60.456 
(4.096) 
Xanthan Gum with Orphenadrine Citrate 
27.140 
(0.080) 
52.127 
(0.080) 
43.798 
(4.165) 
Xanthan Gum with Orphenadrine HCl 
20.199 
(2.366) 
0.730 
(0.191) 
n.d. 
n.d. 
 
Table 6.4. Yield stress values for blank and drug containing Xanthan 
Gum gels, (SD) n=3, (n.d.: not determined, see section 6.2.1.). 
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Statistical analysis using analysis of variance (ANOVA) was carried out to 
elucidate the difference between the yield stress values of the different 
gel systems. For blank Xanthan Gum gels, the results of the analysis of 
variance (ANOVA) indicated a significant influence of gel concentration 
on the yield value (F= 130.875, p < 0.001). Post hoc analysis using the 
Sheffé test (Table 6.5.) revealed a significant difference in the yield stress 
values obtained with all three levels of gel concentration. 
 
For gels containing the drug Orphenadrine Citrate, a similar observation 
was noted. The results of the ANOVA indicated a significant influence on 
the gel yield stress values as a result of the change in gel concentration 
(F= 83.909 ,p < 0.001). The results of the post hoc Sheffé test (Table 
6.6.) indicated a significant difference between the yield stress values of 
all three levels of gel concentration. 
 
 
 
 
 
 
 
 
Table 6.5. Post hoc analysis results for yield stress values of blank 
Xanthan Gum gels. (The values reported are the mean yield stress 
values, and the classification into different subsets is used to indicate 
significant differences between mean values). 
 
  
Scheffe  
Conc N 
Subset 
1 2 3 
2% 3 20.19867     
4% 3   42.45633   
6% 3     60.45633 
Sig.   1.000 1.000 1.000 
* Alpha = .05. 
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Table 6.6. Post hoc analysis results for yield stress values of Xanthan 
Gum gels with Orphenadrine Citrate, (see table 6.5. for further 
explanation) 
 
 
The results of the independent sample t-test for 2% and 4% w/w gels 
containing the drug Orphenadrine HCl, indicated a significant difference 
between the yield values of the two levels of gel concentration (t= 14.209, 
p= 0.005).  
 
 
6.2.2. Thermal investigation of dried Xanthan Gum gel systems: 
The results of the rheological studies indicated a change in the gel 
properties of Xanthan Gum, caused by the addition of both drugs; 
Orphenadrine Citrate, and more significantly, Orphenadrine HCl. Such 
behaviour could, in part, be the result of the potential ionic interaction 
between the anionic Xanthan Gum and the cationic Orphenadrine. Thus, 
thermal investigation studies were carried out for the various gel systems 
studied, and also for dry polymer and drug powders, and powder 
  
Scheffe  
Conc N 
Subset 
1 2 3 
2% 3 27.14000     
6% 3   43.79800   
4% 3     52.12733 
Sig.   1.000 1.000 1.000 
* Alpha = .05. 
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mixtures. This was done to get further insight into the physicochemical 
properties associated with the various samples. 
 
Temperature modulated differential scanning calorimeter (TMDSC) is an 
advanced thermal characterisation technique. It provides a major 
advantage over conventional differential scanning calorimetry (DSC) due 
to its ability to separate the thermal heat flow signal associated with each 
sample into its reversing and non-reversing components. Thus it 
facilitates the characterisation of the various thermal behaviour patterns 
occurring within the sample (Verdonck et al 1999) 
 
 
6.2.2.1. Pure polymer and drug powders: 
The temperature modulated thermograms for the pure powders of the 
polymer and drugs used in this study are shown in Figures 6.21. to 6.23., 
respectively. For Xanthan Gum (Figure 6.21.), one main feature is 
apparent from the thermogram; a broad endotherm is clearly apparent in 
both the overall heat flow and the non-reversing heat flow signals and 
peaks at 100°C. Such broad endotherm is usually associated with 
moisture loss from the polymer lattice. Similar results were reported with 
other hydrophilic polymers such as Hydroxypropyl Methylcellulose (Ford 
1999). The position of such endotherm is highly dependent on the 
encapsulation technique used in sample preparation, where more sealed 
pan types like hermetically sealed ones could slow the process of 
moisture loss and shifts the endotherm upwards (Ford 1999). 
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Figure 6.21. Temperature modulated thermogram of Xanthan Gum 
powder, sample weight 4.8 mg, oscillation amplitude: 0.5 °C, oscillation 
period: 50 seconds. 
 
 
 
The glass transition temperature, i.e. the temperature at which phase 
transition in the polymer structure from the glassy state to the rubbery 
state occurs is often present in the form of a stepwise decline in the 
reversing heat flow signal. However, no glass transition pattern is clearly 
apparent in the thermogram of Xanthan Gum powder. The determination 
of such behaviour in hydrophilic polymers is often difficult, as the 
magnitude of moisture in the sample, and the subsequent loss of such 
water during the heating process, could cause significant changes in the 
shape and shifts in the position of the glass transition pattern. 
Furthermore, the presence of moisture in the polymer lattice could 
 
                                                                                                     Chapter 6 
 273
broaden the range over which glass transition takes place (Joshi and 
Wilson 1993, Ford 1999). 
 
The thermogram of pure Orphenadrine Citrate powder (Figure 6.22.) 
shows a distinctive sharp endothermic peak in all of the heat flow signals 
at about 136°C. Such peak is usually associated with powder melting. 
The finding is in agreement with previously reported reference values of 
137°C (BP 2007). Another endothermic peak is apparent at a higher 
temperature of 170°C. The occurrence of such peak in the overall heat 
flow signal and in the non-reversing heat flow signal is indicative of a 
dehydration process which is typically expected after powder melting.   
 
A similar pattern is observed in the thermogram of pure Orphenadrine 
HCl powder (Figure 6.23.). A sharp endothermic peak is apparent in all 
heat flow signals at about 160°C. This is indicative of powder melting, and 
is in agreement with the previously reported reference value of 160°C (BP 
2007). Furthermore, a broad dehydration endotherm is apparent in the 
non-reversing heat flow signal and in the overall heat flow signal between 
180°C and 225°C, indicating a process of sample dehydration. 
 
 
 
 
 
 
 
                                                                                                     Chapter 6 
 274
 
 
 
 
 
 
 
 
 
Figure 6.22. Temperature modulated thermogram of Orphenadrine 
Citrate powder, sample weight 4.6 mg, oscillation amplitude: 0.5 °C, 
oscillation period: 50 seconds. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.23. Temperature modulated thermogram of Orphenadrine HCl 
powder, sample weight 4.9 mg, oscillation amplitude: 0.5 °C, oscillation 
period: 50 seconds. 
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6.2.2.2. Polymer-drug physical mixtures: 
Temperature modulated thermograms for physical powder mixtures 
containing Xanthan Gum and either of the two drugs are presented in 
Figures 6.24. and 6.25. The thermogram of the physical mixture between 
Xanthan Gum and Orphenadrine Citrate (Figure 6.24.) appears to contain 
the combined thermal patterns of both entities.  An endotherm is apparent 
in all heat flow signals at a temperature of 136°C. Such endotherm is 
comparable to the endotherm associated with the melting point of 
Orphenadrine Citrate (Figure 6.22.). A broad endotherm is observed in 
both the total and the non-reversing heat flow signals between 50°C and 
140°C and this could be in turn attributed to the loss of moisture from the 
hydrophilic Xanthan Gum. Two more endothermic peaks are apparent in 
the total and the non-reversing heat flow signals at 175°C and 200°C 
respectively, and such behaviour probably arises from the dehydration 
process associated with the melted drug powder.  
 
A similar pattern is observed in the thermogram of the physical mixture 
containing Xanthan Gum and the drug Orphenadrine HCl.  A melting 
endotherm is observed with a peak at 160°C, corresponding to the 
melting point of Orphenadrine HCl. A broad dehydration endotherm is 
apparent in both the total and non-reversing heat flow signals between 
25°C and 150°C indicative of moisture loss from Xanthan Gum. Finally an 
endotherm with multiple peaks is apparent in both the total and non-
reversing heat flow signals between 160°C and 200°C, probably 
associated with dehydration of the melted drug. 
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Figure 6.24. Temperature modulated thermogram of Xanthan Gum-
Orphenadrine Citrate physical mixture, sample weight 5.2 mg, oscillation 
amplitude: 0.5 °C, oscillation period: 50 seconds. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.25. Temperature modulated thermogram of Xanthan Gum-
Orphenadrine HCl physical mixture, sample weight 5.2 mg, oscillation 
amplitude: 0.5 °C, oscillation period: 50 seconds. 
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The presence of melting peaks in the physical mixtures containing both 
drugs, and the similarity between the positioning of such peaks with the 
melting peaks detected for the pure drug powders, indicate the presence 
of both drugs in their crystalline state within the mixtures. Thus, no 
significant interaction or complex formation is apparent between Xanthan 
Gum and either drug in the solid state. 
 
6.2.2.3. Polymer-drug dried gel samples: 
Gel samples used for thermal characterisation were subjected to a 
multiple drying process, encompassing oven drying, and further 
dehydration using silica gel. The drying process was carried out in 
accordance with the main objective sought from these studies, i.e. 
investigating any potential interaction between Xanthan Gum and either 
of the two drugs used in this study. Such interaction, if present, could be 
detected more clearly by monitoring the melting signal associated with 
the drugs in the dried films. 
 
6.2.2.3.1. Dried blank Xanthan Gum gels: 
Dried gel samples prepared using Xanthan Gum alone (Figures 6.26 to 
6.28) exhibited a thermal behaviour similar to that exhibited by Xanthan 
Gum powder (Figure 6.21.). The characteristic broad endotherm at lower 
temperatures is present in the total and non-reversing heat flow signals of 
gels prepared at all three concentrations. No significant thermal patterns 
are observed in the reversing heat flow signal of any of the gels. The lack 
of difference between the gels prepared at different concentrations could  
                                                                                                     Chapter 6 
 278
 
 
 
 
 
 
 
 
 
Figure 6.26.  Temperature modulated thermogram of dried Xanthan Gum 
gel, concentration 2% w/w, sample weight 4.9 mg, oscillation amplitude: 
0.5 °C, oscillation period: 50 seconds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.27.  Temperature modulated thermogram of dried Xanthan Gum 
gel, concentration 4% w/w, sample weight 5.0 mg, oscillation amplitude: 
0.5 °C, oscillation period: 50 seconds. 
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Figure 6.28.  Temperature modulated thermogram of dried Xanthan Gum 
gel, concentration 6% w/w, sample weight 4.7 mg, oscillation amplitude: 
0.5 °C, oscillation period: 50 seconds. 
 
 
be attributed to the drying process utilised in this study; the final sample 
weight used in the thermal investigation of the samples comprised mainly 
of polymer molecules. Moreover, the same polymer batch was used in 
the preparation of all gel samples, thus no chemical differences are 
present between samples in terms of their polymer content. 
 
 
6.2.2.3.2. Dried Xanthan Gum gels with added drugs: 
The thermograms of Xanthan Gum gels containing Orphenadrine Citrate 
and Orphenadrine HCl are presented in Figures (6.29. to 6.31.) and 
Figures (6.32. to 6.34.) respectively. The main Observation noted in all 
thermograms is the lack of drug melting endotherms from the reversing 
heat signal of any of the gel samples studied. Such endotherm is usually 
 
                                                                                                     Chapter 6 
 280
associated with the presence of the crystalline form of the drugs in the 
dried gel structure. Such behaviour is indicative of the presence of the 
drugs in the amorphous state, and this is highly associated with the 
interaction between Xanthan Gum and both salts of Orphenadrine used. 
Upon hydration of the gels, the anionic groups present mainly on the side 
chains of Xanthan Gum molecules, namely pyruvate and acetate, 
become ionised and have the potential to interact with the ionised cationic 
Orphenadrine molecules to form a complex which could differ in its 
physicochemical properties from the Orphenadrine salts used. Similar 
observations of drug-polymer ionic interaction and their effect on the 
thermal behaviour of either entities were previously reported (Yuksel et al 
1996, Takka 2003).   
 
The lack of any melting endotherm in the thermal behaviour of gels 
prepared using both drugs indicates that both the highly soluble 
Orphenadrine HCl and the sparingly soluble Orphenadrine Citrate 
underwent interaction with Xanthan Gum upon hydration.  
 
The thermograms of Xanthan Gum gels containing the drug 
Orphenadrine Citrate (Figures 6.29. to 6.31.) exhibited two broad 
endotherms, noted in the total heat flow and the non-reversing heat flow 
signals.  The first endotherm which peaked at around 80°C could be 
attributed to the loss of moisture from the hydrophilic Xanthan Gum,  
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Figure 6.29. Temperature modulated thermogram of dried Xanthan Gum 
gel with Orphenadrine Citrate, concentration 2% w/w, sample weight  
5.4 mg, oscillation amplitude: 0.5 °C, oscillation period: 50 seconds. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.30. Temperature modulated thermogram of dried Xanthan Gum 
gel with Orphenadrine Citrate, concentration 4% w/w, sample weight  
5.0 mg, oscillation amplitude: 0.5 °C, oscillation period: 50 seconds. 
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Figure 6.31. Temperature modulated thermogram of dried Xanthan Gum 
gel with Orphenadrine Citrate, concentration 6% w/w, sample weight  
4.6 mg, oscillation amplitude: 0.5 °C, oscillation period: 50 seconds. 
 
 
whereas, the second endotherm occurred at a much higher temperature, 
and peaked at around 225°C.  
 
Thermograms of Xanthan Gum gels containing the drug Orphenadrine 
HCl (Figures 6.32. to 6.34.) exhibited the presence of one main 
endothermic peak in both the total heat flow and the non-reversing heat 
flow signals. The positioning of this endotherm at lower temperatures with 
a peak around 80°C is once again indicative of its correlation with 
moisture loss from the hydrophilic Xanthan Gum. No other endotherm is 
apparent in the thermograms of these gels which could indicate a 
difference in the interaction pattern between Xanthan Gum and either of 
the two drugs. 
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Figure 6.32. Temperature modulated thermogram of dried Xanthan Gum 
gel with Orphenadrine HCl, concentration 2% w/w, sample weight 4.7 mg, 
oscillation amplitude: 0.5 °C, oscillation period: 50 seconds. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.33. Temperature modulated thermogram of dried Xanthan Gum 
gel with Orphenadrine HCl, concentration 4% w/w, sample weight 4.9 mg, 
oscillation amplitude: 0.5 °C, oscillation period: 50 seconds. 
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Figure 6.34. Temperature modulated thermogram of dried Xanthan Gum 
gel with Orphenadrine HCl, concentration 6% w/w, sample weight 5.0 mg, 
oscillation amplitude: 0.5 °C, oscillation period: 50 seconds. 
 
 
6.2.2.4. Influence of sample encapsulation type on the thermal 
behaviour of samples: 
The thermal behaviour of hydrophilic polymers could be influenced by the 
type of encapsulation used in sample preparation. Highly sealed pans in 
the form of hermetically sealed ones prevent the loss of moisture 
outwards from the internal environment within the pan. This could in turn 
have a clear influence on the thermal behaviour of the studied material. 
In all the thermal analysis studies carried out in this work, normal 
Aluminium crimped pans were used for sample encapsulation, thus 
allowing, to a certain extent, moisture loss from the pan, which is in line 
with the main pattern used in these studies, i.e. minimising the influence 
of water on the thermal behaviour of the samples. In order to investigate 
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any potential effect caused by the moisture content of the powders, if not 
allowed to escape from the internal pan environment, thermal 
investigation was carried out on the physical mixtures containing the 
polymer and either of the two drugs. A method identical to that used with 
the crimped Aluminium pans was used with hermetically sealed pans.  
Significantly different thermal behaviours were noted for both powder 
physical mixtures in comparison to their behaviour using crimped 
Aluminium pans. 
 
The thermal behaviour of Xanthan Gum and Orphenadrine Citrate 
physical powder mixture using hermetically sealed pans is presented in 
Figure 6.35. The thermogram exhibits two main endotherms, the first of 
which occurs in all heat flow signals and could be attributed to a melting 
process associated with the drug. However, the position of the peak is 
shifted downwards to 120°C in comparison to 136°C noted when using 
crimped Aluminium pan (Figure 6.24.).  
 
The second broad endotherm occurs in both the total heat flow and non-
reversing heat flow signals, indicating probably a dehydration process. 
No endotherm is noted at lower temperature values. The presence of 
such an endotherm in the thermogram obtained using Crimped 
Aluminium pans was attributed to the loss of moisture from Xanthan 
Gum. 
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Figure 6.35. Temperature modulated thermogram of Xanthan Gum-
Orphenadrine Citrate physical mixture in a hermetically sealed pan, 
sample weight 5.4 mg, oscillation amplitude: 0.5 °C, oscillation period: 50 
seconds. 
 
 
The change in the thermal behaviour of the physical powder mixture 
containing Xanthan Gum and the drug Orphenadrine HCl was much more 
apparent. The thermogram of such mixture using hermetically sealed 
pans is presented in Figure 6.36. It shows marked difference from the 
thermogram of the same sample using a crimped Aluminum pan (Figure 
6.25.). The melting peak associated with the drug at 160°C, which should 
be clearly apparent mainly in the reversing heat flow signal is missing 
from the thermogram obtained using the hermetically sealed pan.  Such 
behaviour could be attributed to the high aqueous solubility of the drug in 
comparison to the sparingly soluble Orphenadrine Citrate. The presence 
of moisture in the internal environment of the pan could have lead to the 
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dissolution of the drug, and subsequently to its interaction with Xanthan 
Gum. The presence of moisture within the pan is attributed mainly to the 
moisture content of Xanthan Gum, which had been previously determined 
to be 12.5% w/w (Chapter 3). 
 
 
 
 
 
 
 
 
 
 
Figure 6.36. Temperature modulated thermogram of Xanthan Gum-
Orphenadrine HCl physical mixture in a hermetically sealed pan, sample 
weight 5.4 mg, oscillation amplitude: 0.5 °C, oscillation period: 50 
seconds. 
 
 
 
6.3. General discussion and conclusions: 
The results of the rheological investigations presented in this chapter 
clearly indicated a significant influence of the nature of the formulation 
used in tablet production on the properties of the gel layer produced on 
the outer surface of such tablets upon hydration. Changing the type of the 
model drug incorporated into the formulation had a profound influence on 
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the rheological behaviour of the gels produced using the formulation.  
Incorporating the drug Orphenadrine HCl had the most obvious effect on 
the structural integrity of the produced gels. Moreover, the influence 
exerted by the drug became more profound with increased concentration. 
Such results give clear insight into the swelling patterns associated with 
Xanthan Gum tablets containing this drug (Chapter 5), in which enhanced 
erosion was marked in the early hydration stages of the tablets due to the 
high concentration of the soluble drug in the gel layer region. The 
enhanced gel integrity at lower concentrations could also explain the 
enhanced swelling ability of the tablets with continuous hydration due to 
progressive drug out flux from the matrix.  
 
As for the drug Orphenadrine Citrate, the results of the rheological 
studies indicated a rather enhanced structural integrity of Xanthan Gum 
gels in the presence of this drug. However, the calorimetric investigations 
conducted on all gels, indicated that both cationic model drugs exhibited 
clear interaction with the anionic Xanthan Gum upon hydration, and this 
explains the decreased swelling ability of Xanthan Gum gels containing 
either of the two drugs.  
 
With regards to the major differences in the rheological properties of the 
gels produced using either of the two drugs, factors other than the 
potential interaction between drug and polymer may have contributed to 
this behaviour. The difference in drug solubility may have a two fold 
influence on the produced gel layer. Initially, the amount of drug 
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immediately available for interacting with the polymer would be greatly 
enhanced in the case of the more soluble drug Orphenadrine HCl . 
Secondly, the influence of the acidic part of the drug molecule, i.e. the 
Hydrochloride and the Citrate moieties, on the pH of the hydration 
medium available in the internal microenvironment of the gel layer may 
be greatly enhanced by the increased solubility of the drug in the case of 
Orphenadrine HCl. This in turn could have an added inhibitory effect on 
the ionisation of the acidic pyruvate and acetate moieties on the side 
chains of the Xanthan Gum molecules, thus, further diminishing the 
swelling ability of the polymer. 
 
It becomes clear that changing the nature of the formulation used in the 
production of Xanthan Gum hydrophilic matrix tablets, more precisely, the 
nature of the drug incorporated into the formulation, has a profound effect 
on the properties of the gel layer formed on the outer surface of the 
tablets. 
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CHAPTER SEVEN 
  
7. Dissolution Studies 
7.1. Introduction: 
The results obtained form the various in-vitro investigations conducted on 
the Xanthan Gum hydrophilic matrix tablets used in this study indicated 
that changing the face curvature and overall porosity of round and 
elongated tablets exerted a significant influence on the physical 
properties of the tablets and on the hydration behaviour of such tablets. 
Moreover, incorporation of either of the two drugs Orphenadrine Citrate or 
Orphenadrine HCl had a clear and differing influence on tablet behaviour 
and properties. 
 
It was thus the objective of this part of this study to investigate the 
influence of such changes on the ultimate process of tablet dissolution.  
Moreover, it was another objective to investigate the influence of some of 
the hydration patterns noted during tablet hydration studies on drug 
release, namely the occurrence of cracks within the structure of the 
tablets and its possible influence on drug release. 
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Another objective of this part of the work was to explore the potential of 
statistical methods in the comparison of tablet dissolution profiles, and in 
the clarification of the effects associated with different variables and 
possible interactions between such effects.  
 
In a manner similar to that used in the investigation of the hydration 
patterns of the tablets, the results of tablet dissolution studies are 
reported in the form of percentage drug and polymer dissolved. This was 
done in order to elucidate the extent of drug and polymer dissolution in 
releation to their initial amounts in the dry tablets. This would give further 
indication on the extent of tablet hydration and how this is influenced by 
the change in tablet porosity and geometry, leading to the change in the 
internal structure of the different tablets and their surface area to volume 
ratio. This would give a more comparable picture into the overall 
hydration and subsequent dissolution patterns of tablets with different 
curvatures than absolute drug release amounts. Moreover, the use of 
percentage drug release values is a required normalisation process if 
tablets containing different amount of drug in their dry state are to be 
compared. 
 
7.2. Results and Discussion: 
7.2.1. Determination of drug and polymer absorbance contributions: 
Initial investigative studies indicated that within each tablet type, two 
entities contribute to the total absorbance recorded during tablet 
dissolution studies, namely the incorporated drug and the hydrophilic 
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polymer Xanthan Gum. This pattern was utilised to make simultaneous 
determination of drug and polymer absorbance contributions. Two 
wavelengths were chosen to measure dissolution sample absorbance 
during tablet dissolution studies, namely 264 nm and 244 nm. At 264 nm 
both drugs showed maximum absorbance in accordance with previous 
literature (Moffat et al 2004). At 244 nm the drugs absorbed light 
sufficiently to be able to define a clear relationship between concentration 
and absorbance also. At both wavelengths Xanthan Gum showed 
significant light absorption as a function of concentration of the polymer in 
the solution. The absorbance values for all entities at the wavelength of 
244 nm were clearly different from those measured at the wavelength of 
264 nm. 
 
Calibration curves were constructed for both drugs and for Xanthan Gum 
in distilled deaerated water at both wavelengths, covering the complete 
concentration ranges expected during the tablet dissolution investigations 
conducted in this study. The drug Orphenadrine is reported to exhibit no 
alkaline shift in its UV absorbance (Moffat et al 2004), and this was also 
apparent from the high linearity of the calibration curves of both drugs at 
both wavelengths of 264 nm and 244 nm. The linear regression equations 
obtained for the two drugs and polymer are reported in Table 7.1., and 
the graphical representations of the calibration curves are reported in the 
appendix. 
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As a consequence of the presence of two absorbing entities within the 
dissolution medium, the total recorded absorbance at each of the two 
wavelengths is composed of two parts associated with the contributions 
of the dissolved fraction of the drug that is incorporated into the tablet and 
with the dissolved Xanthan Gum which is in a colloidal system in the 
dissolution medium (Equations 7.1. and 7.2.) 
 
Material Wavelength (nm) Calibration equation R2 
Orphenadrine Citrate 264 y = 0.0013x + 0.0039  0.9999 
 244 y = 0.0006x + 0.0040  0.9996 
Orphenadrine HCl 264 y = 0.0020x + 0.0051 0.9999 
 244 y = 0.0009x + 0.0017 0.9999 
Xanthan Gum 264 y = 0.0007x + 0.0074 0.9995 
 244 y = 0.0009x + 0.0097 0.9992 
 
Table 7.1. Calibration equations for drugs and polymer, where y is the 
absorbance of the material at the specified wavelength, and x is the 
concentration of the material. 
 
 
Abs-total-264nm = Abs-drug-264nm + Abs-polymer-264nm                           Equation 7.1. 
 
where Abs-total-264nm is the total measured absorbance at λ = 264 nm, Abs-
drug-264nm is the absorbance attributed to either of the two drugs at λ = 264 
nm, and Abs-polymer-264nm is the absorbance attributed to Xanthan Gum at λ 
= 264 nm. 
 
                                                                                                     Chapter 7 
 294
Abs-total-244nm = Abs-drug-244nm + Abs-polymer-244nm                           Equation 7.2. 
 
where Abs-total-244nm is the total measured absorbance at λ = 244 nm, Abs-
drug-244nm is the absorbance attributed to either of the two drugs at λ = 244 
nm, and Abs-polymer-244nm is the absorbance attributed to Xanthan Gum at λ 
= 244 nm. 
 
The above equations consist of a total of four different unknown values. 
The first two are the absorbance contributions of either of the two drugs 
at 264 nm and at 244 nm. The other two are the absorbance contributions 
of Xanthan Gum at 264 nm and at 244 nm.  
 
The absorbance as a function of concentration was determined for each 
drug and Xanthan Gum individually at both wavelengths. Linear 
regression equations were obtained from each set of absorbance data 
representing the relationship between the absorbance of every absorbing 
entity at the two wavelengths of 264 nm and 244 nm (Equations 7.3. to 
7.5.). 
 
Abs-Xanthan-244nm = 1.1822*Abs-Xanthan-264nm + 0.0009                   Equation 7.3. 
(R2 = 0.9996) 
 
 
Abs-Citrate-244nm = 0.4679*Abs-Citrate-264nm + 0.0023                       Equation 7.4. 
(R2 = 0.9996) 
 
Abs-HCl-244nm = 0.4672*Abs-HCl-264nm - 0.0007                              Equation 7.5. 
(R2 = 0.9998) 
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The determination of the previously mentioned four unknown absorbance 
values was possible using four of the developed linear equations, namely 
equations 7.1., 7.2., 7.3., and either of the two equations 7.4., and 7.5. 
depending on the type of drug incorporated into the studied tablets.  
 
The solution of the required equations to derive the values for the 
absorbance were obtained using the solver “add-in” of the software 
Microsoft Excel® . This programme was used to solve the four linear 
equations simultaneously to obtain the absorbance values associated 
with either of the two drugs and Xanthan Gum at the two wavelengths. As 
mentioned in Chapter 2, each sample was measured for absorbance at 
both wavelengths. Thus, each pair of absorbance readings were 
analysed together for their drug and polymer components. 
 
 
7.2.2. Dissolution studies for round tablets: 
The drug and polymer dissolution profiles for round Xanthan Gum tablets 
containing either Orphenadrine Citrate or Orphenadrine HCl with an 
overall porosity of 12.5% are presented in Figures 7.1. to 7.4. The 
dissolution profiles of tablets produced at the three different degrees of 
tablet overall porosity were rather super-imposable. Thus, the dissolution 
profiles of tablets with the two other degrees of tablet overall porosity are 
presented in the appendix to ensure clarity.  
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In terms of drug dissolution, it is clear that the process of drug release 
from tablets containing the drug Orphenadrine Citrate (Figure 7.1.) 
follows a rather steady rate throughout the dissolution process after an 
initial fast release pattern “burst” within the first 60 minutes. Such pattern 
is more evident in flat tablets and tablets with the lower degree of face 
curvature ratio (R/D) of 0.5. Tablets with the two higher degrees of face 
curvature ratio of 1 and 1.43 exhibited steady drug release behaviour 
throughout the dissolution process without initial burst. A clear reduction 
in the percentage of drug released could be observed with the increase in 
tablet face curvature ratio (R/D). This could be attributed mainly to the 
increase in tablet volume with the increase in tablet face curvature.  
 
Tablets containing the drug Orphenadrine HCl (Figure 7.3.) exhibited a 
rather different dissolution behaviour in terms of drug release. A more 
rapid release of the drug was evident in the initial stages of drug release 
as compared to tablets containing the drug Orphenadrine Citreate. Such 
enhanced drug release was more noticeable in flat tablets, and 
decreased with the increase in tablet face curvature ratio. With 
progressive hydration and thus dissolution, the process of drug release 
seemed to slow down significantly, as noted by the clear flattening of the 
drug release profiles. This behaviour could be attributed to multiple 
reasons. Initially the release of the free dissolved drug from within the 
tablet reduces the osmotic pressure which could be considered as the 
main driving force in the release of the free soluble cationic drug 
Orphenadrine HCl when it is liberated from any ionic interaction with the 
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anionic Xanthan Gum. Another important feature associated with such 
tablets is their hydration and swelling patterns. With progressive 
hydration, a uniform gel layer formed on the surface of the tablets in place 
of the highly irregular gel layer noted within the initial hydration phase. 
This was identified by the enhanced swelling ability of such tablets during 
the later stages of hydration (Chapter 5). This process in turn increased 
the thickness of the gel layer and thus reduced the rate of further 
hydration and any subsequent release of dissolved free drug molecules.  
 
One feature associated with the patterns of drug release from round 
tablets containing the drug Orphenadrine HCl could be noted from the 
drug release profiles associated with tablets with face curvature degrees 
of 0.5 and 1. It can be seen from Figure 7.3., both release profiles are 
rather super-imposable. This finding could be attributed to the process of 
crack formation within such tablets during the initial phases of hydration 
(Chapter 5). This behaviour was more noticeable within tablets with the 
two higher degrees of face curvature ratio of 1 and 1.43. Such crack 
formation could enhance the process of water penetration into the dosage 
form and the subsequent tablet hydration and drug release by increasing 
the surface area in contact with the surrounding hydration medium. This 
pattern is clearly obvious in the enhanced drug release process from 
tablets with a face curvature ratio of 1. Tablets with a face curvature ratio 
of 1.43 exhibited clear crack formation. However, the large volume of 
such tablets and the subsequent need for longer time for thorough tablet 
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hydration may have reduced the effect that such pattern of crack 
formation has on drug dissolution. 
 
More insight into the dissolution behaviour of the different round tablets 
could be noted from the polymer dissolution profiles associated with them 
(Figures 7.2. and 7.4.). Polymer dissolution from tablets containing the 
drug Orphenadrine Citrate (Figure 7.2.) was slow within the initial 
dissolution phase. With progressive hydration an enhancement of 
polymer dissolution could be noted from all Orphenadrine Citrate 
containing tablets, the percentage of which decreased with the increase 
in tablet face curvature ratio (R/D), in a manner similar to that noted with 
drug release. Such enhancement of polymer dissolution could be 
attributed to the polymer erosion process, in which polymer chains 
located on the surface of the gel layer are continuously hydrated and 
diluted until they detach from the surface and dissolve within the 
surrounding dissolution medium.  
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Figure 7.1. Percentage drug released from round Xanthan Gum tablets 
with Orphenadrine Citrate, porosity 12.5%. -♦-(R/D= 0), -■-(R/D=0.5), -
▲-(R/D=1), -●-(R/D=1.43), (n=6). 
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Figure 7.2. Percentage polymer dissolved from round Xanthan Gum 
tablets with Orphenadrine Citrate, porosity 12.5%. -♦-(R/D= 0), -■-
(R/D=0.5), -▲-(R/D=1), -●-(R/D=1.43), (n=6). 
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Figure 7.3. Percentage drug release from round Xanthan Gum tablets 
with Orphenadrine HCl, porosity 12.5%. -♦-(R/D= 0), -■-(R/D=0.5), -▲-
(R/D=1), -●-(R/D=1.43), (n=6). 
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Figure 7.4. Percentage polymer dissolved from round Xanthan Gum 
tablets with Orphenadrine HCl, porosity 12.5%. -♦-(R/D= 0), -■-
(R/D=0.5), -▲-(R/D=1), -●-(R/D=1.43), (n=6).  
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The pattern of polymer dissolution from Orphenadrine Citrate containing 
tablets could give more insight into the drug release patterns exhibited 
with such tablets. The process of polymer erosion and subsequent 
dissolution counteracts the retarding effect on drug release exhibited by 
the progressive formation of the gel layer on the surface of the tablet. 
Polymer erosion leads to the reduction in the thickness of the gel layer 
and thus reduces the pathway needed for water ingress and drug 
release. Moreover, polymer erosion could lead to the release of drug 
molecules together with the eroding polymer chains. Thus, for tablets 
used in this study, the enhanced polymer erosion and subsequent 
dissolution during the latter phases of tablet dissolution would have 
compensated for any reduction in drug release rate due to the thickening 
of the gel layer, giving rise to a steady rate or a zero order drug release 
process. 
 
As for tablets containing the drug Orphenadrine HCl (Figure 7.4.), a 
slower process of polymer dissolution could be noted with such tablets. 
Apart from flat tablets, which exhibited some degree of enhanced polymer 
dissolution with progressive tablet dissolution, minimal increase in the 
percentage of polymer dissolved was noted with the other tablets. This 
behaviour further confirms the reduction of drug release from such tablet 
with progressive tablet dissolution. 
 
During the latter stages of tablet dissolution, some of the flat tablet 
batches with lower weights floated within the dissolution vessels and 
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started hitting the paddle. Thus the samples withdrawn from such vessels 
were not used in further analysis, as indicated by their shorter dissolution 
profiles.  
 
 
7.2.3. Statistical comparison of the dissolution parameters of round 
tablets: 
A combined statistical approach was used for the comparison of the 
dissolution profiles of round tablets. In a manner similar to that employed 
in the comparison of the various swelling profiles of the tablets (Chapter 
5), a combination of analysis of variance (ANOVA) and multivariate 
analysis of variance (MANOVA) was used to make a thorough 
comparison between the  various dissolution profiles. A comprehensive 
statistical comparison was conducted on the dissolution profiles, without 
the previously mentioned segments during which some of the tablets 
were hitting the paddles. Initially, MANOVA was employed to compare 
the complete dissolution patterns under investigation. Then, multiple 
ANOVA investigations were conducted at 60, 180 and 360 minutes. This 
was done to give more insight into the differences between the 
dissolution profiles of the various tablets, and compare any possible 
variations in such differences during the progressive phases of tablet 
dissolution. 
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7.2.3.1. Round Xanthan Gum tablets with Orphenadrine Citrate: 
The results of the MANOVA investigation of drug and polymer dissolution 
profiles from round Xanthan Gum tablets with Orphenadrine Citrate are 
presented in Table 7.2. In terms of drug release it could be noted that 
both variables associated with the dosage form, i.e. tablet face curvature 
ratio and tablet overall porosity have a significant influence on the 
process of drug release from such tablets, and this is indicated by the 
significance p-values associated with these variables which are less than 
0.001, i.e. lower that the significance threshold of 0.05. More importantly, 
it could be noted that the interaction between the two investigated factors 
is significant indicating a high dependence of the influence of either 
variable on the change in the value of the other. 
 
A similar pattern could be noted for the process of polymer dissolution 
where both tablet face curvature ratio and tablet overall porosity seem to 
have a significant influence on polymer dissolution with significance p-
values of less than 0.001 and 0.011, respectively. However, no significant 
interaction could be noted between the two variables, as the interaction 
product has a p-value of 0.128 which is considerably higher than the 
threshold of 0.05. Thus, there is clear indication that the influence on 
either of the two variables on polymer dissolution is completely 
independent from the other. 
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Dissolving 
entity 
Variable 
Hotelling’s 
Trace 
value 
 
F 
 
 
Hypothesis 
df 
Error 
df 
p 
 
 Porosity 1.185 2.963 20.000 100.000 < 0.001 
Drug Curvature 18.553 30.716 30.000 149.000 < 0.001 
 Porosity*Curvature 2.980 2.450 60.000 296.000 < 0.001 
 Porosity 0.820 2.050 20.000 100.000 0.011 
Polymer Curvature 4.771 7.899 30.000 149.000 < 0.001 
 Porosity*Curvature 1.506 1.239 60.000 296.000 0.128 
 
Table 7.2. MANOVA results for the dissolution profiles of round Xanthan 
Gum tablets with Orphenadrine Citrate. 
 
More insight into the differences between the multiple drug and polymer 
dissolution profiles associated with the different Orphenadrine Citrate 
containing tablets could be noted from the results of the two-way ANOVA 
investigations conducted on them.  In terms of drug release (Table 7.3.), 
certain trends can be noted. The influence of tablet face curvature on the 
process of drug release seems to be significant throughout the dissolution 
process, and this can be noted by the p-values associated with this 
variable which are consistently less than 0.001 at the three time points 
investigated. Tablet overall porosity seems to have a significant influence 
on drug release only at the initial time point of 60 minutes, indicated by 
with a p-value of less than 0.001. A significant interaction between the 
two variables can be noted at the first two time points of 60 and 180 
minutes.  
 
A consistently significant influence on polymer dissolution from these 
tablets was associated with the degree of tablet face curvature (Table 
7.4.), and this is mirrored by the p-values associated with this variable 
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which are consistently less than 0.001 at all three time points. The 
influence associated with tablet overall porosity seems to be significant at 
the initial time points only with a p-value of 0.009 and 0.025 at 60 and 180 
minutes, respectively. However, no significance is noted with this variable 
at the later time point of 360 minutes (p = 0.709). The interaction between 
the two variables also seems to be of significance during the initial 
dissolution phase with a p value of 0.039 at 60 minutes. No significance is 
associated with such interaction at the two later time points. 
 
The two-way ANOVA investigations were followed by post hoc analysis 
using the Sheffé test to identify the differences between the various 
degrees of each of the two studied variables. When a significant 
interaction was noted between the two variable, different one-way 
ANOVA investigations were carried out at each of the three levels of 
tablet overall porosity of 12.5%, 15%, and 17.5%, followed by post hoc 
analysis using the Sheffé test to investigate the nature and extent of any 
difference between different degrees of tablet face curvature at every 
porosity value. The results of the Sheffé analysis (reported in the 
appendix) revealed some trends in the effects associated with the two 
variables; a progressive decrease in drug and polymer dissolution was 
noted with the increase in tablet face curvature, and the dissolution ability 
of flat tablets was considerably higher than that of the other tablets. 
Furthermore, small and inconsistent differences were noted between 
tablets produced at the three different values of overall porosity. 
Moreover, tablet overall porosity had a certain degree of influence on the 
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differences between the drug release profiles of Orphenadrine Citrate 
containing tablets with the four different degrees of face curvature. 
However, such differences, although significant in certain cases, were of 
small magnitude and this has to be taken into account during the 
interpretation of the results. 
 
Dissolution 
time (min) 
Variable df F p 
 Porosity 2 16.902 < 0.001 
60 Curvature 3 131.841 < 0.001 
 Porosity*Curvature 6 7.502 < 0.001 
 Porosity 2 1.315 0.276 
180 Curvature 3 180.692 < 0.001 
 Porosity*Curvature 6 4.525 0.001 
 Porosity 2 2.862 0.065 
360 Curvature 3 180.804 < 0.001 
 Porosity*Curvature 6 0.716 0.638 
 
Table 7.3. Two -way ANOVA results for the drug dissolution profiles of 
round Xanthan Gum tablets with Orphenadrine Citrate. 
 
 
Dissolution 
time (min) 
Variable df F p 
 Porosity 2 5.152 0.009 
60 Curvature 3 12.225 < 0.001 
 Porosity*Curvature 6 2.395 0.039 
 Porosity 2 3.935 0.025 
180 Curvature 3 36.762 < 0.001 
 Porosity*Curvature 6 1.766 0.122 
 Porosity 2 0.346 0.709 
360 Curvature 3 71.256 < 0.001 
 Porosity*Curvature 6 1.392 0.233 
 
Table 7.4. Two -way ANOVA results for the polymer dissolution profiles 
of round Xanthan Gum tablets with Orphenadrine Citrate. 
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7.2.3.2. Round Xanthan Gum tablets with Orphenadrine HCl: 
The results of the MANOVA investigation of the dissolution profiles of 
round Xanthan Gum tablets with Orphenadrine HCl are listed in Table 
7.5. A similar pattern could be noted with both drug and polymer 
dissolution, as both studied variables of tablet face curvature and tablet 
overall porosity seem to have a significant influence on the process of 
tablet dissolution as noted by the p values associated with them. Also, a 
significant interaction can be noted between the influence of both 
variables on the process of drug and polymer dissolution. 
 
Dissolving 
entity 
Variable 
Hotelling’s 
Trace 
value 
 
F 
 
 
Hypothesis 
df 
Error 
df 
p 
 
 Porosity 2.082 5.204 20.000 100.000 < 0.001 
Drug Curvature 42.045 69.608 30.000 149.000 < 0.001 
 Porosity*Curvature 1.924 1.582 60.000 296.000 0.007 
 Porosity 7.134 17.836 20.000 100.000 < 0.001 
Polymer Curvature 18.164 30.072 30.000 149.000 < 0.001 
 Porosity*Curvature 2.070 1.702 60.000 296.000 0.002 
 
Table 7.5. MANOVA results for the dissolution profiles of round Xanthan 
Gum tablets with Orphenadrine HCl. 
 
 
Investigating the progressive tablet dissolution stages using two-way 
ANOVA (Tables 7.6. and 7.7.) revealed that for both drug and polymer 
dissolution, the degree of tablet face curvature plays a significant role 
throughout the dissolution process. A rather similar influence could be 
noted associated with tablet porosity with one exception being the lack of 
significance associated with this factor on drug dissolution at 360 
minutes. As for the interaction between the influences of tablet face 
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curvature and tablet overall porosity, an opposing picture could be seen 
with drug and polymer dissolution, where a significant interaction was 
apparent at the two initial time points of 60 and 180 minutes in the case of 
drug dissolution, on the other hand a significant interaction was only 
noted at the latter time point of 360 minutes in the case of polymer 
dissolution. 
 
Multiple one-way ANOVA in the presence of significant interaction 
between the two main variables, and Post hoc analysis using the Sheffé 
test were conducted to allocate the differences between the different 
tablets. The results of such analysis (reported in the appendix) show a 
pattern where tablet dissolution decreases with the increase in tablet face 
curvature, and a smaller influence associated with tablet overall porosity. 
 
It can be noted from the multiple statistical comparisons conducted on the 
different tablets that the magnitude of the F values associated with the 
studied variables in tablets containing the drug Orphenadrine HCl are 
consistently higher than those associated with the same variables in 
tablets containing the drug Orphenadrine Citrate. Such a finding could 
indicate that the magnitude or clarity of the differences between the 
different degrees of the studied variables is higher in tablets containing 
the drug Orphenadrine HCl. This pattern could be related to the different 
hydration and subsequent dissolution patterns associated with the tablets 
produced using the two different drugs. 
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Dissolution 
time (min) 
Variable df F p 
 Porosity 2 28.974 < 0.001 
60 Curvature 3 524.550 < 0.001 
 Porosity*Curvature 6 7.816 < 0.001 
 Porosity 2 22.111 < 0.001 
180 Curvature 3 592.605 < 0.001 
 Porosity*Curvature 6 5.509 < 0.001 
 Porosity 2 2.518 0.089 
360 Curvature 3 319.149 < 0.001 
 Porosity*Curvature 6 1.395 0.232 
 
Table 7.6. Two -way ANOVA results for the drug dissolution profiles of 
round Xanthan Gum tablets with Orphenadrine HCl. 
 
 
Dissolution 
time (min) 
Variable df F p 
 Porosity 2 55.745 < 0.001 
60 Curvature 3 78.469 < 0.001 
 Porosity*Curvature 6 1.281 0.280 
 Porosity 2 70.502 < 0.001 
180 Curvature 3 121.067 < 0.001 
 Porosity*Curvature 6 1.829 0.109 
 Porosity 2 27.013 < 0.001 
360 Curvature 3 139.365 < 0.001 
 Porosity*Curvature 6 2.827 0.017 
 
Table 7.7. Two -way ANOVA results for the Polymer dissolution profiles 
of round Xanthan Gum tablets with Orphenadrine HCl. 
 
 
7.2.4. Dissolution studies of elongated tablets: 
Drug and polymer dissolution profiles for elongated Xanthan Gum tablets 
containing both Orphenadrine Citrate and Orphenadrine HCl are 
presented in Figures 7.5 to 7.8.  A drug-type dependent dissolution 
behaviour can bee seen in terms of drug release. Tablets containing the 
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drug Orphenadrine Citrate exhibit a steady drug release process (Figure 
7.5.), and this could be justified by the enhanced polymer dissolution 
during the later stages of the dissolution process (Figure 7.6) in a manner 
similar to that observed with round tablets. As for tablets containing the 
drug Orphenadrine HCl, a sharp reduction in drug release could be 
observed during the latter stages of tablet dissolution (Figure 7.7.). This 
was coupled with the clear visible formation of a gel layer and 
disappearance of cracks from within the tablet structure. A certain degree 
of polymer dissolution could be observed in these tablets especially flat 
ones (Figure 7.8.). 
 
One factor that may have an additional influence on the dissolution 
characteristics of round and elongated Xanthan Gum tablets containing 
the two different drugs, i.e. Orphenadrine Citrate and Orphenadrine HCl, 
is the potential process of ionic interaction between the polymer and the 
two drugs. The rate of ionic interaction and complex formation between 
the drug and polymer, and the subsequent dissolution of such complex 
leading to drug and polymer release from within the matrix system, can 
be highly influenced by the solubility and dissolution properties of the 
drug particles (Lapidus and Lordi 1968), and of the complex upon 
formation (Takka 2003). Thus, a complex process governs the structural 
and physico-chemical features of the hydrated tablet, leading to variations 
in the properties of the gel layer as noted previously in Chapters 5 and 6. 
This in turn would lead to variations in the diffusion and erosion patterns 
within the tablet. 
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Figure 7.5. Percentage drug released from elongated Xanthan Gum 
tablets with Orphenadrine Citrate, porosity 15.0%. -♦-(curvature height 0 
mm), -■-(curvature height 1mm), -▲-(curvature height 2 mm), (n=3). 
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Figure 7.6. Percentage polymer dissolved from elongated Xanthan Gum 
tablets with Orphenadrine Citrate, porosity 15.0%. -♦-(curvature height 0 
mm), -■-(curvature height 1mm), -▲-(curvature height 2 mm), (n=3). 
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Figure 7.7. Percentage drug released from elongated Xanthan Gum 
tablets with Orphenadrine HCl, porosity 15.0%. -♦-(curvature height 0 
mm), -■-(curvature height 1mm), -▲-(curvature height 2 mm), (n=3). 
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Figure 7.8. Percentage polymer dissolved from elongated Xanthan Gum 
tablets with Orphenadrine HCl, porosity 15.0%. -♦-(curvature height 0 
mm), -■-(curvature height 1mm), -▲-(curvature height 2 mm), (n=3). 
                                                                                                     Chapter 7 
 313
7.2.5. Statistical comparison of the dissolution profiles of elongated 
tablets: 
7.2.5.1. Elongated Xanthan Gum tablets with Orphenadrine Citrate: 
Statistical analysis was carried out to explore the influences of tablet 
variables in terms of face curvature and overall porosity on tablet 
dissolution characteristics. It can be seen from the results of the 
MANOVA investigations conducted on the drug and polymer dissolution 
profiles from elongated Xanthan Gum tablets containing the drug 
Orphenadrine Citrate (Table 7.8.) that the only factor to exert a significant 
influence on the overall drug and polymer dissolution process is the 
degree of tablet face curvature as indicated by the p values associated 
with this variable of less than 0.001 and 0.001 for drug and polymer 
dissolution, respectively. On the other hand, no significant influence can 
be noted due to the change in tablet overall porosity, as the p-values 
associated with this variable are higher than the threshold of 0.05. 
Moreover, no significant interaction can be noted between the two tablet 
variables. 
 
Dissolving 
entity 
Variable 
Hotelling’s 
Trace 
value 
 
F 
 
 
Hypothesis 
df 
Error 
df 
p 
 
 Porosity 4.567 1.827 20.000 16.000 0.113 
Drug Curvature 98.869 39.547 20.000 16.000 < 0.001 
 Porosity*Curvature 5.627 1.055 40.000 30.000 0.445 
 Porosity 4.915 1.966 20.000 16.000 0.087 
Polymer Curvature 11.753 4.701 20.000 16.000 0.001 
 Porosity*Curvature 6.966 1.306 40.000 30.000 0.225 
 
Table 7.8. MANOVA results for the dissolution profiles of elongated 
Xanthan Gum tablets with Orphenadrine Citrate. 
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Time dependent changes in the influences associated with both tablet 
variables were investigated using multiple two-way ANOVA. The results 
of these studies (Tables 7.9. and 7.10.) provide an image of a dissolution 
process in which tablet face curvature is the only variable significantly 
influencing the process of drug and polymer dissolution from within the 
tablet. This is indicated by the p values associated with this variable 
throughout the process of drug and polymer dissolution.  
 
On the other hand, no significance is associated with the change in tablet 
overall porosity, or with the interaction between the two tablet variables 
“face curvature” and “overall porosity”. One exception is the initial phase 
of drug release at 60 minutes where the p-values associated with tablet 
overall porosity and the interaction between the two tablet variables are 
0.001 and 0.013, respectively, and thus are lower than the threshold of 
0.05. This indicates that tablet overall porosity may affect the initial 
process of drug release, but with subsequent hydration its influence 
becomes negligible.  
 
The results of the Sheffé analysis conducted on these tablets (reported in 
the appendix) indicated that for drug release a consistent image was 
observed throughout the dissolution process in which a progressive 
decrease in drug dissolution was noted with the increase in tablet face 
curvature. The differences between tablets with the multiple degrees of 
face curvature in terms of polymer dissolution changed with the increase 
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in time. Small differences were observed between tablets with different 
overall porosities. 
 
Dissolution 
time (min) 
Variable df F p 
 Porosity 2 10.018 0.001 
60 Curvature 2 145.284 < 0.001 
 Porosity*Curvature 4 4.290 0.013 
 Porosity 2 1.352 0.284 
180 Curvature 2 106.956 < 0.001 
 Porosity*Curvature 4 0.763 0.563 
 Porosity 2 0.232 0.795 
360 Curvature 2 235.389 < 0.001 
 Porosity*Curvature 4 0.489 0.744 
 
Table 7.9. Two -way ANOVA results for the drug dissolution profiles of 
elongated Xanthan Gum tablets with Orphenadrine Citrate. 
 
 
 
Dissolution 
time (min) 
Variable df F p 
 Porosity 2 0.544 0.590 
60 Curvature 2 6.041 0.010 
 Porosity*Curvature 4 2.052 0.130 
 Porosity 2 2.038 0.159 
180 Curvature 2 17.273 < 0.001 
 Porosity*Curvature 4 1.542 0.233 
 Porosity 2 2.241 0.135 
360 Curvature 2 33.048 < 0.001 
 Porosity*Curvature 4 1.868 0.160 
 
Table 7.10. Two -way ANOVA results for the polymer dissolution profiles 
of elongated Xanthan Gum tablets with Orphenadrine Citrate. 
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7.2.5.2. Elongated Xanthan Gum tablets with Orphenadrine HCl: 
A rather different behaviour could be seen with elongated Xanthan Gum 
tablets containing the drug Orphenadrine HCl. The MANOVA 
investigation of the dissolution process associated with such tablets 
(Table 7.11.) indicated that the face curvature of the tablets significantly 
influences both drug and polymer dissolution, whereas, tablet overall 
porosity had a significant influence on polymer dissolution only. As for the 
interaction between the two variables, the results of the MANOVA 
investigation indicated that it is of significance for both drug and polymer 
dissolution processes. 
 
Dissolving 
entity 
Variable 
Hotelling’s 
Trace 
value 
 
F 
 
 
Hypothesis 
df 
Error 
df 
p 
 
 Porosity 4.665 1.866 20.000 16.000 0.105 
Drug Curvature 295.467 118.187 20.000 16.000 < 0.001 
 Porosity*Curvature 11.473 2.151 40.000 30.000 0.016 
 Porosity 60.461 24.185 20.000 16.000 < 0.001 
Polymer Curvature 239.221 95.688 20.000 16.000 < 0.001 
 Porosity*Curvature 11.793 2.211 40.000 30.000 0.013 
 
Table 7.11. MANOVA results for the dissolution profiles of elongated 
Xanthan Gum tablets with Orphenadrine HCl. 
 
 
Time dependent changes in the significance characteristics of the 
influences associated with both “face curvature” and “overall porosity” are 
reported in the results of the two-way ANOVA investigations conducted 
for both drug and polymer dissolution (Table 7.12 and 7.13.). The results 
indicate that both variables have a significant influence on the process of 
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drug and polymer dissolution at the multiple time points, as indicated by 
the p-values associated with them. A time dependent significance was 
associated with the interaction between the two variables (see Table 
7.13.). However, it could also be seen that the p-values associated with 
tablet face curvature are considerably lower than those associated with 
tablet overall porosity in the case of drug dissolution. It could thus be 
concluded that tablet face curvature is the main factor governing drug 
release.  
 
The results of the post hoc Sheffé tests conducted on the dissolution 
profiles of these tablets (reported in the appendix), indicated a pattern in 
which drug dissolution progressively decreased with the increase in tablet 
face curvature, with rather minor influence associated with tablet overall 
porosity. In terms of polymer dissolution, increasing the degree of tablet 
face curvature led to a small decrease in the percentage of polymer 
dissolved with small variations between tablets with different overall 
porosity values. 
 
An observation, similar to that noted with round tablets, could be made 
from the statistical comparison of elongated tablets, where the F-values 
associated with tablet variables in tablets containing the drug 
Orphenadrine HCl are consistently higher than those associated with the 
same variables in tablets containing the drug Orphenadrine Citrate. 
 
 
 
                                                                                                     Chapter 7 
 318
Dissolution 
time (min) 
Variable df F p 
 Porosity 2 3.682 0.046 
60 Curvature 2 601.329 < 0.001 
 Porosity*Curvature 4 0.886 0.492 
 Porosity 2 7.711 0.004 
180 Curvature 2 819.130 < 0.001 
 Porosity*Curvature 4 3.938 0.018 
 Porosity 2 3.595 0.049 
360 Curvature 2 293.995 < 0.001 
 Porosity*Curvature 4 2.219 0.108 
 
Table 7.12. Two -way ANOVA results for the drug dissolution profiles of 
elongated Xanthan Gum tablets with Orphenadrine HCl. 
 
 
Dissolution 
time (min) 
Variable df F p 
 Porosity 2 22.390 < 0.001 
60 Curvature 2 43.217 < 0.001 
 Porosity*Curvature 4 3.202 0.038 
 Porosity 2 35.371 < 0.001 
180 Curvature 2 101.919 < 0.001 
 Porosity*Curvature 4 10.779 < 0.001 
 Porosity 2 29.471 < 0.001 
360 Curvature 2 128.238 < 0.001 
 Porosity*Curvature 4 2.101 0.123 
 
Table 7.13. Two -way ANOVA results for the polymer dissolution profiles 
of elongated Xanthan Gum tablets with Orphenadrine HCl. 
 
 
7.3. General discussion and conclusions: 
The results of this chapter clearly indicate the influence of tablet face 
curvature on the dissolution charactersictics of round and elongated 
hydrophilic matrix tablets based on Xanthan Gum. Both drug and polymer 
dissolution patterns were significantly infuenced by the change in tablet 
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face curvature.  Moreover, the increase in tablet face curvature in tablets 
formulated using the drug Orphenadrine HCl, led to increase in the extent 
of crack formation within the tablets during their initial dissolution phases. 
This comes in accordance with similar results obtained from the swelling 
studies conducted on such tablets (Chapter 5). The influence of such 
behaviour on tablet dissolution characteristics was most evident in round 
tablets with a face curvature ratio (R/D) of 1, in which crack formation led 
to an enhanced drug release from the tablets.  
 
In terms of Tablet overall porosity, a less evident influence was noted for 
this variable on tablet dissolution properties. This comes in accordance 
with similar results obtained with tablet swelling studies (Chapter 5).  
 
Tablets formulated using the two different drugs, i.e. Orphenadrine Citrate 
and Orphenadrine HCl, exhibited different dissolution characteristics. 
Drug dissolution from tablets formulated using Orphenadrine Citrate 
followed a steady process. On the other hand, tablets containing the drug 
Orphenadrine HCl exhibited rapid drug release initially followed by a 
progressive decrease in the drug release process. Such difference could 
arise from the different physico-chemical natures of the drugs, in terms of 
their different solubility and their potential interaction with Xanthan Gum. 
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CHAPTER EIGHT 
 
8. General conclusions and future work: 
8.1. General conclusions: 
Hydrophilic matrix tablets provide a therapeutically and economically 
convenient means for oral modified drug delivery. However, the 
mechanism of action of such dosage forms is comprised of a complex 
mixture of water penetration, tablet expansion and swelling leading to the 
formation of a gel layer that acts as the main regulator of further tablet 
hydration and dissolution. Furthermore, a review of the available 
literature, which was reported in Chapter 1, indicated that numerous 
factors could influence the action of such dosage forms. Moreover, 
significant interactions could exist between the influences associated with 
the different factors resulting in a complex process affecting the 
behaviour of such dosage forms. The shape (Ford et al 1987, Reynolds 
et al 2002) and formulation (Lapidus and Lordi 1968, Colombo et al 1995) 
properties of hydrophilic matrix tablets could have a significant influence 
on the in-vitro behaviour of such tablets. It is thus important to have a 
thorough knowledge of the influence of such factors or variables in order 
to facilitate the design and formulation of hydrophilic matrix tablets. 
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However, limited information is available about the influence of changing 
the degree of tablet face curvature on the behaviour of hydrophilic matrix 
tablets.  It was thus the general aim of this research to investigate the 
influence of this factor and the concomitant change in tablet overall 
porosity and formulation nature on the properties and behaviour of 
hydrophilic matrix tablets.  
 
Changing the parameters associated with the shape and structure of 
pharmaceutical tablets, in particular the face curvature of the tablets have 
a profound influence on the physical and structural properties of the 
tablets (Newton et al 2000a, Newton et al 2000b, Eiliazadeh et al 2003). 
The investigation of physical properties of the tablets used in this study 
(Chapter 4) indicated that changing the degree of face curvature of round 
and elongated hydrophilic matrix tablets based on Xanthan Gum had a 
significant effect on the tensile strength of such tablets. Changes in the 
internal structural properties of both round and elongated tablets in terms 
of overall tablet porosity also had a profound influence on the tensile 
strength of tablets. Moreover, it was apparent that the influences 
associated with both of the previously mentioned factors were 
significantly interacting in both round and elongated tablets, indicating 
that both factors have to be considered concurrently during the design of 
hydrophilic matrix tablets.  
 
A clear change in the tensile strength values associated with round and 
elongated tablets, with the different face curvature and overall porosity 
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values, was noted upon changing the nature of the formulation used in 
tablet production. This was justified by the possible difference in the 
compaction properties of the different formulations as a result of the 
differences in the physico-chemical characteristics of the powders 
incorporated into them. These differences in powder properties were 
observed and reported in Chapter 3.  
 
One of the main objectives of this work was to perform a comprehensive 
study of the hydration characteristics associated with round and 
elongated hydrophilic matrix tablets, and to investigate the influence of 
tablet face curvature, tablet overall porosity and formulation nature on the 
hydration and dimensional expansion of the tablets. The results of this 
investigation (Chapter 5) indicated that tablet face curvature acts as a 
significant factor on the dimensional swelling and expansion of round and 
elongated hydrophilic matrix tablets in the various tablet dimensions, 
where a decrease in tablet swelling ability was generally noted with the 
increase in tablet face curvature. This could be attributed to the change in 
the shape and volume of the tablets upon changing the degree of face 
curvature. This change, in addition to the resulting change in the internal 
structural nature of the tablets, would influence the nature and extent of 
tablet hydration and dimensional expansion. 
 
A rather minor influence associated with tablet overall porosity on tablet 
swelling was noted. It could thus be concluded that although tablet overall 
porosity exerts a profound influence on the structural and physical 
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properties of tablets in their dry state, this variable exerts a much smaller 
influence on the hydration behaviour of the tablets.  
 
One of the aims of this study was to investigate the influence of 
formulation nature on the behaviour of hydrophilic matrix tablets, more 
precisely, the influence of changing the solubility of the drug incorporated 
into the formulation. A particular case of hydrophilic matrix tablets was 
investigated in this study, in which there was a potential for an ionic 
interaction between the ionic and oppositely charged polymer and drug. 
This phenomenon could be regarded as a possible means to enhance the 
retardation of drug release from the matrix system.  In this study the ionic 
entities with potential ionic interactions were the anionic Xanthan Gum 
and the two cationic drugs Orphenadrine Citrate and Orphenadrine HCl 
which differed in their solubility; the latter being more soluble. The results 
of the swelling studies (Chapter 5) indicated that incorporating either of 
the two drugs into Xanthan Gum tablets resulted in a significant decrease 
in the swelling ability of the tablets. Moreover, the effect seen upon 
incorporating Orphenadrine HCl was more profound than that of 
incorporating Orphenadrine Citrate.  
 
The previously mentioned influence of drug incorporation on the swelling 
ability of round and elongated Xanthan Gum tablets was further clarified 
by the use of rheological and thermal studies (Chapter 6). The results of 
the thermal studies indicated that both cationic drugs seem to undergo a 
process of interaction with the anionic Xanthan Gum. This was evident 
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from the thermal behaviour of the drug-polymer dried gel samples. The 
melting peaks associated with both drugs, which were present in the 
thermograms of the drug-polymer physical mixtures, were not visible in 
the thermograms of the drug-polymer dried gel samples. This behaviour 
could be explained by the loss of drug crystallinity due to its interaction 
with the polymer. Moreover, such behaviour can be associated with the 
hindered swelling ability of Xanthan Gum tablets upon incorporation of 
either of the two drugs. This is due to the inability of Xanthan Gum to 
hydrate fully because of its interaction with the drugs.  
 
However, the nature and properties of the gel layers formed on the 
surface of Xanthan Gum tablets containing the two drugs were 
significantly different. This was noticeable from the difference in the 
rheological behaviour of the Xanthan Gum gel systems containing the two 
drugs. Moreover, this difference in drug influence was also clear in the 
scanning electron microscopy images of the gel layers formed on the 
different tablets (Section 5.3.3.). Such variation in the drug influence was 
attributed to the different solubility of the two drugs with Orphenadrine 
HCl being more soluble. Moreover, the stronger acidic hydrochloride 
moiety in Orphenadrine HCl when compared to the citrate moiety in 
Orphenadrine Citrate could have played an additional role in hindering 
the hydration of Xanthan Gum. This was indicated by the increased 
inhibitory influence of Orphenadrine HCl on Xanthan Gum rheological 
properties with increased gel concentration.   
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The results of the qualitative investigations of Xanthan Gum gels 
(Chapter 6) clarified some of the characteristics associated with the 
hydration patterns of round and elongated Xanthan Gum tablets (Chapter 
5). The occurrence and later disappearance of cracks within the structure 
of the tablets during the hydration process was only noted in tablets 
containing the drug Orphenadrine HCl. This pattern was clearly mirrored 
in the rheological properties of the gels containing such drug. Moreover, 
the magnitude of crack formation was more profound in tablets with 
higher degrees of face curvature. This indicated a correlation between the 
influence of tablet and formulation variables on the hydration behaviour of 
this type of hydrophilic matrix tablets. It could thus be concluded that drug 
solubility and salt form become of special importance during the design of 
hydrophilic matrix tablets with potentially interacting polymer and drug. 
Moreover, the choice of the degree of tablet face curvature should be 
given special attention as tablets with deeper curvatures could undergo 
undesirable behavioural patterns and loss of structural integrity. 
 
The results of tablet dissolution studies (Chapter 7) indicated a trend 
consistent with the hydration behaviour of the tablets where the degree of 
tablet face curvature was the main significant factor influencing the 
dissolution characteristics of both drugs and polymer. The effect of tablet 
overall porosity on tablet dissolution characteristics was less evident. 
Thus the degree of tablet face curvature could be considered the main 
dosage form related driving force for tablet dissolution. 
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As a general conclusion, it could be stated that the degree of tablet face 
curvature, the overall porosity of the tablet, and the nature of the 
formulation used in tablet production including the solubility of the used 
drug, are all important and correlated factors that should be taken into 
account during the design and formulation of pharmaceutical tablets 
based on the hydrophilic matrix technology. The influence of these factors 
on tablet properties varies in magnitude. However, they all have a 
potential to influence the formulation, manufacturing, handling and 
subsequently behaviour of hydrophilic matrix tablets.  
 
A further outcome of this study is the understanding of the strengths and 
limitations of statistical analysis techniques in the investigation, 
comparison, and presentation of the in-vitro behavioural characteristics 
associated with hydrophilic matrix tablets. The use of analysis of variance 
(ANOVA) provided a comprehensive method for the investigation of the 
tensile strength values associated with round and elongated hydrophilic 
matrix tablets with the added ability to identify cases of significant 
differences between the tensile strength values of the different tablets.  
 
In terms of tablet swelling and dissolution profiles, the use of ANOVA 
provided an intensive technique of investigating the different stages of 
tablet hydration. The use of multivariate analysis of variance (MANOVA) 
presented a desirable method for investigating the entire tablet swelling 
and dissolution process, providing the ability to compare the overall 
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swelling and dissolution processes associated with tablets of different 
face curvatures and porosities.   
 
It could thus be concluded that the use of statistical analysis techniques 
provided a convenient and informative method in the investigation of the 
in-vitro behaviour of hydrophilic matrix tablets.  
 
 
8.2. Future work:  
One possible option for future work could be the investigation of the 
influence of varying the nature of the formulations used in tablet 
production, mainly the size parameters of the formulation ingredients. 
Changing the particle size of either the polymer or drug, or both of them, 
could have a significant influence on the compaction properties of the 
powder mixtures and thus lead to variations in the internal structural 
properties of the produced tablets, and thus their physical and hydration 
properties. Moreover, the dissolution and hydration properties of the drug 
and polymer would be significantly influenced by the change in their 
particle size. This becomes particularly important with formulations similar 
to the ones used in this study, in which there is a potential for an ionic 
interaction between the two entities.  
 
Another possibility for further investigation is associated with the 
properties of the gel layers produced by such formulations upon 
hydration. The in vitro behaviour of flat and curved-face hydrophilic matrix 
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tablets formulated using other ionic polymers, excipients, and drugs with 
different physico-chemical properties could be undertaken, by exploring 
the relationships between the rheological properties of the gel layers 
formed on the surface of such tablets and the in vitro behaviour of the 
tablets, for example, swelling and dissolution.   
 
In terms of variables associated with the nature of the dosage form, one 
potential future aim could be to investigate the influence of any 
concurrent change in tablet size and degree of tablet face curvature, i.e. 
to investigate the degrees of tablet face curvature used in this study in 
tablets with different height and diameter values. This would give further 
insight into the influence of tablet face curvature on the characteristics of 
tablets with different overall sizes, as the overall size of the tablets could 
have a clear influence on their structural and hydration patterns.  
 
All the hydrophilic matrix tablets investigated in this study were produced 
by the process of direct compression of the different powder mixtures. 
This method is widely used in tablet production. However, other 
techniques have also been employed in the production of hydrophilic 
matrix tablets to manipulate their physical and dissolution properties. 
Some of these methods include the production of layered tablets. Such 
tablets comprise of multiple layers which are formulated using different 
materials, and pressed together into one tablet to provide particular 
dissolution characteristics or pulsatile drug release (Conte et al 1993, Qiu 
et al 1998, Sungthongjeen et al 2004, Shajan and Poddar 2004). The 
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presence of multiple layers within the tablet may influence its structural 
properties. It is thus a potential future investigation to study the influence 
of tablet face curvature and formulation properties on the hydration and 
dissolution patterns of layered tablets.  
 
Another possibility for future work exists in exploring the nature and 
development of structural changes occurring within the hydrating tablets, 
using non-destructive methods. Such investigation would provide further 
understanding of the occurrence and propagation of cracks within tablets 
containing the drug Orphenadrine HCl. Furthermore, it would help in 
investigating the possible existence of such cracks in the other tablets. 
The investigative use of such techniques was initiated using ultrasound 
imaging. Preliminary ultrasound imaging studies were conducted on 
round convex tablets produced using the three different formulations, 
before and during tablet hydration. However, the specifications of the 
imaging system available did not facilitate the attainment of images with 
sufficient resolution to point out any specific differences between the 
different tablets. Thus one potential possibility for future work is the 
investigation of the hydration of the tablets using an ultrasound imaging 
system with higher resolution power to get more insight into the internal 
structural changes occurring within the hydrating tablets. 
 
Other imaging techniques, which are non destructive in general and 
require minimal sample preparation and manipulation, have been 
introduced into literature for the investigation of the structural properties 
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of tablets in their solid state, including x-ray microtomography (Sinka et al 
2004), and terahertz imaging (Ho et al 2007). It would thus be a 
possibility to study the potential use of such techniques in the 
investigation of hydrophilic matrix tablets prior and during their in-vitro 
hydration to correlate the external structural changes with any possible 
changes occurring within the internal structure of the tablets. Such 
techniques, as well as ultrasound imaging, would present a particular 
advantage in the investigation of hydrophilic matrix tablets in which ionic 
interactions take place upon tablet hydration, due to the fact that no 
colouring or contrast agent is usually needed in their use. 
 
The aim of this work was to investigate the influence of factors associated 
with the shape, structure and formulation of hydrophilic matrix tablets on 
the in vitro performance of such tablets. This focused nature of the study 
was chosen in order to present a clear picture about the influence of 
these factors without any complications or influences from external 
factors not directly related to the properties of the dosage form “tablet”. 
However, one other major influencing factor on the performance of 
hydrophilic matrix tablets is the surrounding hydration or dissolution 
medium, whether in terms of its physico-chemical properties or its 
hydrodynamics. Such variables could have a major influence on the 
hydration and erosion of the polymer incorporated into the formulation of 
hydrophilic matrix tablets, such as Xanthan Gum, in addition to their effect 
on drug solubility. They could thus affect the process of tablet hydration 
and drug release.  It is thus a main option for future work to investigate 
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the same tablet properties and behaviours that were examined in this 
study but using different compositions and hydrodynamics of the 
hydration or dissolution medium surrounding the tablets.   
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